Fermer X Les cookies sont necessaires au bon fonctionnement de 24hGold.com. En poursuivant votre navigation sur notre site, vous acceptez leur utilisation.
Pour en savoir plus sur les cookies...
AnglaisFrancais
Cours Or & Argent en

Clean Energy Fuels

Publié le 05 novembre 2015

4:13 pm Clean Energy Fuels beats by $0.05, misses on revs

( 0 vote, 0/5 ) Imprimer l'article
  Article Commentaires Commenter Notation Suivre la société  
0
envoyer
0
commenter

4:13 pm Clean Energy Fuels beats by $0.05, misses on revs

7:20 pm Charter Comm prices $2.5 bln of 5.750% senior unsecurednotes due 2026 (CHTR):  

7:00 pm Halliburton announces pricing of offering of $7.5 bln ofsenior notes (HAL): The notes are being issued in five tranches: $1.25 billion of5-year notes bearing interest at a fixed rate of 2.70% per year andmaturing on November 15, 2020; $1.25 billion of 7-year notesbearing interest at a fixed rate of 3.375% per year and maturing onNovember 15, 2022; $2 billion of 10-year notes bearing interest ata fixed rate of 3.80% per year and maturing on November 15, 2025;$1 billion of 20-year notes bearing interest at a fixed rate of4.85% per year and maturing on November 15, 2035; and $2 billion of30-year notes bearing interest at a fixed rate of 5.00% per yearand maturing on November 15, 2045. The offering is expected toclose on November 13, 2015.

6:55 pm First Data announces pricing of $1 bln of 5.00% seniorsecured first lien notes due 2024 and $2.2 bln of 5.750% seniorsecured second lien notes due 2024 (FDC):  

6:47 pm TC Pipelines President Steve Becker resigns (TCP): The co announced the appointment of Brandon Anderson to theposition of President and Director of TC PipeLines GP, Inc.effective January 1, 2016. Anderson succeeds Steve Becker who willcontinue working with TransCanada Corporation, the owner of TCPipelines GP, Inc., until his retirement in early 2016. Anderson isthe Senior Vice-President and General Manager, US Natural GasPipelines for TransCanada Corporation.

6:44 pm Globe Specialty Metals misses by $0.01, misses on revs (GSM):

  • Reports Q1 (Sep) earnings of $0.11 per share, excluding non-recurring items, $0.01 worse than the Capital IQ Consensus of $0.12; revenues fell 15.2% year/year to $174.76 mln vs the $191.09 mln Capital IQ Consensus.
  • Sales volume of 63,807 MT and net sales of $174.8 million - a 13% decrease compared to Q4 2015.
  • Continued progress on cost reductions primarily through SG&A and supply chain efficiencies.
  • Business combination with Grupo FerroAtlntica remains on track: expected to complete by the end of the year.

6:12 pm Con Edison misses by $0.03; reaffirms FY15 EPS guidance(ED):

  • Reports Q3 (Sep) earnings of $1.45 per share, excluding non-recurring items, $0.03 worse than the Capital IQ Consensus of $1.48.
  • Co reaffirms guidance for FY15, sees EPS of $3.90-4.05, excluding non-recurring items, vs. $4.00 Capital IQ Consensus Estimate.

6:08 pm McGrath RentCorp announces issuance of $60 mln of 3.845unsecured senior notes due 2022 (MGRC): Proceeds from the offering will be used to reduce the outstandingbalance on the Company's revolving credit line. The senior noteshave been issued pursuant to the Company's amended $200 millionnote purchase and private shelf agreement with PrudentialInvestment Management, Inc.

6:04 pm Alliant Energy beats by $0.10, misses on revs; narrowsFY15 EPS guidance; guides FY16 EPS in-line (LNT):

  • Reports Q3 (Sep) earnings of $1.63 per share, excluding non-recurring items, $0.10 better than the Capital IQ Consensus of $1.53; revenues rose 6.6% year/year to $898.9 mln vs the $1093.82 mln two analyst estimate.
  • Co issues in-line guidance for FY15, sees EPS of $3.50-3.65 (narrowed from $3.45-3.75) vs. $3.63 Capital IQ Consensus Estimate.
  • Co issues in-line guidance for FY16, sees EPS of $3.60-3.90 vs. $3.83 Capital IQ Consensus Estimate.

5:58 pm Exxon Mobil to hold media call on New York AttorneyGeneral subpoena for production of documents relating to climatechange today at 5:45pm ET (XOM):  

5:54 pm Alexandria RE announces pricing of $300 mln of 4.30%senior notes due 2026 (ARE): The notes were priced at 99.624% of the principal amount with ayield to maturity of 4.345%.

5:44 pm Willbros Group announces its Board has elected S. MillerWilliams Chairman of the Board; Michael J. Fournier appointed CEO (WG): Co announces that its Board of Directors has elected S. MillerWilliams, 64, Chairman of the Board. Michael J. Fournier, 52,currently President and Chief Operating Officer ("COO"), inaddition to his current duties, has also been appointed ChiefExecutive Officer ("CEO"). Mr. Fournier has also been appointed tothe Board of Directors and will serve on the Finance and ExecutiveCommittees. John T. McNabb, II, current Chairman and CEO willreturn to his role on the Board of Directors and on the Finance andExecutive Committees and complete his term as director, but choseto not stand for re-election at the Company's next Annual Meetingto be held in June 2016. These Director and management changes willbe effective December 1, 2015.

5:39 pm Iconix Brand to restate its historical financialstatements, sees Q3 EPS, revs below consensus, slashes FY15 EPS,revs guidance (shares halted) (ICON):

  • As previously announced, a Special Committee of the Company's Board, along with its independent legal and accounting advisors has been conducting a review of the accounting treatment related to certain transactions. The advisors have presented their analysis and conclusion and t he Special Committee has now completed the review.
  • Company will restate 4Q13, 2014, 1Q15 and 2Q15 to correct certain errors in accounting.
  • Amount adjusted
    • 2013- None; 2014 decrease operating income by $6 mln and increase in 1H15 by $1.6 mln
    • adjustments do not impact cash and will have no impact on the Company's previously reported free cash flow or securitized net cash flow
  • 3Q15 results will include three items as described below:
    • a) additional reserves of approximately $12.2 million should be taken with respect to certain of the Company's accounts receivable; 
    • b) adjustment of approximately $3.8 million, will have a negative impact to third quarter 2015 diluted EPS of approximately $0.08.
    • c) incurred approximately $7.1 million of charges for professional fees,  negative impact to diluted EPS of approximately $0.10 .
  • The Company expects third quarter 2015 licensing revenue to be approximately $89 million vs. estimates for total revs of $105.67 mln.
  • The Company expects third quarter 2015 non-GAAP diluted EPS to be approximately $0.09 (includes above mentioned) vs estimates of $0.51.

For the full year 2015, the Company is revising its guidance as follows:

  • The Company is revising its 2015 licensing revenue guidance to a range of $370 million-$380 million from $410 million-$425 million.
  • The Company is revising its 2015 "Other Revenue" guidance to zero from $5 million to $15 million.
    • Total revenues estimates for the year were $421-7 mln
  • The Company is revising its 2015 non-GAAP diluted EPS guidance to a range of $1.35-$1.40 from $2.00-$2.15.
    • Full year non-GAAP EPS estimate are for $2.07

The Company also remains engaged in a previously disclosedcomment letter process with the Staff of the U.S. Securities andExchange Commission relating to an ongoing review of the Company'sForm 10-K for the year ended December 31, 2014. The ultimateoutcome of the Staff's comment letter process is unknown at thistime.

5:38 pm Sparton Corporation beats by $0.25, reports revs in-line(SPA):

  • Reports Q1 (Sep) earnings of $0.41 per share, excluding non-recurring items, $0.25 better than the Capital IQ Consensus of $0.16; revenues rose 38.5% year/year to $106.69 mln vs the $107.52 mln Capital IQ Consensus.
  • Sonobuoy sales to the U.S. Navy increased to $22.7 million from $16.7 million in Q1 fiscal 2015; sonobuoy sales to foreign governments increased to $4.4 million from $1.0 million.
  • Consolidated gross margin was 19.8%, compared to the 16.7% in the prior year quarter.
  • "Although the Company's organic sales pipeline continues to grow, the softening we have been experiencing in the MDS legacy business is a concern that we are closely monitoring as the inherent fluctuations in this market space can have a quarter-to-quarter impact on the business."

5:38 pm AxoGen reports Q3 EPS of ($0.11) vs ($0.12) Capital IQConsensus estimate; revs $8.15 mln vs $6.6 mln estimate (AXGN):  

5:37 pm Vectren misses by $0.14; guides FY15 EPS belowconsensus; guides FY16 EPS in-line (VVC):

  • Reports Q3 (Sep) earnings of $0.48 per share, $0.14 worse than the Capital IQ Consensus of $0.62.
  • Co issues downside guidance for FY15, sees EPS of $2.30-2.40 vs. $2.45 Capital IQ Consensus Estimate.
  • Co issues in-line guidance for FY16, sees EPS of $2.45-2.65 vs. $2.61 Capital IQ Consensus Estimate.

5:35 pm Synta Pharma reports Q3 EPS of ($0.13) vs ($0.16)Capital IQ Consensus estimate; announces reduction in force by 60%(SNTA):

  • Co expects its cash resources of ~$88.3 mln as of September 30, 2015, along with lower operating expenses following the termination of the GALAXY-2 trial and the subsequent restructuring in the fourth quarter of 2015, will be sufficient to fund operations at least through the first half of 2017. This estimate assumes no additional funding from new partnership agreements, equity financings or further sales under the Company's ATM facility. The timing and nature of certain activities contemplated for the remainder of 2015 and 2016 will be conducted subject to the availability of sufficient financial resources.
  • To align its resources with the operational needs going forward, Synta announced that it is reducing its workforce by ~60% to 33 full time employees. The Company estimates annual savings of at least $8 mln in compensation-related costs as a result of the restructuring. Cash payments in connection with the workforce reduction, comprised principally of severance, unused vacation payments, benefits continuation costs and outplacement services, will range from $2.5 mln to $2.6 mln. The Company expects the restructuring to be substantially completed, and the majority of the related cash payments to be paid, during the fourth quarter of 2015.

5:34 pm Erickson Air-Crane misses by $0.06, misses on revs;guides FY15 revs below consensus (EAC):

  • Reports Q3 (Sep) earnings of $1.09 per share, $0.06 worse than the two analyst estimate of $1.15; revenues fell 14.5% year/year to $101.1 mln vs the $121.6 mln Capital IQ Consensus.
  • Co is restating its guidance, issuing downside guidance for FY15, sees FY15 revs of approx $300 mln vs. $332.93 mln Capital IQ Consensus Estimate.
  • "The additional contraction in the oil and gas markets, a slower than anticipated global firefighting season, and a decline in operational tempo and delay in contract awards in our Government business all impacted the third quarter of 2015. Our updated outlook and guidance for the remainder of the year reflects this reality.

5:30 pm KaloBios Pharma to reduce workforce by ~61%, pausesenrollment in KB004 Phase 2 study, will explore strategicalternatives (shares halted) (KBIO):

The co announced that it will reduce its workforce as part of aplan to reduce operating costs. This action will reduce thecompany's workforce by approximately 17 employees (or 61%), andwill focus the company's resources on the ongoing development oflenzilumab, also known as KB003, in chronic monomyelocyticleukemia, while it continues to pursue strategic alternatives forthe company.

  • As a part of its restructuring, the company also announced that it will pause enrollment in the Phase 2 cohort expansion phase of its ongoing clinical study of KB004 in certain hematologic malignancies. The company has also announced its intent to repay in full its outstanding secured loan obligation to MidCap Financial, secured lender to the company, in the approximate amount of $6.6 million , which will generate significant cash savings when compared to repayment of the debt in the ordinary course of business.
  • The company is currently evaluating strategic alternatives for the organization, including potentially the sale of the company or its assets, or a corporate acquisition, and may retain an investment bank to assist in those efforts. Since these efforts may not be successful, in light of its limited cash reserves the company is considering all possible alternatives, including further restructuring activities, wind-down of operations and bankruptcy proceedings.  
  • As a result of these developments, the company will likely not be able to file its Form 10-Q for the third quarter on a timely basis. KaloBios will make that filing as soon as practicable, and intends to file a Form 12b-25 to that effect.

5:30 pm Assured Guaranty beats Q3 estimates (AGO):

  • Reports Q3 (Sep) adj. earnings of $1.12 per share, excluding non-recurring items, $0.49 better than the Capital IQ Consensus of $0.63; adj. rev rose 34.7% year/year to $369 mln vs the $279.37 mln Capital IQ Consensus. 
  • Operating shareholders' equity per share and adjusted book value per share reached new records of $41.87 and $59.97, respectively.
  • Third quarter 2015 share repurchases totaled $135 million, or 5.4 million shares.
  • By reaching agreements in early October with certain providers of representations and warranties (R&W), the Company has completed its direct pursuit of R&W claims in its insured residential mortgage-backed securities portfolio.

5:24 pm Bright Horizons beats by $0.02, reports revs in-line;raises low end of FY15 EPS guidance, lowers top end of revsguidance (BFAM):

  • Reports Q3 (Sep) earnings of $0.43 per share, $0.02 better than the Capital IQ Consensus of $0.41; revenues rose 9.2% year/year to $365.94 mln vs the $365.3 mln Capital IQ Consensus.
  • Co issues in-line guidance for FY15, sees EPS of $1.81-1.83 (+25-26%, prior +23-26%) vs. $1.82 Capital IQ Consensus Estimate; sees FY15 revs of $1.45-1.47 bln (+7-9%, prior +7-10%) vs. $1.46 bln Capital IQ Consensus Estimate.

5:21 pm Novatel Wireless reports Q3 results; issues outlook (MIFI):

  • Novatel Wireless prelim Q3 ($0.04) vs ($0.05) two analyst estimate; revs +23% YoY to $54.6 mln vs $56.28 mln two analyst estimate.
  • Novatel Wireless sees Combined Company Q4 ($0.08)-($0.05) vs $0.00 two analyst estimate; sees revs $66-72 mln vs $76.36 mln two analyst estimate.

5:20 pm MasterCraft Correction: Beats by $0.03, beats on rev;updates FY16 guidance (MCFT):

  • Reports Q3 (Sep) adj. earnings of $0.30 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of $0.27; revenues rose 6.4% year/year to $54.9 mln vs the $54.17 mln Capital IQ Consensus. 
  • MasterCraft reiterates its expectations for MasterCraft sales and unit volume growth, as compared to fiscal 2015 sales and unit volume excluding Hydra-Sports, in the high-single to low-double digit range. Gross margin and adjusted EBITDA margin are both expected to increase at least 200 basis points from fiscal year 2015, with contributions from higher net sales and continued operating efficiency gains offsetting the absorption of public company costs following the company's July IPO. Adjusted net income is expected to grow faster than adjusted EBITDA, while GAAP net income will be impacted by charges related to changes in the fair value of the company's common stock warrants, as well as stock compensation expense related primarily to restricted stock and options granted prior to and in connection with the IPO.

5:18 pm IRIDEX reports Q3 results, revs down 3% YoY (IRIX):

  • Co reports Q3 (Sep) EPS of $0.04 vs $0.05 last year; revenue fell 3% Yoy to $9.8 mln. There are no analyst estimates.
  • Guidance: For Q4, co expects revenue of $11.5-11.9 mln.

5:14 pm XOMA beats by $0.16, misses on revs; earlier announcedsale of biologics manufacturing facilities, equipment, andassociated real estate (XOMA):

  • Reports Q3 (Sep) net of breakeven, $0.16 better than the Capital IQ Consensus of ($0.16); revenues fell 58.8% year/year to $2.1 mln vs the $3.72 mln Capital IQ Consensus.
  • Co separately announced today it has agreed to sell its biologics manufacturing facilities, equipment, and associated real estate to Agenus ( AGEN ), for approximately $5.0 million in cash up-front and $1.0 million in common stock.

5:14 pm Turquiose Hill Resources misses by $0.01, misses on revs(TRQ):

Reports Q3 (Sep) earnings of $0.01 per share, $0.01 worse thanthe Capital IQ Consensus of $0.02; revenues fell 12.2% year/year to$431.7 mln vs the $511.84 mln Capital IQ Consensus.

  • Oyu Tolgoi's Q3'15 mine production was at record levels while concentrate produced and contained copper was on par with Q2'15 even considering the planned concentrator shutdown in July. During Q3'15, mined production increased 8.5% over Q2'15 due to shorter hauling routes and ongoing productivity initiatives. Copper in concentrates for Q3'15 increased 1.3% due to higher head grades. Gold in concentrates for the quarter decreased 48.3% over Q2'15 due to slower than anticipated access to gold-rich ore.
  • Following the filing of revised schedules for the 2015 Oyu Tolgoi Feasibility Study with the Mongolian Minerals Council in August 2015, pre-start activities are underway in parallel with an update to the capital estimate, which is expected to be completed in Q1'16.
  • Capital expenditure for 2015 is now expected to be approximately $120 million, of which approximately $115 million relates to sustaining capital. The Company previously expected capital expenditure of approximately $230 million, of which approximately $185 million related to sustaining capital.
  • Increased copper and gold production is expected in Q4'15 when compared to Q3'15 as higher-grade ore is anticipated to be accessed in the open pit. Sales contracts have been signed for more than 80% of Oyu Tolgoi's expected 2016 concentrate production.

5:11 pm American Homes 4 Rent reports FFO in-line, beats on revs(AMH):

  • Reports Q3 (Sep) funds from operations of $0.19 per share, in-line with the Capital IQ Consensus of $0.19; revenues rose 56.3% year/year to $172.6 mln vs the $159.62 mln Capital IQ Consensus.
  • Core Net Operating Income from Same-Home properties increased 10.7% yr/yr
  • Repurchased 3.4 mln outstanding Class A common shares for a total price of $53.7 mln.

5:11 pm Goldman Sachs BDC beats by $0.09, beats on revs (GSBD):

  • Reports Q3 (Sep) net investment income of $0.57 per share, excluding non-recurring items, $0.09  better than the Capital IQ Consensus of $0.48; total investment income rose 72.3% year/year to $32.9 mln vs the $29.55 mln Capital IQ Consensus.

5:10 pm Great Plains Engy misses by $0.06; guides FY15 EPS belowconsensus (GXP):

  • Reports Q3 (Sep) earnings of $0.82 per share, $0.06 worse than the Capital IQ Consensus of $0.88.
  • Co issues downside guidance for FY15, sees EPS of $1.35-1.45 vs. $1.49 Capital IQ Consensus Estimate, narrowed from prior guidance of $1.35-1.60, citing mild weather, soft wholesale market conditions due to lower natural gas prices, and the impact of regulatory outcomes in its recent KCP&L rate cases. Earlier this week, the board of directors approved an approximate 7 percent increase in the quarterly dividend.

5:09 pm CubeSmart beats by $0.02, beats on revs; guides Q4 AFFOabove consensus (CUBE):

  • Reports Q3 (Sep) adjusted FFO of $0.34 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of $0.32; revenues rose 19.4% year/year to $115.97 mln vs the $113.31 mln Capital IQ Consensus.
  • Co issues upside guidance for Q4, sees adjusted FFO of $0.32-0.33, excluding non-recurring items, vs. $0.31 Capital IQ Consensus Estimate.
  • "Favorable industry fundamentals continue to drive strong operating performance throughout CubeSmart's portfolio. Our same-store revenue growth increased 60 basis points sequentially to 7.4%, primarily due to record occupancies and our ability to accelerate net effective rents during the quarter."

5:09 pm Ritchie Bros. beats by $0.04, beats on revs; acquires75% stake in Xcira (RBA):

  • Reports Q3 (Sep) earnings of $0.19 per share, $0.04 better than the Capital IQ Consensus of $0.15; revenues rose 6.9% year/year to $109.3 mln vs the $107.9 mln Capital IQ Consensus.
  • Subsequent to the third quarter, Ritchie Bros. acquired a majority interest in Xcira LLC, a Florida based company specializing in leading edge technology related to live auction bidding and sales. Ritchie Bros. believes this acquisition will be marginally accretive immediately.

5:09 pm News Corp. beats by $0.16, misses on revs (NWSA):

  • Reports Q3 (Sep) earnings of $0.22 per share, $0.16 better than the Capital IQ Consensus of $0.06; revenues fell 4.5% year/year to $2.01 bln vs the $2.09 bln Capital IQ Consensus. Adjusted revenues declined 1% compared to the prior year, as strong growth in the Digital Real Estate Services segment from REA Group Limited was offset by lower advertising revenues at the News and Information Services segment.

5:08 pm CB&I reports Q3 results in-line withpre-announcement; reaffirms FY15 EPS guidance (CBI):

  • Reports Q3 (Sep) earnings of $1.54 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $1.53; revenues fell 1.7% year/year to $3.32 bln vs the $3.57 bln Capital IQ Consensus.
    • On Oct 27 co guided for Q3 adjusted EPS of $1.54 on revs of ~$3.3 bln
  • Backlog remains fairly constant at $29.9 billion, including a year-to-date adverse foreign exchange impact of approximately $450 million.
  • Co issues guidance for FY15, sees EPS of $5.55-6.05, excluding non-recurring items, vs. $5.73 Capital IQ Consensus Estimate; sees FY15 adjusted revs of $14.0-14.4 bln and GAAP revs of $13.1-13.6 bln vs. $13.62 bln Capital IQ Consensus Estimate.

5:06 pm Sierra Wireless misses by $0.03, misses on revs; guidesQ4 EPS below consensus, revs below consensus (SWIR):

  • Reports Q3 (Sep) earnings of $0.23 per share, $0.03 worse than the Capital IQ Consensus of $0.26; revenues rose 7.9% year/year to $154.6 mln vs the $159.02 mln Capital IQ Consensus.
  • Co issues downside guidance for Q4, sees EPS of $0.09-0.11 vs. $0.30 Capital IQ Consensus Estimate; sees Q4 revs of $148-151 mln vs. $165.63 mln Capital IQ Consensus Estimate.

5:06 pm Pembina Pipeline reports Q3 EPS of $0.29 vs. $0.20 inEPS a year ago; revenue fell 29% to $1.03 blbn (PBA): Pembina delivered strong operational results which includedincreases to our operating margin, EBITDA, adjusted cash flow fromoperating activities, and earnings in the third quarter of 2015compared to the same period last year.

In a separate news release, the co announced that it plans toconstruct, own and operate a new 100 million cubic feet per day("MMcf/d") shallow cut gas plant ("Duvernay I" or "the Facility"),in close proximity to Pembina's Fox Creek Terminal. The expectedcapital cost for this project, including supporting infrastructure,is expected to be approximately $125 million.

Duvernay I, which is underpinned by a long-term agreement with alarge and diversified investment grade oil and gas producer,involves the construction of a new 100 MMcf/d shallow cut gasprocessing facility and incremental pipeline lateral capital.Pembina expects Duvernay I to have natural gas liquids ("NGL")extraction capacity of ~5,500 barrels per day ("bpd"), subject togas compositions.

5:05 pm Aceto beats by $0.03, misses on revs, reaffirms FY16guidance (ACET):

  • Reports Q1 (Sep) earnings of $0.37 per share, $0.03 better than the two analyst estimate of $0.34; revenues rose 2.1% year/year to $133.5 mln vs the $139.9 mln two analyst estimate.
  • Total company gross profit was $34.6 mln, an increase of 25.1%, compared to $27.7 mln in 1Q15. Gross margin for the first quarter was 25.9% compared to 21.1% in the prior year period.
  • Outlook : For FY16, co reaffirms its earnings outlook (Capital IQ Consensus is for EPS of $1.66), continues to expect sales growth in the mid-single digit range and net income growth in the low double-digit range. The outlook assumes that gross margin for fiscal 2016 will expand modestly over fiscal 2015, but that the gain will be smaller than what we have realized for each of the past couple of years. Co also continues to project $8-$10 million in R&D spending at Rising Pharmaceuticals.

5:04 pm Aratana Therapeutics misses by $1.16, beats on revs (PETX):

  • Reports Q3 (Sep) loss of $1.58 per share, $1.16 worse than the Capital IQ Consensus of ($0.42).
  • "Our portfolio of pet therapeutics continues to move through the regulatory process and if successful, we expect to bring an unprecedented number of innovative products to veterinarians and pet owners beginning in 2016," stated Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics.

5:04 pm Quintiles Transnational announces that founder Dr.Dennis Gillings will retire as Executive Chairman at the end of theyear (Q): The Board has appointed Jack M. Greenberg to serve as Chairman ofthe Board, effective January 1, 2016.

5:03 pm OvaScience beats by $0.02, provides update (OVAS):

  • Reports Q3 (Sep) loss of $0.66 per share, $0.02 better than the Capital IQ Consensus of ($0.68); revenues came in at $75,000 vs zero last year.
  • "The recent publication of the AUGMENT patient experiences highlighted the clinical benefit of the treatment in patients with poor fertility prognoses...We continue to adapt our commercial operations to reflect rapid changes in the fertility market. Our high-quality, scalable manufacturing and technical operations give us confidence in our ability to expand into new territories, such as Europe and Japan, while building a strong foundation for introducing our other treatments. We remain on track to introduce our OvaPrime treatment this year through a preceptorship program in at least one international region to evaluate its potential in women with too few or no eggs. We also continue to expect to communicate by year end a development pathway for OvaTure, our next-generation, hormone-free approach to IVF."

5:03 pm Provectus Pharma reports results that reveal aclinically relevant immunoadjuvant pathway triggered by tumor celldeath secondary to ablation with RB (PVCT):

Co announces that researchers from Moffitt Cancer Center inTampa, Florida, presented a poster titled, "Intralesional RoseBengal in Melanoma Elicits Tumor Immunity via High Mobility GroupBox 1," at the SITC Meeting in Maryland.

  • Authors stated, "results reveal a clinically relevant immunoadjuvant pathway triggered by tumor cell death secondary to ablation with RB."
  • In the reported work, the authors showed that tumor-specific T cells were increased in the blood of both mouse and man after tumor ablation with PV-10.
  • This was initiated by tumor cell necrosis, leading to release of High Mobility Box Group 1 (HMBG1), one of a class Damage-Associated Molecular Pattern molecules (DAMPs) released by dying cancer cells that can lead to activation of dendritic cells.
    • HMBG1 release was observed in vitro and after ablation of melanoma tumors in mice and clinical trial participants.
    • This was also correlated with dendritic cell activation and infiltration into lymph nodes draining ablated tumors.

5:02 pm Escalera Resources files Chapter 11 bankruptcy (ESCR): Escalera will continue to operate the business asdebtors-in-possession under the jurisdiction of the Court. TheCompany has filed a series of first day motions with the Court thatwill allow it to continue to conduct business without interruption.These motions are designed primarily to minimize the impact on theCompany's operations, customers and employees. In connection withthe bankruptcy process, Escalera has an agreement regarding the useof cash collateral.

5:01 pm Magnum Hunter reports refinancing its existing seniorsecured revolving credit facility (MHR):

The new term loan credit facility consists of a single trancheterm loan in the aggregate principal amount of $60 million, whichfunded on November 5, 2015. $44 million of proceeds from the newterm loan credit facility were used to refinance existing loansoutstanding and cash collateralize letters of credit outstandingunder the prior revolving credit facility with certain banks. Theremaining $16 million of proceeds will be used for generalcorporate purposes.

  • Furthermore, the new term loan facility includes an uncommitted incremental credit facility for up to an additional $10 million

5:01 pm Paylocity beats by $0.09, beats on revs; guides Q2 EPSabove consensus, revs above consensus; guides FY16 EPS aboveconsensus, revs above consensus (PCTY):

  • Reports Q1 (Sep) earnings of $0.02 per share, $0.09 better than the Capital IQ Consensus of ($0.07); revenues rose 37.9% year/year to $42.9 mln vs the $41.73 mln Capital IQ Consensus.
  • Co issues upside guidance for Q2, sees EPS of ($0.04)-($0.02) vs. ($0.08) Capital IQ Consensus Estimate; sees Q2 revs of $48.0-49.0 mln vs. $45.49 mln Capital IQ Consensus Estimate.
  • Co issues upside guidance for FY16, sees EPS of $0.04-$0.07 vs. ($0.05) Capital IQ Consensus Estimate; sees FY16 revs of $210-214 mln vs. $201.62 mln Capital IQ Consensus Estimate.

5:00 pm Universal Corp reports Q2 EPS of $0.81 vs $0.48 yr-ago;revs declined 1.6% to $456.38 mln (UVV):  

5:00 pm Marcus & Millichap misses by $0.07, misses on revs (MMI):

  • Reports Q3 (Sep) earnings of $0.39 per share, $0.07 worse than the Capital IQ Consensus of $0.46; revenues rose 9.9% year/year to $165.9 mln vs the $182.6 mln Capital IQ Consensus.
  • "Looking ahead, we believe we are well positioned for future growth albeit at more normalized rates. Our leading market position and room for share expansion within the vast, more stable and active private client segment, national coverage in all property types and opportunity to grow our financing business further remain the key drivers of our growth plan. We continue to benefit from a healthy environment for commercial real estate, capital availability and a highly experienced management team supportive of our strategy."

5:00 pm BioMed Realty reports Q3 FFO of $0.44 per share vs.estimates of $0.40; revs +3.2% y/y to $174.35 mln vs. $159.3 mlnestimate; acquisition by Blackstone expected to close in Q1 (BMR):  

4:59 pm Hudbay Minerals reports Q3 net loss of ($0.05)/share,Revenue increased 58.5% y/y to $269.8 mln (HBM):

  • Reports Q3 (Sep) loss of $0.05 per share compared to EPS of $0.21 year ago. The Capital IQ Consensus is CAD0.11. The company is now reporting results in U.S. Dollars, as it previously reported in Canadian Dollars.
  • Net earnings decreased by $58.0 mln. This change occurred primarily as a result of a $34.5 mln impairment charge associated with equipment inherited from the acquisition of Augusta. In addition, in 3Q14, HBM recorded net gains of $56.2 mln related to the Augusta acquisition.
  • Revenues rose 58.5% year/year to $269.8 mln. The Capital IQ Consensus is CAD354.42 mln.
  • Operating cash flows before stream deposit and changes in non-cash working capital increased 559% to $79.9 million for the three months ending September 30, 2015 compared to the same period in the prior year.
  • Metals production increases included 389% for copper, 329% for silver, 45% for gold and 7% for zinc, and cash cost per pound of copper produced, net of by-product credits, was $0.90. While operating cash flows benefitted from the significant increase in sales volumes and a low cash cost, these factors were partly offset by lower realized prices for all metals when compared to the prior year's quarter.

4:59 pm Genesis Healthcare reports EPS in-line, misses on revs;reaffirms FY15 EPS guidance (GEN):

  • Reports Q3 (Sep) earnings of $0.07 per share, in-line with the Capital IQ Consensus of $0.07; revenues rose 0.9% year/year to $1.41 bln vs the $1.43 bln Capital IQ Consensus.
  • Co reaffirms guidance for FY15, sees EPS of $0.34-0.39 vs. $0.37 Capital IQ Consensus Estimate; EBITDA $267.6-282.6 mln.

4:57 pm SAGE Therapeutics reports Q3 results and providesclinical upadte (SAGE):

  • Co reports Q3 (Sep) loss of $(0.84) per share vs $(0.84) Capital IQ consensus. Co has no revenue.
  • Co says "Enrollment of our Phase 3 STATUS Trial evaluating SAGE-547 as a treatment for super-refractory status epilepticus is on track, and we have made important recent progress in advancing our earlier stage next generation pipeline. SAGE-217, our first oral New Chemical Entity, is now in Phase 1 clinical development with broad potential across multiple GABA-related disorders. We have initiated our placebo-controlled proof-of-concept study of SAGE-547 in severe postpartum depression. We are also pleased to have selected three new compounds as development candidates, including our first NMDA modulator targeted at two orphan indications where no approved therapies exist. These activities exemplify SAGE's focus on innovation to address treatment of CNS diseases."

4:56 pm Amplify Snack Brands beats by $0.02, reports revsin-line; guides FY15 revs in-line (BETR):

  • Reports Q3 (Sep) earnings of $0.12 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of $0.10; revenues rose 48.3% year/year to $45.91 mln vs the $45.7 mln Capital IQ Consensus.
  • Adjusted EBITDA increased 9.7% year-over-year to $18.1 million, representing 39.4% of net sales; Gross margin was 55.9% 
  • Co issues in-line guidance for FY15, sees FY15 revs of $180-182 mln vs. $181.14 mln Capital IQ Consensus Estimate. Co sees FY15 adjusted EBITDA of $71.7-72.5 mln

4:55 pm Cedar Realty Trust reports Q3 FFO of $0.14 vs. $0.14Capital IQ Consensus Estimate; revs down 1.1% to $36.1 mln vs.$36.68 mln estimates; raises low end of FY15 FFO guidance (CDR): The co raised the low end of its FY15 FFO guidance from$0.52-0.54 to $0.53-0.54 vs. the $0.54 Capital IQ consensusestimate

4:55 pm California Resources Corp reports Q3 adj loss of $0.22vs the -$0.29 Capital IQ Consensus Estimate; suspends $0.01 pershare quarterly dividend (CRC): "We continue to focus significant attention on deleveraging ourbalance sheet. In conjunction with our recent cost saving actionsand the current environment, we felt it was prudent to suspend ourdividend."

4:53 pm Vectren increases dividend 5.3% from $0.38/share to$0.40/share (VVC):  

4:53 pm Synthetic Biologics reports Q3 (SYN): Reports Q3 (Sep) loss of ($0.12) per share, in-linewith the Capital IQ dual analyst est of ($0.12); $0 inrevs vs. $8 mln consensus.

4:53 pm CareTrust REIT beats by $0.01, beats on revs (CTRE):

  • Reports Q3 (Sep) funds from operations of $0.20 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.19; revenues rose 13.0% year/year to $17.95 mln vs the $17 mln Capital IQ Consensus.

4:53 pm Energy Recovery beats by $0.03, beats on revs (ERII):

  • Reports Q3 (Sep) loss of $0.01 per share, $0.03 better than the Capital IQ Consensus of ($0.04); revenues rose 126.7% year/year to $12.1 mln vs the $9.5 mln two analyst estimate. Co says it's seeing strengthening demand and sales in the global desalination market.

4:52 pm Paramount Group reports FFO in-line, beats on revs;guides FY15 FFO in-line (PGRE):

  • Reports Q3 (Sep) funds from operations of $0.20 per share, in-line with the Capital IQ Consensus of $0.20.
  • Co issues in-line guidance for FY15, sees FFO of $0.80-0.82, excluding non-recurring items, vs. $0.81 Capital IQ Consensus Estimate.

4:52 pm Energen beats by $0.09, misses on revs; reaffirms CY15production guidance (EGN):

  • Reports Q3 (Sep) earnings of $0.36 per share, excluding non-recurring items, $0.09 better than the Capital IQ Consensus of $0.27; revenues fell 40.6% year/year to $295.57 mln vs the $301.67 mln Capital IQ Consensus.
  • Reaffirms CY15 production guidance midpoint at 22.7 MMBOE (62,252 boepd).

4:51 pm Bankrate beats by $0.03, beats on revs; guides Q4 revsabove consensus; guides FY15 revs above consensus; announced saleof Insurance business (RATE):

  • Reports Q3 (Sep) earnings of $0.19 per share, $0.03 better than the Capital IQ Consensus of $0.16; revenues fell 0.6% year/year to $140.8 mln vs the $129.2 mln Capital IQ Consensus.
  • Co issues upside guidance for Q4, sees Q4 revs of $130-135 mln vs. $126.71 mln Capital IQ Consensus Estimate.
  • Co issues upside guidance for FY15, sees FY15 revs of $545-550 mln vs. $530.34 mln Capital IQ Consensus Estimate.
  • In a separate press release today Bankrate announced the sale of its Insurance business to All Web Leads, Inc. for total consideration of $165 mln. The Company recorded a goodwill impairment charge of $35 million for its Insurance business in the quarter

4:51 pm Air Transport Services Group misses by $0.01, misses onrevs; reaffirms FY15 EBITDA guidance (ATSG):

  • Reports Q3 (Sep) earnings of $0.10 per share, $0.01 worse than the Capital IQ Consensus of $0.11; revenues rose 2.8% year/year to $142.3 mln vs the $148.77 mln Capital IQ Consensus.
  • Co continues to project that its Adjusted EBITDA from Continuing Operations for 2015 will be in a range of $190 to 195 million.

4:50 pm United Continental releases a statement from Presidentand CEO Oscar Munoz; stating that based upon discussion withdoctors, he will be back in the first quarter (UAL): Munoz's letter stated: "Thank you for all the thoughts andprayers you sent to my family and me over the past few weeks. I amexcited to tell you that I am on the road to recovery. My time awaywill be a little longer than I would like, but based upondiscussion with my doctors I will be back in the first quarter. Ilook forward to seeing you in 2016 to continue working together tobuild a great airline."

4:50 pm MRC Global beats by $0.07, reports revs in-line (MRC):

  • Reports Q3 (Sep) earnings of $0.10 per share, excluding non-recurring items, $0.07 better than the Capital IQ Consensus of $0.03; revenues fell 33.8% year/year to $1.07 bln vs the $1.07 bln Capital IQ Consensus.

4:50 pm Workiva beats by $0.07, beats on revs; guides Q4 EPSbelow consensus, revs in-line (WK):

  • Reports Q3 (Sep) loss of $0.29 per share, $0.07 better than the Capital IQ Consensus of ($0.36); revenues rose 29.9% year/year to $36.27 mln vs the $35.45 mln Capital IQ Consensus.
  • Co issues guidance for Q4, sees EPS of ($0.25)-($0.24) vs. ($0.21) Capital IQ Consensus Estimate; sees Q4 revs of $37.6-38.1 mln vs. $38.01 mln Capital IQ Consensus Estimate.
  • Workiva had 2,468 customers as of September 30, 2015, a net increase of 292 customers from September 30, 2014.

4:49 pm EOG Resources beats by $0.32, misses on revs (EOG):

  • Reports Q3 (Sep) earnings of $0.02 per share, excluding non-recurring items, $0.32 better than the Capital IQ Consensus of ($0.30); revenues fell 57.6% year/year to $2.17 bln vs the $2.31 bln Capital IQ Consensus.
  • In the third quarter 2015, total crude oil and condensate production exceeded prior guidance due to improved well productivity.
  • Total co production decreased 5% compared to the third quarter 2014 excluding production related to EOG's Canadian operations, which were divested in the fourth quarter 2014.
  • Total capital expenditures decreased 36% compared to the same prior year period.
  • EOG also continued to reduce completed well costs and operating costs compared to the same quarter last year.
  • Lease and well expenses decreased 17% on a per-unit basis due to improved operational efficiencies and reduced service costs. Per-unit transportation costs decreased 11%, and total general and administrative expenses declined 6%.
  • EOG is maintaining full-year 2015 capital spending guidance. U.S. crude oil production guidance increased due to strong well performance.
    • Total co crude oil production guidance is slightly lower due to delays in the startup of the U.K. Conwy project. Delaware Basin

4:49 pm Evolent Health beats by $0.08, beats on revs; guides Q4revs in-line (EVH):

  • Reports Q3 (Sep) loss of $0.16 per share, $0.08 better than the Capital IQ Consensus of ($0.24); revenues rose 44.8% year/year to $43.3 mln vs the $41.73 mln Capital IQ Consensus.
  • Co issues in-line guidance for Q4, sees Q4 revs of $43-44 mln vs. $44.12 mln Capital IQ Consensus Estimate; sees Adjusted EBITDA of -$10.5 mln to -$9.5 mln.

4:49 pm Apollo Residential Mortg beats by $0.02, beats on revs (AMTG):

  • Reports Q3 (Sep) earnings of $0.54 per share, $0.02 better than the Capital IQ Consensus of $0.52; net interest income rose 6.4% year/year to $32.8 mln vs the $27.47 mln Capital IQ Consensus.
  • Avg leverage of 4.1x
  • Book value $17.08 vs $18.31 at June 30, 2015.
  • Repurchased 360,800 shares of common stock at avg price of $13.86, representing approx 1% of shares outstanding

4:49 pm Nelnet misses by $0.14 (NNI):

  • Reports Q3 (Sep) adj. earnings of $1.43 per share, $0.14 worse than the single analyst estimate of $1.57. 
  • 15% increase in Tuition Payment Processing and Campus Commerce revenue
  • Purchased $1.8 billion of student loans
  • Board increased quarterly dividend 20% to $0.12 per share

4:48 pm Bill Barrett reports EPS in-line, misses on revs;reaffirms FY15 CapEx and production guidance (BBG):

  • Reports Q3 (Sep) loss of $0.09 per share, excluding non-recurring items,  in-line with the Capital IQ Consensus of ($0.09); revenues fell 63.3% year/year to $49.68 mln vs the $92.93 mln Capital IQ Consensus.
  • Oil, natural gas and natural gas liquids ("NGL") production from the DJ Basin and UOP totaled 1.7 million barrels of oil equivalent ("MMBoe") in Q3 compared with 1.4 MMBoe in the third quarter of 2014.
  • Co reiterates guidance for FY15 CapEx of $315-325 mln; production of 6.3-6.5 MMBoe

4:48 pm FXCM reports Q3 results, Net revenue decreased 35% y/yto $59.6 mln (FXCM):

  • Reports Q3 (Sep) GAAP earnings of $1.76 per share, does not compare to the two analyst estimate of ($1.60).
  • Net revenue decreased 35% y/y to $59.6 mln.
  • Adjusted EBITDA from continuing and discontinued operations was $5.2 million.
  • Reports retail customer trading volume of $335 bln in October 2015, 3% higher than September 2015 and 25% lower than October 2014 ... Institutional customer trading volume of $34 billion in October 2015, 28% lower than September 2015 and 63% lower than October 2014.
  • Active retail accounts of 178,273 as of October 31, 2015, a decrease of 1,848, or 1%, from September 2015, and an increase of 17,222, or 11%, from October 2014.

4:48 pm Science Applications receives contract from the GeneralServices Admin to provide a broad array of IT services; totalcontract value of $549 mln if all options are exercised (SAIC):

 The General Services Administration awarded Co aprime task order contract to provide a broad array of informationtechnology services.

  • Awarded under the GSA Alliant Government-wide Acquisition Contract, the single-award, cost-plus-award-fee task order has a one-year base period of performance, four one-year options, and a total contract value of $549 mln , if all options are exercised.

4:48 pm Alimera Sciences beats by $0.02, reports revs in-line;guides FY15 revs below consensus (ALIM):

  • Reports Q3 (Sep) loss of $0.21 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of ($0.23); revenues rose 187.5% year/year to $6.9 mln vs the $6.96 mln Capital IQ Consensus.
  • Co issues downside guidance for FY15, sees FY15 revs at the low end of the $20 mln range vs. $24.75 mln Capital IQ Consensus Estimate.
    • 'We expect fourth quarter revenues to be affected by the typical seasonality , as well as a lack of clarity about the possible impact of the now announced J-code in the U.S. This may cause some doctors to postpone treatment until the J-code is available in January 2016. As a result, we expect full year 2015 revenue to be in the low $20 million range . We believe that the specific J-code reimbursement will drive additional use and market acceptance of ILUVIEN, and therefore we expect significant growth in 2016'. 

4:47 pm ARC Group misses by $0.02, misses on revs (ARCW):

  • Reports Q1 (Sep) loss of $0.03 per share, $0.02 worse than the Capital IQ Consensus of ($0.01); revenues fell 14.7% year/year to $24.49 mln vs the $27.43 mln Capital IQ Consensus.
  • ARC has hired Mr. Stuart Gold in a newly created position, as Executive Vice President of Global Sales & Marketing for the Company. While near term headwinds remain, Management says it is optimistic about the medium to long term forecast for the Company.

4:46 pm Aspen Aerogels misses by $0.04, beats on revs; guidesFY15 EPS in-line, revs above consensus; guides FY16 below consensus(ASPN):

  • Reports Q3 (Sep) loss of $0.11 per share, $0.04 worse than the Capital IQ Consensus of ($0.07); revenues rose 24.0% year/year to $31.5 mln vs the $30.85 mln Capital IQ Consensus.
  • Co issues guidance for FY15, sees EPS of ($0.31)-(0.28) vs. ($0.29) Capital IQ Consensus Estimate; sees FY15 revs of $120-122 mln vs. $118.57 mln Capital IQ Consensus Estimate.
  • Co issues downside guidance for FY16, sees EPS of ($0.15)-(0.06) vs. $0.00 Capital IQ Consensus Estimate; sees FY16 revs of $117-122 mln vs. $137.76 mln Capital IQ Consensus Estimate.
  • "We expect continued solid growth in the refinery, petrochemical and LNG segments of the energy market in 2016. However, we will be challenged to offset the expected decrease in revenue due to the completion of the multi-year Asian petrochemical project, and a reduction in the number and volume of subsea projects from this year's record levels. Accordingly, we are projecting revenue for 2016 at approximately the same level projected for 2015. We are also committed to improving manufacturing performance in 2016 to improve our profit margins."

4:45 pm Kemper beats by $0.14, beats on revs (KMPR):

  • Reports Q3 (Sep) net operating income of $0.70 per share, $0.14 better than the Capital IQ Consensus of $0.56; revenues rose 14.0% year/year to $615.4 mln vs the $558.11 mln two analyst estimate.

4:45 pm Emergent BioSolutions beats by $0.28, beats on revs;guides FY15 revs in-line (EBS):

  • Reports Q3 (Sep) earnings of $0.83 per share, $0.28 better than the Capital IQ Consensus of $0.55; revenues rose 19.5% year/year to $164.9 mln vs the $151.42 mln Capital IQ Consensus.
  • Co issues in-line guidance for FY15, sees FY15 revs of $520-540 mln vs. $523.86 mln Capital IQ Consensus Estimate.
  • EBITDA: Q3 2015 of $61.8 million, or $1.29 per diluted share, +54% Y/Y; nine months 2015 of $71.5 million, or $1.52 per diluted share, +83% Y/Y

4:45 pm Gastar Exploration misses by $0.04, beats on revs;provides Q4 production guidance (GST):

  • Reports Q3 (Sep) loss of $0.18 per share, $0.04 worse than the Capital IQ Consensus of ($0.14); revenues fell 32.0% year/year to $28.39 mln vs the $27.87 mln Capital IQ Consensus.
  • Q4 production guidance includes 13.2-13.7 net average daily mboe/d, 52-56% liquids
  • At September 30, 2015, the co had approximately $10.4 million in available cash and cash equivalents and $120.0 million of availability under its $200 million revolving credit facility borrowing base, or total available liquidity of $130.4 million.
  • Average daily production for the third quarter of 2015 was 13,600 barrels of oil equivalent per day as compared to 9,800 Boe/d in the third quarter of 2014 and 13,900 Boe/d in the second quarter of 2015.

4:45 pm Capstone Turbine reports in-line with preannouncement (CPST):

  • Reports Q2 (Sep) loss of $0.02 per share, in-line with the Capital IQ Consensus of ($0.02); revenues fell 44.4% year/year to $17.9 mln vs the $19.06 mln Capital IQ Consensus. 
  • Financial results are in line with the Company's revised expectations announced on Oct 1
  • "As disappointed as we are in reporting financial results that were below our original internal and Street expectations, we are taking actions to expedite the shipment of orders that were left in finished goods from the second quarter and have accelerated our initiative to lower our cash burn by continuing to reduce our overall operating expenses."

4:44 pm Brooks Automation beats by $0.04, beats on revs; guidesDecQ EPS below consensus, revs below consensus (BRKS):

  • Reports Q4 (Sep) earnings of $0.17 per share, excluding non-recurring items, $0.04 better than the Capital IQ Consensus of $0.13; revenues rose 19.0% year/year to $145.8 mln vs the $143.2 mln Capital IQ Consensus.
  • Co issues downside guidance for Q1 (Dec), sees EPS of $(0.03)-0.01, excluding non-recurring items, vs. $0.13 Capital IQ Consensus Estimate; sees Q1 revs of $110-117 mln vs. $140.5 mln Capital IQ Consensus Estimate.

4:42 pm Quintiles Transnational announces a $300 mln increase toits common share repurchase authorization (Q): The share repurchase program does not obligate the Co to acquireany particular amount of common stock, has no end date, and may bemodified, suspended, or discontinued at any time.

4:42 pm WageWorks beats by $0.07, beats on revs (WAGE):

  • Reports Q3 (Sep) earnings of $0.36 per share, excluding non-recurring items, $0.07 better than the Capital IQ Consensus of $0.29; revenues rose 22.4% year/year to $83.2 mln vs the $82.35 mln Capital IQ Consensus.

4:42 pm ServiceMaster announces the sale of ~28.96 mln shares ofits common stock by a selling stockholder associated with Clayton,Dubilier & Rice and StepStone Group (SERV): Co announced  the sale of an aggregate of 28,961,763 sharesof the Company's common stock by investment funds associated withClayton, Dubilier & Rice, LLC and StepStone Group

4:41 pm Applied Optoelectronics reports EPS in-line, beats onrevs; guides Q4 below consensus (AAOI):

  • Reports Q3 (Sep) earnings of $0.40 per share, in-line with the Capital IQ Consensus of $0.40; revenues rose 56.4% year/year to $57.1 mln vs the $52.54 mln Capital IQ Consensus.
  • Co issues downside guidance for Q4, sees EPS of $0.28-0.33 vs. $0.42 Capital IQ Consensus Estimate; sees Q4 revs of $49-52 mln vs. $54.29 mln Capital IQ Consensus Estimate.
  • "We achieved record revenue that exceeded the high end of our guidance for the third quarter. Our strong topline results were driven by accelerated shipments for our 40G datacenter products, partially offset by lower than expected revenue for our CATV products. Revenue for our datacenter products grew 30% sequentially and 92% year-over-year, bringing our year-to-date growth to 71%, which is well above our initial annual target. Looking into the fourth quarter, given the accelerated datacenter demand in the third quarter and consolidation activities in CATV, we expect revenue to decline sequentially and to return to more normalized order patterns in the first quarter of 2016."

4:41 pm Skyworks reports EPS in-line, revs in-line; guides Q1EPS above consensus, revs above consensus (SWKS):

  • Reports Q4 (Sep) adj earnings of $1.52 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of $1.52; revenues rose 22.6% year/year to $880.8 mln vs the $879.08 mln Capital IQ Consensus.
  • Co issues upside guidance for Q1, sees EPS of $1.60 vs. $1.56 Capital IQ Consensus Estimate; sees Q1 revs of $925-930 mln vs. $921.43 mln Capital IQ Consensus Estimate. Co sees non-GAAP gross margin in the range of 51%

4:41 pm Cytori Therapeutics misses by $0.01, misses on revs (CYTX):

  • Reports Q3 (Sep) loss of $0.04 per share, $0.01 worse than the Capital IQ Consensus of ($0.03); revenues rose 125.5% year/year to $2.48 mln vs the $3.27 mln Capital IQ Consensus. Cytori ended the second quarter of 2015 with $19 million of cash and cash equivalents.Upcoming Near Term Catalysts:
    • Evaluate and release 24-week data from 94 patient US pilot/phase IIb ACT-OA trial (anticipated Q1 2016) and identify partner for late stage US clinical development 
    • Complete enrollment of US STAR trial (anticipated mid 2016) for scleroderma hand dysfunction
    • Complete enrollment of EU pivotal/phase III SCLERADEC-II trial (anticipated mid 2016) for scleroderma hand dysfunction
    • Complete enrollment of Japanese pivotal/phase III ADRESU trial (anticipated 2017) for stress urinary incontinence
    • Work with FDA to plan a burn wound therapy trial related to contract with BARDA (anticipated in 2016)

4:40 pm Redwood Trust misses Q3 estimates (RWT):

  • Reports Q3 (Sep) earnings of $0.22 per share, $0.13 worse than the Capital IQ Consensus of $0.35; revenues were unchanged from the year-ago period at $40 mln.
  • At Sept 30, 2015, Redwood reported a book value per share of $14.69, as compared to $14.96 at June 30, 2015, and $15.21 at September 30, 2014.

4:40 pm Hawaiian Electric beats by $0.02, misses on revs; willrestate prior financials, discovers material weakness in internalcontrol over financial reporting (HE):

  • Reports Q3 (Sep) core earnings of $0.49 per share, $0.02 better than the two analyst estimate of $0.47; revenues fell 17.3% year/year to $717.2 mln vs the $875.21 mln single analyst estimate.
  • On November 4, 2015, the board of directors maintained HE's quarterly cash dividend of $0.31 cents per share, payable on December 10, 2015, to shareholders of record at the close of business on November 23, 2015 (ex-dividend date is November 19, 2015). The dividend is equivalent to an annual rate of $1.24 per share.
  • In the course of preparing the third quarter financial statements, HEI's and Hawaiian Electric Company's management determined that Hawaiian Electric Company's capital expenditures on HEI's and Hawaiian Electric Company's Consolidated Statements of Cash Flows did not correctly account for the beginning of period unpaid invoices and accruals (that were paid in cash during the period). Accordingly, HEI and Hawaiian Electric Company are each restating or revising their previously filed Consolidated Statements of Cash Flows for the periods stated below to correct for such misstatements by adjusting cash used for "Capital expenditures" and the change in accounts payable.
  • In light of the above matter, management, in consultation with the Audit Committees, has determined that a material weakness in HEI's and Hawaiian Electric Company's internal control over financial reporting existed at December 31, 2014. HEI and Hawaiian Electric Company intend to restate management's report on internal control over financial reporting and its evaluation of disclosure controls and procedures and expect to receive an adverse opinion on the internal control over financial reporting as of December 31, 2014, from PricewaterhouseCoopers LLP.

4:40 pm Main Street Capital beats by $0.01 (MAIN):

  • Reports Q3 (Sep) net investment income of $0.56 $0.01 better than the Capital IQ Consensus of $0.55.
  • Total investment income of $42.6 million, representing a 17% increase from Q3 of 2014
  • Improved industry leading ratio of total non-interest operating expenses as a percentage of quarterly average total assets on an annualized basis to 1.3% in Q3 of 2015

4:40 pm Pros Holdings beats by $0.05, misses on revs; guides Q4EPS below consensus, revs below consensus (PRO):

  • Reports Q3 (Sep) loss of $0.16 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus of ($0.21); revenues fell 12.5% year/year to $40.86 mln vs the $41.56 mln Capital IQ Consensus.
  • Co issues downside guidance for Q4, sees EPS of ($-0.21)-($0.19) vs. ($0.12) Capital IQ Consensus Estimate; sees Q4 revs of $40.7-42.7 mln vs. $47.07 mln Capital IQ Consensus Estimate.

4:39 pm Entravision reports EPS in-line, beats on revs (EVC):

  • Reports Q3 (Sep) earnings of $0.10 per share, in-line with the Capital IQ Consensus of $0.10; revenues rose 11.2% year/year to $69.26 mln vs the $65.31 mln Capital IQ Consensus.

4:38 pm Roadrunner Transportation misses by $0.03, reports revsin-line (RRTS):

  • Reports Q3 (Sep) earnings of $0.15 per share, $0.03 worse than the Capital IQ Consensus of $0.18; revenues fell 0.2% year/year to $497.2 mln vs the $494.98 mln Capital IQ Consensus.
  • Note that on Oct 26 co pre-announced Q3 EPS of $0.14-0.17 vs consensus at the time of $0.44.

4:38 pm Nektar Therapeutics beats by $0.18, beats on revs (NKTR):

  • Reports Q3 (Sep) loss of $0.06 per share, $0.18 better than the Capital IQ Consensus of ($0.24); revenues fell 54.9% year/year to $59.95 mln vs the $44.27 mln Capital IQ Consensus.

4:37 pm Erickson Air-Crane secures $60 mln in contractextensions, renewals and new wins awarded in the last 30 days; newrevs to be recognized in coming quarters (EAC):

The co announces $60 mln in contract extensions, renewals andnew wins awarded in the last 30 days.

  • The new revs, combined from the Government, Commercial and Manufacturing and MRO (Maintenance, Repair and Overhaul) business units, will be realized in the coming quarters. 
  • Award split up into biz units: Government Services secured $46 mln, Commercial Services secured $7.5 mln, and Manufacturing and MRO secured $5.9 mln

4:37 pm Tucows reports EPS in-line, misses on revs (TCX):

  • Reports Q3 (Sep) earnings of $0.28 per share, in-line with the Capital IQ Consensus of $0.28; revenues rose 14.7% year/year to $44.6 mln vs the $45.25 mln two analyst estimate.

4:37 pm DXP Enterprises misses by $0.04, misses on revs (DXPE):

  • Reports Q3 (Sep) earnings of $0.32 per share, excluding non-recurring items, $0.04 worse than the Capital IQ Consensus of $0.36; revenues fell 21.7% year/year to $303 mln vs the $308.05 mln Capital IQ Consensus.

4:37 pm ChannelAdvisor beats by $0.10, beats on revs; guides Q4revs in-line (ECOM):

  • Reports Q3 (Sep) loss of $0.07 per share, $0.10 better than the Capital IQ Consensus of ($0.17); revenues rose 16.3% year/year to $24.38 mln vs the $23.86 mln Capital IQ Consensus.
  • Co issues in-line guidance for Q4, sees Q4 revs of $26.2-26.6 mln vs. $26.21 mln Capital IQ Consensus Estimate. Adjusted EBITDA between $0.6 million and $1.0 million.
  • Total customer count was 2,910 at the end of the third quarter, an increase of 5 percent from 2,781 customers at the end of the third quarter of 2014.

4:37 pm Medivation beats by $0.02, beats on revs (MDVN):

  • Reports Q3 (Sep) earnings of $0.35 per share, $0.02 better than the Capital IQ Consensus of $0.33; revenues rose 30.0% year/year to $260.7 mln vs the $257.83 mln Capital IQ Consensus.
  • The sequential quarter increase in net sales was primarily due to an increase in underlying demand (mid-single digit percent growth, compared with June 2015 quarter) and a lower gross-to-net rate recorded by Astellas in the third quarter, which was offset by changes in channel partner inventory levels during the quarters.
  • Co states: "In October, we successfully completed the acquisition for the late stage asset talazoparib, a highly-potent, orally-available poly ADP ribose polymerase inhibitor. With the acquisition of talazoparib, we now have further diversified our late-stage pipeline beyond XTANDI and pidilizumab to complement our early development programs, providing significant opportunities for growth."

4:37 pm InnerWorkings beats by $0.02, reports revs in-line;guides FY15 EPS in-line, reaffirms rev guidance (INWK):

  • Reports Q3 (Sep) earnings of $0.11 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of $0.09; revenues rose 5.2% year/year to $264.7 mln vs the $263.41 mln Capital IQ Consensus.
  • Co issues in-line guidance for FY15, sees EPS of $0.25-0.27, excluding non-recurring items, vs. $0.25 Capital IQ Consensus Estimate. The Company reaffirms its revenue guidance of 8% to 11% growth over 2014 in constant currency. The Company also reaffirms its 2015 Non-GAAP Adjusted EBITDA guidance of $49 million to $51 million

4:36 pm Stamps.com beats by $0.28, beats on revs; guides FY15EPS above consensus, revs above consensus (STMP):

  • Reports Q3 (Sep) earnings of $1.14 per share, excluding non-recurring items, $0.28 better than the Capital IQ Consensus of $0.86; revenues rose 36.6% year/year to $51.67 mln vs the $48.14 mln Capital IQ Consensus.
  • Co issues upside guidance for FY15, sees EPS of $3.60-4.00, excluding non-recurring items, vs. prior guidance of $3.10-3.50 and vs $3.37 Capital IQ Consensus Estimate; sees FY15 revs of $198-208 mln vs. prior guidance of $170-190 mln and vs $191.7 mln Capital IQ Consensus Estimate.
  • Co provides update on its pending acquisition of Endicia, a wholly-owned subsidiary of Newell Rubbermaid ( NWL ), for $215 million in cash. On November 2, 2015, the parties received written notice from the US Dept of Justice that it had closed its investigation. As a result, the acquisition is expected to close November 18, 2015.

4:36 pm Entellus Medical misses by $0.07, beats on revs; lowersFY15 EPS below consensus, raises revs above consensus (ENTL):

  • Reports Q3 (Sep) loss of $0.32 per share, $0.07 worse than the Capital IQ Consensus of ($0.25); revenues rose 26.5% year/year to $14.8 mln vs the $14.19 mln Capital IQ Consensus.
  • Co issues guidance for FY15, lowers EPS of ($1.12) - ($0.99) from ($1.10) - ($0.80) vs. ($0.92) Capital IQ Consensus Estimate; raises FY15 revs to $60.5-61.5 mln from $58.5-61.0 mln vs. $60.35 mln Capital IQ Consensus Estimate.  Gross margin will be in a range of 76.5% to 77.5%

4:36 pm Norwegian Cruise Line prices its private offering of$600 mln in senior unsecured notes due November 2020 at 4.625% (NCLH): The size of the offering was increased from $500.0 million to$600.0 million.The Company expects to use the net proceeds from theOffering, to redeem and discharge its outstanding 5.00% SeniorNotes due 2018 and for other general corporate purposes

4:35 pm Preferred Apt. Communities declares an increase in itsquarterly common stock distribution to $0.1925/share, up from$0.18/share Q/Q (APTS):  

4:35 pm Portfolio Recovery Assoc. misses by $0.17, misses onrevs; announces $125 mln repurchase program (PRAA):

  • Reports Q3 (Sep) earnings of $0.99 per share, $0.17 worse than the Capital IQ Consensus of $1.16; revenues fell 4.0% year/year to $229.43 mln vs the $249.64 mln Capital IQ Consensus.
  • Principal amortization of finance receivables in the third quarter was $172.6 million or 45.3% of cash collections, compared with 39.8% in the year-ago quarter.  
  • The Company also announced that its Board of Directors authorized a new $125 million share repurchase program.

4:34 pm Applied Genetic Technologies misses by $0.34, beats onrevs (AGTC):

  • Reports Q1 (Sep) loss of $0.53 per share, $0.34 worse than the Capital IQ Consensus of ($0.19); revenues rose 1468.8% year/year to $11.06 mln vs the $5.91 mln Capital IQ Consensus. The increase was largely attributable to the recognition as revenue of a portion of the nonrefundable upfront fees received in August 2015 by the company under its collaboration agreement with Biogen, and milestone revenue of $5.0 million that was recorded during the quarter following achievement of a patient enrollment-based milestone under that collaboration.
  • Based on AGTC's strong cash position of $199 million as of September 30, 2015, the company expects to have sufficient cash for at least the next two years for the completion of the ongoing phase 1/2 human clinical trial for XLRS and the planned phase 1/2 human clinical trial for ACHM. AGTC also expects to be able to fund pre-clinical research and the initiation and complete enrollment of human clinical trials for a second form of ACHM and for the company's partnered program to treat X-linked Retinitis Pigmentosa (:XLRP). The above expectations assume that the company remains within its development timelines and estimated budgets, does not exercise its option to cost and profit share with Biogen on either the XLRS or XLRP programs, does not enter into any material new transactions, and does not undergo any other unexpected events.

4:34 pm Encore Capital beats by $0.03, misses on revs (ECPG):

  • Reports Q3 (Sep) earnings of $1.34 per share, $0.03 better than the Capital IQ Consensus of $1.31; revenues rose 5.3% year/year to $287.8 mln vs the $300.56 mln Capital IQ Consensus.
  • Adjusted EBITDA rose 7% to $268 mln

4:33 pm Inventure Foods misses by $0.06, reports revs in-line (SNAK):

  • Reports Q3 (Sep) adjusted loss of $0.05 per share, $0.06 worse than the Capital IQ Consensus of $0.01; revenues fell 3.7% year/year to $69.9 mln vs the $70.44 mln Capital IQ Consensus.
  • Gross profit decreased $4.2 mln to $8.7 mln, or 12.5% as a percentage of net revenues, compared to $12.9 mln, or 17.8% as a percentage of net revenues, in 3Q14.
  • Adjusted EBITDA was $2.4 mln compared to $5.9 mln in the prior year period.

4:33 pm Aegean Marine Petrol enters into a $120 million creditfacility, for its Fujairah Oil Terminal (ANW):

Proceeds from the loan were used to repay the indebtednesscurrently outstanding on that facility of $45.2 mln.

  • The balance of proceeds are expected to be used to purchase supply

4:33 pm Geron reports EPS in-line, beats on revs (GERN):

  • Reports Q3 (Sep) earnings of $0.17 per share, in-line with the Capital IQ Consensus of $0.17; revenues rose year/year to $35.4 mln (from $160K) vs the $17.87 mln Capital IQ Consensus.
  • Research and development expenses for the first nine months of 2015 were $13.8 million compared to $16.4 million for the comparable 2014 period.
  • The decrease in research and development expenses for the three and nine month periods ending Sept 30, 2015, compared to the same periods in 2014, was primarily the net result of lower costs for the manufacturing of imetelstat and reduced personnel-related costs resulting from the organizational resizing, partially offset by increased costs for the development of imetelstat for hematologic myeloid malignancies in collaboration with Janssen.
  • The co expects research and development expenses to increase during the remainder of the year as the development of imetelstat continues in collaboration with Janssen.

4:32 pm Qualcomm and Huizhou TCL Mobile Communication Co., Ltd.sign 3G/4G Chinese patent license agreement (QCOM):

QCOM has granted Huizhou a royalty bearing patent license tomanufacture and sell certain sub units.

  • The royalties payable by TCL are consistent with the terms of the rectification plan submitted by Qualcomm to China's National Reform and Development Commission.

4:31 pm Diamondrock Hospitality misses by $0.01, reports revsin-line; guides FY15 FFO in-line (DRH):

  • Reports Q3 (Sep) funds from operations of $0.26 per share, excluding non-recurring items, $0.01 worse than the Capital IQ Consensus of $0.27; revenues rose 4.1% year/year to $238.5 mln vs the $240.33 mln Capital IQ Consensus.
  • Co issues in-line guidance for FY15, sees FFO of $1.00-1.02 vs. $1.02 Capital IQ Consensus Estimate; ProForma RevPAR Growth 4.25-5.00% (Prior 6.00-7.00%); Adjusted EBITDA $264-269 mln (Prior ($266.5-276.5 mln).

4:31 pm Zion Oil & Gas launches new rights offering with a10% convertible bond (ZN):

Co has distributed at no cost, non-transferable subscriptionrights to persons who owned shares of our Common Stock on October15, 2015, with each subscription right consisting of two 10%Convertible Senior Bonds, par value $100.00 each, due February 15,2021.

  • Each whole subscription right entitles shareholders to purchase two (2) convertible bonds at a purchase price of $100.00 per bond.

4:30 pm Honeywell to acquire COM DEV International's satelliteequipment business for ~$345 mln, net of cash and debt (HON):

The co has signed a definitive agreement to acquire Ontario,Canada-based COM DEV International for a purchase price ofC$455 mln ($345 million USD), net of cash and debt acquired.

  • COM DEV's estimated 2015 revenue is approximately C$210 mln ($160 mln USD). Honeywell is acquiring COM DEV's electrical and optical components and subsystems equipment businesses. COM DEV will simultaneously spin-off its exactEarth subsidiary to current shareholders prior to closing.
  • The acquisition is expected to close by the end of the first quarter in 2016

4:30 pm Century Communities misses by $0.04, misses on revs (CCS):

  • Reports Q3 (Sep) earnings of $0.50 per share, $0.04 worse than the Capital IQ Consensus of $0.54; revenues rose 98.7% year/year to $182.73 mln vs the $198.2 mln Capital IQ Consensus.
  • At the end of the third quarter 2015, the Company had 904 homes in backlog, representing $325.1 million of backlog dollar value, compared to 472 homes, representing $190.0 million of backlog dollar value in the prior year quarter.
  • "We are encouraged by the sustained level of incremental improvement in our results during the first nine months of 2015. As a result we are tightening our full year 2015 guidance ranges." Based on the Company's current market outlook for the full year 2015 it now expects home deliveries to be in the range of 2,350 to 2,500 homes and home sales revenues to be in the range of $700 million to $750 million, excluding the potential impact of any future acquisitions. At the end of the full year 2015, the Company anticipates that the active selling community count will range from 90 to 95 communities.

4:30 pm CDI Corp awarded engineering and marine servicescontract by U.S. Navy, two-year single-award contract has a maximumvalue of $38.3 million (CDI):  

4:29 pm PerkinElmer reports EPS in-line, beats on revs; guidesFY15 EPS in-line (PKI):

  • Reports Q3 (Sep) earnings of $0.60 per share, in-line with the Capital IQ Consensus of $0.60; revenues rose 3.9% year/year to $563.4 mln vs the $554.63 mln Capital IQ Consensus.
  • Adjusted operating profit margin was 17.0% as a percentage of adjusted revenue, as compared to 16.8% for the same period a year ago.
  • Co issues in-line guidance for FY15, sees EPS of $2.56-$2.59 vs. $2.58 Capital IQ Consensus Estimate.

4:29 pm Exar reports EPS in-line, revs in-line; guides Q3 EPSin-line, revs in-line; guides FY16 EPS above consensus, revsin-line (EXAR):

  • Reports Q2 (Sep) earnings of $0.06 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of $0.06; revenues fell 14.1% year/year to $37.2 mln vs the $36.99 mln Capital IQ Consensus.
  • Co issues in-line EPS guidance for Q3, sees EPS of $0.06-0.08, excluding non-recurring items, vs. $0.06 Capital IQ Consensus Estimate; sees upside Q3 revs guidance, sees guidance flat to up 3%, which equates to ~$38.3 mln vs. $37.68 mln Capital IQ Consensus Estimate.
  • Co issues guidance for FY16, sees EPS of $0.30-0.34, excluding non-recurring items, vs. $0.28 Capital IQ Consensus Estimate; sees FY16 revs of $153-156 mln vs. $153.94 mln Capital IQ Consensus Estimate.

4:29 pm Ignite Restaurant beats by $0.05, misses on revs (IRG):

  • Reports Q3 (Sep) earnings of $0.07 per share, $0.05 better than the Capital IQ Consensus of $0.02; revenues fell 4.2% year/year to $133.4 mln vs the $136.37 mln Capital IQ Consensus.

4:28 pm Veracyte beats by $0.01, misses on revs; reaffirms FY15revs guidance (VCYT):

  • Reports Q3 (Sep) loss of $0.32 per share, $0.01 better than the Capital IQ Consensus of ($0.33); revenues rose 25.4% year/year to $12.33 mln vs the $12.57 mln Capital IQ Consensus.
  • Co reaffirms guidance for FY15, sees FY15 revs of $48-53 mln vs. $50.25 mln Capital IQ Consensus Estimate.

4:28 pm Masimo beats by $0.05, beats on revs; raises FY15guidance (MASI):

  • Reports Q3 (Sep) GAAP earnings of $0.36 per share, $0.05 better than the Capital IQ Consensus of $0.31; revenues rose 5.9% year/year to $152.6 mln vs the $149.31 mln Capital IQ Consensus.
  • Co issues upside guidance for FY15, sees EPS of $1.49 from $1.43 vs. $1.43 Capital IQ Consensus; sees FY15 revs $627 mln from $621 mln vs. $622.09 mln Capital IQ Consensus Estimate.

4:28 pm Men's Wearhouse slashes Q3, FY16 EPS guidance well belowestimates (MW):

Men's Wearhouse sees Q3 EPS of $0.46-0.51 vs $0.99 Capital IQConsensus Estimate and FY16 EPS of $1.75-2.00 vs $2.78 CapitalIQ Consensus Estimate

  • The Company is providing an update today to reflect significant comparable sales weakness at Jos. A. Bank. During the third quarter comparable sales decreased 14.6% at Jos. A. Bank, far below the Company's earlier expectations. This decrease was primarily driven by a decline in traffic as the Company began the transition away from the Buy-One-Get-Three promotional events.
  • Fourth quarter comparable sales at Jos. A. Bank are now expected to decrease between 20% and 25% resulting from both a decline in traffic continuing from the third quarter trend and a previously expected decline in units per transaction as customers adapt to the shift in the promotional strategy. The Company expects its legacy retail brands to average a comparable sales increase of 3% to 4%.

4:28 pm Bravio Brio beats by $0.01, reports revs in-line; guidesFY15 EPS in-line, revs below consensus; names new CEO (BBRG):

  • Reports Q3 (Sep) earnings of $0.06 per share, $0.01 better than the Capital IQ Consensus of $0.05; revenues rose 3.9% year/year to $98.3 mln vs the $98.06 mln Capital IQ Consensus.
  • Total comparable restaurant sales decreased 3.5%. Comparable restaurant sales decreased 3.1% at BRAVO! and 3.8% at BRIO.
  • Co issues guidance for FY15, sees EPS of $0.65-0.70 vs. $0.68 Capital IQ Consensus Estimate; sees FY15 revs of $422-424 mln vs. $426.38 mln Capital IQ Consensus Estimate.
  • Promotes Brian O'Malley to CEO and President, effective Dec 28.

4:27 pm Navigators Group beats by $0.03, beats on revs (NAVG):

  • Reports Q3 (Sep) earnings of $1.37 per share, $0.03 better than the Capital IQ Consensus of $1.34; revenues fell 0.4% year/year to $268.2 mln vs the $261 mln two analyst estimate. 
  • Gross written premiums and net written premiums for the three months ended September 30, 2015 were $354.1 million and $251.9 million, respectively, an increase of 8.1% and 10.3% from the comparable period in 2014.

4:26 pm Pixelworks beats by $0.03, misses on revs (PXLW):

  • Reports Q3 (Sep) loss of $0.01 per share, $0.03 better than the Capital IQ Consensus of ($0.04); revenues fell 2.9% year/year to $16.6 mln vs the $17.17 mln Capital IQ Consensus.
  • Gross profit margin was 50.2%, compared to 48.3% in 2Q15 and 50.4% in the year-ago quarter.

4:25 pm Hercules Tech beats by $0.08, beats on revs (HTGC):

  • Reports Q3 (Sep) earnings of $0.33 per share, $0.08 better than the Capital IQ Consensus of $0.25; revenues rose 27.3% year/year to $47.13 mln vs the $39.58 mln Capital IQ Consensus.

4:25 pm ServiceSource Intl beats by $0.04, beats on revs (SREV):

  • Reports Q3 (Sep) adj. loss of $0.02 per share, $0.04 better than the two analyst estimate of ($0.06); adj. revenues fell 8.5% year/year to $59.5 mln vs the $58.65 mln two analyst estimate.

4:25 pm New Relic beats by $0.05, beats on revs; guides Q3 EPSbelow consensus, revs above consensus; acquires Opsmatic; names newCMO (NEWR):

  • Reports Q2 (Sep) loss of $0.17 per share, $0.05 better than the Capital IQ Consensus of ($0.22); revenues rose 69.3% year/year to $42.93 mln vs the $41.2 mln Capital IQ Consensus.
  • Co issues mixed guidance for Q3, sees EPS of ($0.31)-($0.29) vs. ($0.27) Capital IQ Consensus Estimate; sees Q3 revs of $45-46 mln vs. $44.41 mln Capital IQ Consensus Estimate.
  • The co also announced it has acquired Opsmatic, a San Francisco-based startup focused on live-state infrastructure monitoring for modern DevOps teams; terms not disclosed
  • The co further announced that Robson Grieve has joined the company as chief marketing officer. Grieve most recently was senior vice president and chief marketing officer at Citrix ( CTXS )

4:24 pm THL Credit reports EPS in-line (TCRD):

  • Reports Q3 (Sep) earnings of $0.35 per share, in-line with the Capital IQ Consensus of $0.35.
  • Net investment income totaled $11.6 million and $12.2 million, or $0.35 and $0.36 per share based upon 33,506,914 and 33,905,202 weighted average common shares outstanding, respectively, for the three months ended Sept. 30, 2015 and 2014, respectively.
  • The decrease in net investment income for the respective periods is primarily attributable to increased costs associated with borrowings outstanding and accelerated amortization of deferred financing costs related to a recent amendment, which was offset by a favorable income tax benefit compared to the prior quarter.

4:24 pm Raptor Pharma beats by $0.05, beats on revs (RPTP):

  • Reports Q3 (Sep) loss of $0.14 per share, $0.05 better than the single analyst estimate of ($0.19); revenues rose 8.7% year/year to $25.8 mln vs the $24.46 mln Capital IQ Consensus. 

Anticipated Upcoming Milestones

  • 4Q 2015 -- 36-month data from the RP103 Phase 2/3 CYST-HD study in Huntington's disease
  • 4Q 2015 -- Regulatory guidance update regarding the clinical development and regulatory pathway of RP103 in Huntington's disease
  • 1Q 2016 -- Interim Phase 2 data for RP103 (n=12) in mitochondrial diseases
  • 1H 2016 -- QUINSAIR launch in Europe and Canada
  • 1H 2016 -- Regulatory discussions with FDA regarding pathway to approval in CF in the U.S.
  • 2016 -- Initiation of one or more clinical programs for MP-376 in BE and/or lung infections associated with NTM

4:24 pm NVIDIA beats by $0.11, beats on revs; guides Q4 revsabove consensus (NVDA):

  • Reports Q3 (Oct) earnings of $0.46 per share, $0.11 better than the Capital IQ Consensus of $0.35; revenues rose 6.5% year/year to $1.3 bln vs the $1.18 bln Capital IQ Consensus.
  • Co issues upside guidance for Q4, sees Q4 revs of $1.30 bln (+/- 2%) vs. $1.21 bln Capital IQ Consensus Estimate.
  • Announces 18% increase in quarterly dividend to $0.115 from $0.0975 per share.

4:24 pm Demand Media beats by $0.15, misses on revs (DMD):

  • Reports Q3 (Sep) loss of $0.27 per share, $0.15 better than the two analyst estimate of ($0.42); revenues fell 31.0% year/year to $28.5 mln vs the $30.36 mln single analyst estimate.
  • Content & Media revenue declined 53% year-over-year driven primarily by traffic declines to eHow and lower ad monetization yields ... Marketplaces revenue grew 63% year-over-year, driven primarily by new product introductions, increased conversion rates and traffic growth on Society6, as well as increased average revenue per transaction resulting from a shift towards higher priced items on Society6 and the acquisition of Saatchi Art in August 2014.
  • In its Content & Media segment, visits declined 26% y/y to 780,990 and Revenue per Visit declined 36% y/y to $20.33.

4:23 pm Green Dot beats by $0.07, misses on revs (GDOT):

  • Reports Q3 (Sep) earnings of $0.15 per share, $0.07 better than the Capital IQ Consensus of $0.08; revenues fell 0.2% year/year to $146.5 mln vs the $148.11 mln Capital IQ Consensus.
  • "Looking forward, however, we are feeling more optimistic. The MoneyPak related declines have now been stable for a number of months and we're seeing the ecosystem effects now stabilizing, as well. So we believe that, taking into account the new initiatives planned for next year, we expect to have the opportunity to turn the corner and get back to growth as we head into 2017. The new initiatives for next year include, among others, new product offerings in our branded and private label business lines that have the potential to generate higher unit sales and better unit economics, in addition to introducing a new version of our MoneyPak product with enhanced risk controls. We also expect to begin to realize revenue synergies from our TPG acquisition with the deployment of an integrated Green Dot Account/TPG tax refund program distributed through a number of TPG's tax preparation partners in Q1 next year."  

4:23 pm Weight Watchers beats by $0.10, beats on revs; raisesFY15 EPS in-line (WTW):

  • Reports Q3 (Sep) earnings of $0.39 per share, excluding non-recurring items, $0.10 better than the Capital IQ Consensus of $0.29; revenues fell 20.8% year/year to $273.3 mln vs the $266.46 mln Capital IQ Consensus.
  • Co issues raised guidance for FY15, sees EPS of $0.64-0.74 from $0.57-0.72 vs. $0.67 Capital IQ Consensus Estimate.
  • This updated guidance excludes the negative impact of one-time transaction expenses associated with the Company entering into its previously announced partnership with Winfrey and $0.14/share of stock option expense in connection with the Company granting Ms. Winfrey a fully vested option to purchase 3.5 million shares, both of which occurred in Q4 2015.

4:23 pm Constant Contact reports Q3 (Sep) results, misses onrevs (CTCT):

  • Reports Q3 (Sep) GAAP earnings of $0.19 per share, may not be comparable to the Capital IQ Consensus of $0.38; revenues rose 10.1% year/year to $91.9 mln vs the $92.86 mln Capital IQ Consensus.
  • In light of the agreement and plan of merger between Constant Contact and Endurance International Group ( EIGI ) previously announced on November 2, 2015, Constant Contact has cancelled its third quarter results conference call that had been scheduled for Thursday, November 5, 2015 at 5:00 pm ET.

4:23 pm Walt Disney beats by $0.06, reports revs in-line (DIS):

  • Reports Q4 (Sep) earnings of $1.20 per share, $0.06 better than the Capital IQ Consensus of $1.14; revenues rose 9.1% year/year to $13.51 bln vs the $13.52 bln Capital IQ Consensus. 
  • Media Networks revenues for the quarter increased 12% to $5.8 billion, and segment operating income increased 27% to $1.8 billion.
    • Operating income at Broadcasting was essentially flat at $164 million for the quarter
    • Operating income at Cable Networks increased $381 million to $1.7 billion for the quarter due to an increase at ESPN and, to a lesser extent, A&E Television Networks (A & E) and the Disney Channels. The increase at ESPN reflected higher affiliate and advertising revenues, partially offset by an increase in programming costs. Affiliate revenue growth was driven by contractual rate increases and an increase in subscribers. The increase in subscribers was due to a full quarter of the SEC Network, which launched in August 2014, partially offset by a decline in subscribers at certain of our networks . Growth in advertising revenue reflected higher units sold, partially offset by lower ratings.
  • Parks and Resorts revenues for the quarter increased 10% to $4.4 billion, and segment operating income increased 7% to $738 million.
    • Operating income growth for the quarter was due to an increase at our domestic operations, partially offset by a decrease at our international operations.
  • Studio Entertainment revenues for the quarter were relatively flat at $1.8 billion, and segment operating income increased $276 million to $530 million.
    • Operating income growth was due to increased TV/SVOD distribution results, lower film cost impairments, improved theatrical results and a higher revenue share with the Consumer Products segment. These increases were partially offset by lower home entertainment results.

4:22 pm Neustar agrees to acquire MarketShare Partners for $450mln (NSR):

  • Co acquires MarketShare Partners, LLC, marketing analytics technology provider to major brands for $450 mln (~$390 mln after taking into account tax benefits resulting from the transaction).
  • MarketShare is expected to provide positive EBITDA contribution in 2016.
  • The transaction is expected to generate $10-15 mln in cost synergies over the next 18 months.
  • Co expects to fund the acquisition with a combination of cash on hand and $350 mln in committed financing.
  • The transaction is expected to close in 4Q15.

4:22 pm Mitek Systems beats by $0.06, beats on revs (MITK):

  • Reports Q4 (Sep) earnings of $0.09 per share, $0.06 better than the Capital IQ Consensus of $0.03; revenues rose 43.6% year/year to $7.9 mln vs the $6.59 mln Capital IQ Consensus.

4:22 pm Advisory Board beats by $0.19, beats on revs; reaffirmsFY15 guidance; adds $100 mln to repurchase program (ABCO):

  • Reports Q2 (Sep) earnings of $0.33 per share, excluding non-recurring items, $0.19 better than the Capital IQ Consensus of $0.14; revenues rose 38.8% year/year to $200.24 mln vs the $188.52 mln Capital IQ Consensus.
  • Co reaffirms guidance for FY16, sees EPS of $1.30-1.37, may not be comparable to $1.64 Capital IQ Consensus Estimate; sees FY16 adjusted revs of $780-790 mln, may not be comparable to $894.29 mln Capital IQ Consensus Estimate.
  • The Company also announced that its Board of Directors authorized an increase in its share repurchase program of up to an additional $100 million of the Company's common stock, bringing the total amount authorized to be spent under the program to $550 million.

4:21 pm Insulet misses by $0.07, beats on revs; raised lower endof guidance FY15 revs above consensus (PODD):

  • Reports Q3 (Sep) loss of $0.33 per share, $0.07 worse than the Capital IQ Consensus of ($0.26); revenues rose 16.4% year/year to $87.3 mln vs the $83.46 mln Capital IQ Consensus.
    • Co sees YoY revenue growth in all four product lines
  • Co raised lower end of guidance for FY15, sees FY15 revs of $310-320 mln vs. $308.82 mln Capital IQ Consensus Estimate, up from $302-320 mln.

4:21 pm Univ Elec misses by $0.05, misses on revs; guides Q4 EPSin-line, revs in-line (UEIC):

  • Reports Q3 (Sep) earnings of $0.78 per share, excluding non-recurring items, $0.05 worse than the Capital IQ Consensus of $0.83; revenues rose 8.6% year/year to $160.5 mln vs the $167.27 mln Capital IQ Consensus.
  • Co issues in-line guidance for Q4, sees EPS of $0.79-0.89, excluding non-recurring items, vs. $0.84 Capital IQ Consensus Estimate; sees Q4 revs of $159-167 mln vs. $164.84 mln Capital IQ Consensus Estimate.

4:21 pm OUTFRONT Media misses by $0.02, reports revs in-line (OUT):

  • Reports Q3 (Sep) funds from operations of $0.50 per share, excluding non-recurring items, $0.02 worse than the single analyst estimate of $0.52; revenues rose 14.9% year/year to $386.7 mln vs the $386.95 mln Capital IQ Consensus.

4:20 pm Ubiquiti Networks beats by $0.03, reports revs in-line;guides Q2 EPS in-line, revs in-line; launches $50 mln repurchase (UBNT):

  • Reports Q1 (Sep) earnings of $0.51 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of $0.48; revenues rose 0.9% year/year to $151.4 mln vs the $149.9 mln Capital IQ Consensus.
  • Co issues in-line guidance for Q2, sees EPS of $0.49-0.56 vs. $0.50 Capital IQ Consensus Estimate; sees Q2 revs of $150-160 mln vs. $156.25 mln Capital IQ Consensus Estimate.
  • Initiated a new stock repurchase program, authorizing the Company to repurchase up to $50 million of its common stock

4:20 pm ChannelAdvisor appoints Richard Cornetta as ChiefAccounting Officer (ECOM): The co announced the promotion of Richard Cornetta to vicepresident of finance and chief accounting officer. Cornetta willreport to CFO Mark Cook. Prior to ChannelAdvisor, Cornetta servedas director of financial reporting and accounting at Dex Media,Inc., a public company providing local marketing solutions

4:20 pm Tangoe misses by $0.07, misses on revs; guides Q4 EPSbelow consensus, revs below consensus (TNGO):

  • Reports Q3 (Sep) earnings of $0.04 per share, $0.07 worse than the Capital IQ Consensus of $0.11; revenues rose 3.9% year/year to $56.6 mln vs the $58.43 mln Capital IQ Consensus.
  • The company generated $2.4 mln in net cash from operations for 3Q15, compared to $6.3 mln during 3Q14. The company generated $1.5 mln in unlevered free cash flow for the quarter, compared to $5.6 mln during 3Q14.
  • Co issues downside guidance for Q4, sees EPS of $0.03-$0.04 vs. $0.17 Capital IQ Consensus Estimate; sees Q4 revs of $55.5-$56.8 mln vs. $61.76 mln Capital IQ Consensus Estimate.

4:20 pm Tremor Video misses by $0.04, misses on revs; reaffirmsFY15 revs guidance (TRMR):

  • Reports Q3 (Sep) loss of $0.11 per share, excluding non-recurring items, $0.04 worse than the Capital IQ Consensus of ($0.07); revenues rose 26.2% year/year to $49.27 mln vs the $50.96 mln Capital IQ Consensus.
    • Excluded item was ($0.44) per share in non-cash impairment charges
  • Adjusted EBITDA was ($1.5) million compared to Adjusted EBITDA of ($2.3) million for the same period one year ago.
  • Gross margin was 35.7% compared to 38.4% for the same period one year ago.
  • Co reaffirms guidance for FY15, sees FY15 revs of $195-200 mln vs. $197.15 mln Capital IQ Consensus Estimate. Co sees FY15 adjusted EBITDA of ($7.0)-(5.0) mln

4:20 pm Molina Healthcare announces pricing of upsized offeringof $700 mln of senior notes due 2022 (MOH): The offering size was increased to $700 mln from the previouslyannounced $500 mln. The Notes will bear interest at the rateof 5.375% per year. The Company intends to use the net proceeds ofthis offering for general corporate purposes

4:19 pm OXiGENE reports initial data from a Phase 1b/2 study ofCA4P in combination with Votrient; results are 'encouraging and weexpect to move into the phase 2 portion of the study in early 2016'(OXGN):

Co announced initial data from a Phase 1b/2 study of co's leadinvestigational drug, CA4P, in combination with the anti-angiogenicagent Votrient in patients with advanced recurrent ovariancancer.

  • Eight of the ten patients with evaluable data demonstrated decreases in the tumor marker CA125, with three achieving a response according to CGIC criteria.
  • Safety data showed that the combination of CA4P and pazopanib was generally well tolerated with no Grade 4-5 adverse events (AEs).

4:19 pm Arista Networks beats by $0.06, beats on revs; guides Q4revs above consensus (ANET):

  • Reports Q3 (Sep) earnings of $0.59 per share, excluding non-recurring items, $0.06 better than the Capital IQ Consensus of $0.53; revenues rose 39.9% year/year to $217.5 mln vs the $211.31 mln Capital IQ Consensus.
  • Co issues upside guidance for Q4, sees Q4 revs of $238-242 mln vs. $229.32 mln Capital IQ Consensus Estimate; sees non-GAAP gross margin between 62-65%, and non-GAAP operating margin of approximately 26%.

4:19 pm SemGroup reports Q3 (Sep) results, misses on revs (SEMG):

  • Reports Q3 (Sep) earnings of $0.11 per share, may not be comparable to the two analyst estimate of $0.47; revenues fell 33.2% year/year to $397.1 mln vs the $441.34 mln Capital IQ Consensus.
  • Co guides 2015 adj EBITDA to $305-315 mln from prior guidance of $320-360 mln.

4:19 pm WEX announces that Roberto Simon will be appointed CFOon or about February 26 (WEX):

The co announced that Roberto Simon will be appointed CFO, on orabout February 26, 2016. Steve Elder, WEX's current CFO, willremain with WEX to assume the newly created position of senior VP,investor relations.

  • Simon joins WEX from Revlon ( REV ), where he most recently served as executive VP and CFO

4:19 pm Infinity Pharmaceutical beats ests including milestonepayment from Abbvie (ABBV); reaffirms FY15 rev (INFI):

  • Reports Q3 (Sep) earnings of $0.84 per share, $1.75 better than the Capital IQ Consensus of ($0.91); revenues fell 43.5% year/year to $90.7 mln vs the $28.71 mln Capital IQ Consensus.
  • Co issues in-line guidance for FY15, sees FY15 revs of $100-120 mln vs. $112.42 mln Capital IQ Consensus Estimate. 
  • In September, Infinity announced it had reached target enrollment in DYNAMO, a global, Phase 2 open-label, single-arm, monotherapy study of duvelisib (25 mg BID) in approximately 120 patients with iNHL whose disease is refractory to rituximab and to either chemotherapy or radioimmunotherapy. The primary endpoint is overall response rate. Topline data from the study are anticipated in the third quarter of 2016. The enrollment milestone triggered a $130 million milestone payment from AbbVie .
  • Infinity Receives FDA Fast Track Designation for Duvelisib for Follicular Lymphoma in Patients Who Have Received at Least Two Prior Therapies
  • DUO Study On-Track for Enrollment Completion By Year End
  • Three Clinical Studies with Duvelisib Expected to Initiate by Year End
  • Preclinical Data and Data from Investigator-Sponsored Studies of Duvelisib to Be Presented at ASH

4:19 pm Ruby Tuesday enters into an agreement with Rubio'sRestaurants, to sell eight corporate-owned Lime Fresh Mexican Grilllocations in Florida for ~$6.3 mln (RT):

Co announced that it has entered into an agreement with Rubio'sRestaurants, Inc. to sell eight corporate-owned Lime Fresh MexicanGrill locations in Florida for approximately $6.3 million.

  • In addition, the Company will close its 11 remaining corporate-owned Lime Fresh Mexican Grill restaurants immediately and maintain its eight franchised locations. All 19 corporate-owned restaurants are leased locations. The completion of the transaction is targeted for January of 2016

4:19 pm Corcept Therapeutics beats by $0.01, misses on revs;reaffirms FY15 revs in-line (CORT):

  • Reports Q3 (Sep) loss of $0.01 per share, $0.01 better than the Capital IQ Consensus of ($0.02); revenues rose 82.2% year/year to $13.3 mln vs the $13.9 mln Capital IQ Consensus.
  • Co reaffirms guidance for FY15, sees FY15 revs of $49-53 mln vs. $52.05 mln Capital IQ Consensus Estimate.

4:18 pm KMG Chemicals updates status of form 10-k filing; filingwill be made as promptly as practicable (KMG): Co expects to regain compliance with all New York Stock Exchangelisting requirements following the filing of the 10-K.

4:18 pm Alexander & Baldwin misses by $0.09, misses on revs(ALEX):

  • Reports Q3 (Sep) earnings of $0.11 per share, excluding non-recurring items, $0.09 worse than the Capital IQ Consensus of $0.20; revenues fell 5.7% year/year to $144.7 mln vs the $169.15 mln two analyst estimate.

4:18 pm Torchlight Energy Resources agrees to sell certain ofits Hunton Assets to Husky Ventures, for $4.6 mln (TRCH):

Co to sell certain assets in one of its six AMI's withHusky.

  • The terms of the agreement call for a sale price of ~$4.6 mln, which would net the company ~$1.4 mln after paying off the operator payable and the fees and expenses relating to the transaction.
  • The closing is set for November 30 and is part of the previously announced transaction between Gastar and Husky.

4:18 pm TCP International announces delay in reporting thirdquarter 2015 financial results; due to a pending Audit Committeeinvestigation; offers prelim Q3 results (TCPI):

  • Preliminary financial results for the third quarter 2015 are expected to include revenues within the range of $89 million to $91 million (vs. $118.5 mln consensus), with diluted earnings per share within the range of $0.00 to $0.03 per share (versus a $0.04 consensus).
  • Revenue decreased in the quarter, compared with the third quarter of 2014, due to lower sales of both CFL and LED products primarily due to lower demand in North America and Asia.

4:17 pm Air Lease misses by $0.01, beats on revs (AL):

  • Reports Q3 (Sep) earnings of $0.71 per share, $0.01 worse than the Capital IQ Consensus of $0.72; revenues rose 19.5% year/year to $313 mln vs the $309.29 mln Capital IQ Consensus.
  • "Continued positive global passenger traffic trends have generated robust demand for aircraft in our order book and maintained the values of our used aircraft. This year to date, ALC has added 17 new customers and signed 67 lease agreements. Airline customer demand for both the modern narrowbody and widebody aircraft in our fleet remains healthy and we see stability in the market for aircraft pricing as evidenced by our aircraft sales to date and what we see in our forward deal pipeline."

4:17 pm Mohawk misses by $0.01, misses on revs; guides Q4 EPSbelow consensus (MHK):

  • Reports Q3 (Sep) earnings of $2.98 per share, $0.01 worse than the Capital IQ Consensus of $2.99; revenues rose 8.0% year/year to $2.15 bln vs the $2.19 bln Capital IQ Consensus.
  • Co states: "..Looking to the fourth quarter, we anticipate that the U.S. economy will continue its gradual growth. We expect year-over-year margin growth to continue in all segments as a result of our strategies and acquisitions. We are selectively increasing our SG&A relative to sales to optimize future market share. Our recent acquisitions are being integrated into our businesses and are positively impacting our earnings. The costs associated with new plant start-ups, interruption of our board production and four fewer days will be absorbed in the period.."
  • Co issues downside guidance for Q4, sees EPS of $2.66-$2.75 vs. $2.75 Capital IQ Consensus Estimate.

4:17 pm TearLab reports EPS in-line, beats on revs; names COOSeph Jensen as CEO (TEAR):

  • Reports Q3 (Sep) loss of $0.24 per share, in-line with the Capital IQ Consensus of ($0.24); revenues rose 26.9% year/year to $6.6 mln vs the $6.22 mln Capital IQ Consensus.
  • A net total of 228 TearLab systems were added in the third quarter, of which 239 were under the Company's new Flex program and 68 were purchased outside of the U.S., offset partially by a reduction in the number of the Company's Use contracts.
  • TearLab also announced that its President and Chief Operating Officer, Seph Jensen, will succeed Mr. Vamvakas as Chief Executive Officer, effective January 1, 2016. At that time, Mr. Vamvakas will become Executive Chairman of the Company, continuing to be active with the business by providing counsel and support to Mr. Jensen, particularly in the areas of corporate strategy and finance, and leading the Company's Board of Directors.

4:17 pm HC2 reports expecting to receive an $8.2 mln dividendfrom its subsidiary, Schuff International (HCHC):

  • On November 4, 2015, Schuff announced it will pay a dividend of $2.34 per share on December 1, 2015 to stockholders of record at the close of business on November 16, 2015

4:17 pm Glu Mobile enters into additional exclusive partnershipagreements with a number of new male and female celebrities (GLUU): Taking into account these new partnerships, together with Glu'spreviously announced partnerships with Katy Perry, Kim KardashianWest, Kendall and Kylie Jenner, Britney Spears, Nicki Minaj, andJason Statham, Glu will now be developing games featuringcelebrities whose combined social media audience exceeds 1 billionfollowers. Glu anticipates titles featuring these celebritiessupported by more than one billionfollowers to launch between the fourth quarter of 2015 and the endof 2017.

4:16 pm Orexigen Therapeutics beats by $0.07 (OREX):

  • Reports Q3 (Sep) loss of $0.09 per share, $0.07 better than the Capital IQ Consensus of ($0.16); revenues fell 67.7% year/year to $9.97 mln vs the $12.17 mln Capital IQ Consensus.
  • According to IMS Health, 190,201 prescriptions of Contrave (naltrexone HCl and bupropion HCl extended-release tablets) were filled in the third quarter 2015, an increase of 10% compared to the second quarter.
  • As of September 30, 2015, Orexigen had $154.3 million in cash and cash equivalents and an additional $79.2 million in marketable securities, for a total of $233.4 million.

4:16 pm BioSpecifics Tech reports that Endo International (ENDP) has exercised its early opt-in for CCH to include two newpotential indications; lateral thigh fat and plantar fibromatosis (BSTC):

Co announces that its partner Endo International plc (ENDP) has exercised an early opt-in for CCH to include two newpotential indications, lateral thigh fat and plantarfibromatosis.

  • Co will receive a $0.5 mln opt-in fee for each indication.

4:16 pm Stein Mart announced President and Chief MerchandisingOfficer, Brian R. Morrow, resigned to accept a position at anothercompany; initiated a search for a new chief merchandising officer (SMRT):  

4:15 pm Cornerstone OnDemand misses by $0.02, misses on revs (CSOD):

  • Reports Q3 (Sep) loss of $0.05 per share, $0.02 worse than the Capital IQ Consensus of ($0.03); revenues rose 28.0% year/year to $87.4 mln vs the $88.37 mln Capital IQ Consensus.
  • Bookings rose 26% yr/yr to $103.7 mln.

4:15 pm Cerus misses by $0.01, misses on revs (CERS):

  • Reports Q3 (Sep) loss of $0.17 per share, $0.01 worse than the Capital IQ Consensus of ($0.16); revenues fell 22.4% year/year to $8.04 mln vs the $9.92 mln Capital IQ Consensus.
  • Co said, "Based on unexpectedly strong headwinds in Russia, and more broadly, in the Commonwealth of Independent States (:CIS) region, in the second half of 2015, we now expect 2015 annual revenue for our core European and Middle Eastern markets to be in the range of $34 to $36 million."

4:15 pm Bridgepoint Education beats by $0.07, beats on revs (BPI):

  • Reports Q3 (Sep) earnings of $0.13 per share, excluding non-recurring items, $0.07 better than the Capital IQ Consensus of $0.06; revenues fell 13.5% year/year to $140.8 mln vs the $139.18 mln Capital IQ Consensus.

Student Enrollment:

  • Total student enrollment at Bridgepoint Education's academic institutions, Ashford University and University of the Rockies, was 49,982 students at September 30, 2015, compared with 59,552 students at September 30, 2014.
  • For the third quarter of 2015, the twelve-month retention for all Ashford students who were active on the last day of the third quarter of 2014 was 60.1%.
  • For the third quarter of 2014, the twelve-month retention for all Ashford students who were active on the last day of the third quarter of 2013 was 65.8%.

4:15 pm ACADIA Pharmaceuticals beats by $0.01 (ACAD):

  • Reports Q3 (Sep) loss of $0.39 per share, $0.01 better than the Capital IQ Consensus of ($0.40); revenues rose 160.0% year/year to $0.04 mln vs the $0.05 mln Capital IQ Consensus.
  • "Our third quarter was highlighted by the September submission to the FDA of our New Drug Application for the use of NUPLAZID in the treatment of Parkinson's disease psychosis, a condition for which there is no FDA-approved therapy. We're pleased by the FDA's recent decision to grant Priority Review status to our NUPLAZID application, resulting in a projected accelerated timeline for review and an FDA goal of May 1, 2016 for taking action under the Prescription Drug User Fee Act, or PDUFA. We continue to advance our preparations for the planned commercial launch of NUPLAZID in the United States and to lay the foundation for additional development with pimavanserin in other areas of significant unmet medical need."

4:15 pm The Children's Place enters into a franchise agreementwith El Palacio de Hierro to open free-standing stores and shop inshops in Mexico, with the potential to open 35 locations over time,beginning this month (PLCE): The co announced that it has entered into a franchise agreementwith El Palacio de Hierro to open free-standing stores and shop inshops in Mexico, with the potential to open 35 locations over time,beginning this month

4:15 pm Pericom Semi: Montage Technology Group Limited files aninvestor presentation with the SEC relating to its offer to acquirePericom; underscores financing certainty and lack of regulatoryrisk (PSEM):  

4:14 pm Merchants Bancsh. and NUVO Bank & Trust Companyannounce receipt of all regulatory and shareholder approvals formerger; transaction closure expected on/about Dec. 4, 2015 (MBVT):  

4:13 pm Boingo Wireless beats by $0.05, beats on revs; guidesFY15 EPS below consensus, revs in-line (WIFI):

  • Reports Q3 (Sep) loss of $0.13 per share, $0.05 better than the Capital IQ Consensus of ($0.18); revenues rose 20.8% year/year to $37.2 mln vs the $35.97 mln Capital IQ Consensus.
    • Connects were 27.8 mln, an increase of 26.9% compared to 21.9 mln in the third quarter of 2014
    • Retail subscribers were 212,000, a decrease of 24.0% compared to 279,000 in the third quarter of 2014.
    • Military subscribers were 46,000 compared to 7,000 in the third quarter of 2014.
  • Co issues guidance for FY15, sees EPS of ($0.77)-($0.69) vs. ($0.68) Capital IQ Consensus Estimate; sees FY15 revs of $136-141 mln vs. $140.42 mln Capital IQ Consensus Estimate.

4:13 pm Clean Energy Fuels beats by $0.05, misses on revs (CLNE):

  • Reports Q3 (Sep) loss of $0.23 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus of ($0.28); revenues fell 10.7% year/year to $92.3 mln vs the $93.97 mln Capital IQ Consensus.
    • Gallons delivered for the third quarter of 2015 increased 17% to 80.6 mln gallons, compared to 68.6 mln gallons delivered in the same period a year ago. Gallons delivered for the nine months ended September 30, 2015 increased 19% to 230.2 mln gallons, compared to 192.7 mln gallons delivered in the same period a year ago.

4:13 pm Esperion Therapeutics reports Q3 results and providesETC-1002 development program update (ESPR):

  • Co reports Q3 EPS of ($0.57) vs ($0.60) Capital IQ Consensus estimate. Esperion expects that the net cash used to fund operating activities in 2015 will be ~$42 million and that its cash and cash equivalents and investment securities available-for-sale will total ~$290 million at December 31, 2015. The Company estimates that current cash resources are sufficient to fund the Company through at least the end of 2018 and the potential approval of ETC-1002.
  • Upcoming Milestones
    • December 2015: Initiation of the Phase 2 ETC-1002-035 clinical study evaluating ETC-1002 in combination with high-dose statins ( HDS ); Initiation of the Phase 3 ETC-1002-040 long-term safety study evaluating ETC-1002 compared to placebo in patients on background statin therapy.
    • 1H 2016: File Investigational New Drug Application ( IND ) for the fixed dose combination of ETC-1002 and ezetimibe; Announce Phase 3 worldwide development plans for ETC-1002.
    • Mid-2016: Announce top-line results from the Phase 2 ETC-1002-035 clinical study evaluating ETC-1002 in combination with high-dose statins ( HDS ); Initiation of the Phase 3 efficacy study of ETC-1002 in patients with statin intolerance.
    • 2H 2016: Initiation of the Phase 3 cardiovascular outcomes study for ETC-1002.

4:13 pm Varonis Systems beats by $0.07, beats on revs; guides Q4EPS in-line, revs in-line (VRNS):

  • Reports Q3 (Sep) loss of $0.10 per share, $0.07 better than the Capital IQ Consensus of ($0.17); revenues rose 22.1% year/year to $31.2 mln vs the $30.5 mln Capital IQ Consensus.
  • Total revenues in the United States increased 17% over the prior-year period to $17.7 mln, total revenues from EMEA increased 29% over the prior-year period to $11.0 mln, and total revenues from Rest of World increased 31% over the prior-year period to $2.5 mln.
  • Generated 63% of license and first year maintenance revenues from new customers and 37% from existing customers in 3Q15, compared to 64% and 36%, respectively, in the prior-year period.
  • Added 241 new customers during 3Q15 compared with 223 in the prior-year period.
  • Co issues in-line guidance for Q4, sees EPS of $0.13-$0.16 vs. $0.16 Capital IQ Consensus Estimate; sees Q4 revs of $40.6-$43.3 mln vs. $41.84 mln Capital IQ Consensus Estimate.

4:13 pm Diodes authorizes a $100 mln stock repurchase program (DIOD):  

4:13 pm Shake Shack beats by $0.05, beats on revs; guides FY15revs above consensus; guides FY16 revs above consensus (SHAK):

  • Reports Q3 (Sep) earnings of $0.12 per share, $0.05 better than the Capital IQ Consensus of $0.07; revenues rose 67.5% year/year to $53.3 mln vs the $47.27 mln Capital IQ Consensus.
    • Same Shak Sales- Q3 17.1%; Q2 12.9%;
    • Operating Profit- Q3 30.4%; Q2 30.3%; Q1 25.7%.
    • Food & Paper Costs- Q3 29.1%; Q2 29.4%; Q1 30.5%.
    • Labor & Related Costs- Q3 23.7%; Q2 24.0%; Q1 25.2%. 
  • Co issues upside guidance for FY15, sees FY15 revs of $189-190 mln vs. $180.33 mln Capital IQ Consensus Estimate (Prior $171-174 mln)
    • SHAK increased it's Same-Shack sales growth of 11-12% (Prior mid- to high-single digits).
    • SHAK new domestic company-operated Shacks to be opened in 2015 to 12 (Reaffirm).
  • Co issues upside guidance for FY16, sees FY16 revs of $237-242 mln vs. $228.01 mln Capital IQ Consensus Estimate.
    • Sees Same Shak Sales Growth of 2.5-3.0%.

4:13 pm Qorvo beats by $0.11, beats on revs; guides Q4 EPS aboveconsensus, revs below consensus; announces $1 bln repurchase (QRVO):

  • Reports Q3 (Sep) earnings of $1.22 per share, excluding non-recurring items, $0.11 better than the Capital IQ Consensus of $1.11; revenues rose 11.6% year/year to $707.4 mln vs the $699.4 mln Capital IQ Consensus.
  • Co issues mixed guidance for Q4, sees EPS of $1.25-1.30 vs. $1.25 Capital IQ Consensus Estimate; sees Q4 revs of $720-730 mln vs. $738.68 mln Capital IQ Consensus Estimate.
  • Qorvo also announced that its Board of Directors has authorized a new one-year $1 billion share repurchase program.

4:12 pm Mettler-Toledo beats by $0.08, beats on revs; guides Q4EPS in-line; guides FY16 EPS in-line; board authorizes additional$1.5 bln stock repurchase program (MTD):

  • Reports Q3 (Sep) adj earnings of $3.26 per share, $0.08 better than the Capital IQ Consensus of $3.18; revenues fell 4.0% year/year to $604.2 mln vs the $596.08 mln Capital IQ Consensus.
  • Co issues in-line guidance for Q4, sees adj EPS of $4.58-4.63 vs. $4.62 Capital IQ Consensus Estimate.
  • Co issues in-line guidance for FY16, sees adj EPS of $14.10-14.30 vs. $14.24 Capital IQ Consensus Estimate.

4:12 pm Dreamworks Animation beats by $0.06, beats on revs (DWA):

  • Reports Q3 (Sep) earnings of $0.02 per share, excluding non-recurring items, $0.06 better than the Capital IQ Consensus of ($0.04); revenues rose 43.3% year/year to $259.2 mln vs the $206.72 mln Capital IQ Consensus.

4:12 pm Monster Beverage beats by $0.03, beats on revs (MNST):

  • Reports Q3 (Sep) earnings of $0.84 per share, $0.03 better than the Capital IQ Consensus of $0.81; revenues rose 19.0% year/year to $756.6 mln vs the $731.44 mln Capital IQ Consensus.
  • Gross and net sales for the three-months ended September 30, 2015 were impacted by advance purchases made by customers due to a pre-announced price increase effective August 31, 2015 on certain Monster Energy brand energy drinks. 

4:12 pm PharMerica completes the acquisition of Luker PharmacyManagement; terms not disclosed (PMC): Luker provides comprehensive pharmacy management services tohospitals and other healthcare facilities, primarily in Texas

4:11 pm Financial Engines beats by $0.01, reports revs in-line;lowers FY15 revs guidance; guides FY16 revs above consensus;acquires The Mutual Fund Store for $560 mln (FNGN):

  • Reports Q3 (Sep) earnings of $0.24 per share, $0.01 better than the Capital IQ Consensus of $0.23; revenues rose 8.3% year/year to $78.81 mln vs the $79.42 mln Capital IQ Consensus.
  • Co issues in-line guidance for FY15, sees FY15 revs of $311-313 mln vs. $312.52 mln Capital IQ Consensus Estimate.
  • Co issues upside guidance for FY16, sees FY16 revs of $4.03-410 mln vs. $351.58 mln Capital IQ Consensus Estimate.
  • Co issues in-line guidance for FY15, sees FY15 revs of $311-313 mln vs. $312.52 mln Capital IQ Consensus Estimate. For the company, post-acquisition, based on financial markets remaining at November 2, 2015 levels, through all of 2016, and taking into account an anticipated closing of the acquisition of The Mutual Fund Store in the first quarter of 2016, Financial Engines estimates its 2016 revenue will be in the range of $403 million and $410 million and 2016 non-GAAP adjusted EBITDA will be in the range of $125 million to $130 million. Under typical market conditions, Financial Engines estimates that 2016 revenue will be in the range of $419 million to $426 million and non-GAAP adjusted EBITDA will be in the range of $137 million to $142 million. We expect to realize financial synergies from the combination over time.
  • The co also announced that it has signed a definitive agreement to acquire The Mutual Fund Store, L.L.C., a nationally-branded independent Registered Investment Adviser, from Warburg Pincus and management for total consideration of approximately $560 million, including cash and stock. The total transaction purchase consideration includes approximately $250 million in cash and 10 million shares of Financial Engines common stock. The combined company will be debt free following the transaction.
  • The transaction is expected to produce 2016 earnings per share accretion of approximately 25%, assuming the transaction closes late in the first quarter of 2016, and to increase the longer-term growth rate of the combined company. Based on the terms of the transaction, Warburg Pincus is expected to become Financial Engines' largest stockholder with a beneficial ownership of approximately 12.5% following the closing of the transaction and Michael Martin, managing director of Warburg Pincus, will be appointed to Financial Engines' board of directors upon closing.

4:11 pm Take-Two beats by $0.15, beats on revs; guides Q3 EPSin-line, revs in-line; guides FY16 EPS in-line, revs in-line (TTWO):

  • Reports Q2 (Sep) earnings of $0.30 per share, excluding non-recurring items, $0.15 better than the Capital IQ Consensus of $0.15; revenues rose 174.7% year/year to $347 mln vs the $324.63 mln Capital IQ Consensus.
  • Co issues in-line guidance for Q3, sees EPS of $0.40-0.50, excluding non-recurring items, vs. $0.45 Capital IQ Consensus Estimate; sees Q3 revs of $400-450 mln vs. $443.25 mln Capital IQ Consensus Estimate.
  • Co issues in-line guidance for FY16, sees EPS of $1.00-1.15, excluding non-recurring items, vs. $1.02 Capital IQ Consensus Estimate; sees FY16 revs of $1.33-1.43 bln vs. $1.42 bln Capital IQ Consensus Estimate.

4:11 pm TripAdvisor misses by $0.02, misses on revs (TRIP):

  • Reports Q3 (Sep) earnings of $0.53 per share, excluding non-recurring items, $0.02 worse than the Capital IQ Consensus of $0.55; revenues rose 17.2% year/year to $415 mln vs the $428.89 mln Capital IQ Consensus.

4:10 pm Varonis Systems beats by $0.07, beats on revs; guides Q4EPS in-line, revs in-line (VRNS):

  • Reports Q3 (Sep) loss of $0.10 per share, excluding non-recurring items, $0.07 better than the Capital IQ Consensus of ($0.17); revenues rose 22.1% year/year to $31.2 mln vs the $30.5 mln Capital IQ Consensus.
  • Co issues in-line guidance for Q4, sees EPS of $0.13-0.16 vs. $0.16 Capital IQ Consensus Estimate; sees Q4 revs of $40.6-43.3 mln vs. $41.84 mln Capital IQ Consensus Estimate.

4:10 pm TrueCar beats by $0.02, beats on revs; guides Q4 revsin-line (TRUE):

  • Reports Q3 (Sep) loss of $0.03 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of ($0.05); revenues rose 27.5% year/year to $72.4 mln vs the $66.18 mln Capital IQ Consensus.
  • Co issues in-line guidance for Q4, sees Q4 revs of $64.0-65.5 mln vs. $64.28 mln Capital IQ Consensus Estimate. Adjusted EBITDA is expected to be $0.5 million to $1 million.
  • Average monthly unique visitors increased 43% to a record 6.6 million in Q3, up from ~4.6 million in the third quarter of 2014.

4:10 pm Kraft Heinz increases its quarterly dividend to 4.5% to$0.575/share, from $0.55/share Q/Q (KHC):  

4:10 pm Atara Biotherapeutics reports Q3 EPS of ($0.43) vs($0.56) Capital IQ Consensus estimate (ATRA): As of September 30, 2015, the company had $334.3 million in cashand cash equivalents and short-term available-for-saleinvestments.

4:09 pm Achillion Pharma beats by $0.15, beats on revs; guidesFY15 EPS above consensus, reaffirms FY15 revs guidance (ACHN):

  • Reports Q3 (Sep) GAAP earnings of $0.19 per share, $0.15 better than the Capital IQ Consensus of $0.04. Revs $33.82 mln vs $32.62 mln consensus
  • At September 30, 2015, Achillion had cash, cash equivalents, marketable securities, and interest receivable of $476 million
  • Co issues guidance for FY15, sees EPS of ($0.10)-(0.08) vs. ($0.39) Capital IQ Consensus Estimate; sees FY15 revs of ~$66 mln vs. $65.97 mln Capital IQ Consensus Estimate. Net cash used in operating activities in 2015 is expected to be approximately $60 - 65 million, exclusive of the $66 million in revenue associated with the JJDC premium, based on current operating plans, timelines and costs, as compared to previous guidance of $100 - $110 million.

4:09 pm Callidus Software reports EPS in-line, beats on revs;guides Q4 EPS in-line, revs above consensus; guides FY16 revs aboveconsensus (CALD):

  • Reports Q3 (Sep) earnings of $0.06 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of $0.06; revenues rose 28.4% year/year to $44.94 mln vs the $42.59 mln Capital IQ Consensus.
  • Co issues guidance for Q4, sees EPS of $0.06-0.09, excluding non-recurring items, vs. $0.07 Capital IQ Consensus Estimate; sees Q4 revs of $46-47 mln vs. $44.45 mln Capital IQ Consensus Estimate.
  • Co issues upside guidance for FY16, sees FY16 revs of $210-215 mln vs. $195.5 mln Capital IQ Consensus Estimate.

4:09 pm RE/MAX Holdings beats by $0.06, beats on revs; guides Q4revs below consensus, Raises FY15 Adjusted EBITDA margin guidance (RMAX):

  • Reports Q3 (Sep) earnings of $0.46 per share, $0.06 better than the Capital IQ Consensus of $0.40; revenues rose 2.0% year/year to $45.1 mln vs the $43.91 mln Capital IQ Consensus.
  • Total agent count grew by 5,844 agents to 103,491 agents or 6.0% compared to the third quarter ended September 30, 2014. 
  • Adjusted EBITDA margin was 55.7%, up from 52.8%
  • Co issues downside guidance for Q4, sees Q4 revs decreasing 4.5-5.0% year/year, equating to revs of approximately $40.4-$40.7 vs. $42.07 mln Capital IQ Consensus Estimate. Sees Q4 Adjusted EBITDA margin in the 48.0% to 49.0% range.

    For FY15, RMAX is raising its agent count outlook to 5.6% to 5.8% from 5.0% to 5.5% over 2014. Revenue is estimated to increase by 1.0% to 2.0% over 2014 (trending to the high end). RMAX increases  Adjusted EBITDA margin estimate to 50.0% to 51.0% from 49.0% to 50.0%.

4:09 pm Cardica hires Thomas Palermo as COO, effective November16, 2015 (CRDC): Most recently, Palermo served as acting CEO of UlceRxMedical, a start-up chronic wound care company. Prior to UlceRx, Palermo was president and CEO of ReVascular Therapeutics(acquired by Boston Scientific in 2011)

4:09 pm Air Methods beats by $0.19, beats on revs (AIRM):

  • Reports Q3 (Sep) earnings of $1.16 per share, $0.19 better than the Capital IQ Consensus of $0.97; revenues rose 12.4% year/year to $311.3 mln vs the $289.56 mln Capital IQ Consensus.
  • The Company also provided an update on preliminary October 2015 flight volume. Total community-based transports increased 12.3% to 5,840 during October 2015, compared with 5,199 in October 2014. October 2015 Same-Base Transports increased by 20 transports as compared with October 2014. Weather cancellations during October 2015 for these same bases increased by 193 compared with the prior-year month.

4:09 pm ICU Medical beats by $0.19, beats on revs; guides FY15EPS above consensus, revs above consensus (ICUI):

  • Reports Q3 (Sep) earnings of $1.00 per share, excluding non-recurring items, $0.19 better than the Capital IQ Consensus of $0.81; revenues rose 11.0% year/year to $86 mln vs the $81.14 mln Capital IQ Consensus.
  • Co issues upside guidance for FY15, sees EPS of $3.88-3.96 vs. $3.47 Capital IQ Consensus Estimate; sees FY15 revs of $335-340 mln vs. $329.02 mln Capital IQ Consensus Estimate.
  • Sees FY15 adjusted EBITDA of $110-112 mln vs prior range of $100-105 mln.

4:08 pm Cyber-Ark Software beats by $0.13, beats on revs; guidesQ4 above consensus (CYBR):

  • Reports Q3 (Sep) earnings of $0.26 per share, excluding non-recurring items, $0.13 better than the Capital IQ Consensus of $0.13; revenues rose 43.2% year/year to $40.1 mln vs the $37.12 mln Capital IQ Consensus; license rev +49%.
  • Co issues upside guidance for Q4, sees EPS of $0.18-0.20, excluding non-recurring items, vs. $0.17 Capital IQ Consensus Estimate; sees Q4 revs of $43-44 mln vs. $42.00 mln Capital IQ Consensus Estimate.

4:08 pm Wingstop beats by $0.02, beats on revs; guides FY15 revsabove consensus (WING):

  • Reports Q3 (Sep) earnings of $0.11 per share, $0.02 better than the Capital IQ Consensus of $0.09; revenues rose 16.5% year/year to $19.1 mln vs the $18.62 mln Capital IQ Consensus. Domestic same store sales increased 6.3%.
  • Co issues  guidance for FY15, sees FY15 revs of $76.8-77.2 mln vs. $76.46 mln Capital IQ Consensus Estimate.
    • Sees 125-130 net system-wide franchise restaurant openings
    • Domestic same store sales increase of between 7.25% to 7.50%

4:08 pm Bravio Brio appoints Brian O'Malley as CEO andPresident, effective December 28, 2015 (BBRG): O'Malley currently serves as Co's President and COO.

4:08 pm Closing Market Summary: Stocks Slip Ahead of OctoberEmployment Report (:WRAPX):

The major averages registered their second consecutive declineon Thursday with the S&P 500 shedding 0.1% while the NasdaqComposite (-0.3%) underperformed.

Broadly speaking, the Thursday affair was fairly quiet, but thatwas not particularly surprising considering Friday morning willfeature the release of the Employment Situation report for October.The Briefing.com consensus expects the report to reveal theaddition of 181,000 payrolls while hourly earnings are expected tohave increased 0.2% in October.

Tomorrow's report could lead to volatility in the market, makingtoday's reluctance among investors to push the market in eitherdirection rather understandable. The S&P 500 is set to enterthe Friday session with a week-to-date gain of 1.0% while theNasdaq is higher by 1.5% for the week despite today'sunderperformance.

Biotechnology was largely responsible for today's relativeweakness in the tech-heavy Nasdaq. Valeant Pharmaceuticals(VRX 78.77, -13.21) was in focus once again as the stock dove 14.4%amid continued concerns about the company's revenue recognitionpractices. However, biotech's woes were not isolated to Valeant as GileadSciences(GILD 107.83, -1.15) lost 1.1% while Celgene(CELG 120.46, -6.71) dove 5.3% after reporting a one-cent beat onbelow-consensus revenue. For its part, the broader iSharesNasdaqBiotechnologyETF(IBB 331.16, -6.47) lost 1.9% while the health care sectorsurrendered 0.4% after being down more than 1.0% in the earlygoing.

Similar to health care, influential sectors like energy (-1.0%)and technology (-0.3%) also finished among the laggards. The energysector narrowed its week-to-date gain to 2.9% amid a decline incrude oil. To that point, WTI crude fell 2.3% to $45.26, wideningthis week's decline to 2.9% after being up nearly 4.0% at its bestlevel on Tuesday.

As for technology, the top-weighted sector struggled amidweakness in the chipmaker arena after Qualcomm's(QCOM 51.07, -9.19) cautious guidance overshadowed better thanexpected earnings. Shares of QCOM fell 15.3% while the PHLXSemiconductor Index fell 2.1%. Elsewhere in the tech sector, Facebook(FB 108.76, +4.82) surged 4.6% in reaction to better than expectedresults.

Treasuries spent the day in negative territory, ending roughlyin the middle of their ranges with the 10-yr yield rising one basispoint to 2.24%.

Today's participation was roughly in line with average as morethan 870 million shares changed hands at the NYSE floor.

Economic data released today included initial claims andproductivity/unit labor cost data:

  • Initial claims for the week ending October 31 increased 16,000 to 276,000 (Briefing.com consensus 262,000) from an unrevised 2600,000 level in the prior week. There were no special factors influencing the jump in claims, which are still running at encouragingly low levels.
    • The four-week moving average for initial claims increased by 3,500 to 259,250
    • Continuing claims for the week ending October 24 increased 17,000 to 2.163 million (Briefing.com consensus 2.145 mln) from the prior week's upwardly revised level of 2.146 million (from 2.144 mln)
  • The preliminary third quarter productivity report showed nonfarm business productivity increasing 1.6% quarter to quarter (Briefing.com consensus -0.2%) versus 3.5% in the second quarter
    • Output increased 1.2% while hours worked decreased 0.5%, marking the first decline in that series since the third quarter of 2009
    • Unit labor costs were up just 1.4% (Briefing.com consensus 2.2%)

Tomorrow, October Nonfarm Payrolls (Briefing.com consensus181,000) will be reported at 8:30 ET while the September ConsumerCredit report (consensus $18.00 billion) will be released at 15:00ET.

  • Nasdaq Composite +8.3% YTD
  • S&P 500 +2.0% YTD
  • Dow Jones Industrial Average +0.2% YTD
  • Russell 2000 -1.1% YTD

4:07 pm Allscripts Healthcare beats by $0.01, reports revsin-line; narrowed EPS guidance FY15 EPS in-line, slightly reducedguidance revs, in-line (MDRX):

  • Reports Q3 (Sep) earnings of $0.13 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.12; revenues rose 2.6% year/year to $354.5 mln vs the $353.75 mln Capital IQ Consensus.
  • Co narrowed EPS guidance for FY15, sees EPS of $0.45-0.47, excluding non-recurring items, vs. $0.46 Capital IQ Consensus Estimate, from $0.42-0.50; slightly reduced guidance for FY15 revs of $1.39-1.41 bln vs. $1.4 bln Capital IQ Consensus Estimate, from $1.40-1.43 bln.

4:07 pm Diversified Restaurant Holdings announces its tickersymbol will change to 'SAUC' effective on November 9, 2015 (BAGR):  

4:07 pm Solera misses by $0.08, beats on revs (SLH):

  • Reports Q1 (Sep) earnings of $0.62 per share, excluding non-recurring items, $0.08 worse than the Capital IQ Consensus of $0.70; revenues rose 11.9% year/year to $313.3 mln vs the $308.03 mln Capital IQ Consensus.
  • Adjusted EBITDA for the first quarter was $109.8 million, a 3.6% decrease versus the prior year first quarter Adjusted EBITDA of $113.9 million.

4:06 pm CytomX Therapeutics announces a collaboration with TheUniversity of Texas MD Anderson Cancer Center, to researchProbody-enabled CAR-NK cell therapies (CTMX):

The co entered into a collaboration with The University of TexasMD Anderson Cancer Center to research Probody-enabled chimericantigen receptor natural killer (CAR-NK) cell therapies, to beknown as ProCAR-NK cell therapies. MD Anderson will leverage itsexpertise in developing allogeneic umbilical cord blood andperipheral blood derived NK-cell therapies and combine it withCytomX's Probody technology to address new targets for this novelmodality in cancer immunotherapy.

  • Under the collaboration, CytomX and MD Anderson will develop ProCAR-NK cell therapies against multiple targets, and CytomX will have the option to license therapeutics that demonstrate preclinical proof of concept for clinical and commercial development

4:06 pm RE/MAX Holdings beats by $0.06, beats on revs (RMAX):

  • Reports Q3 (Sep) earnings of $0.46 per share, $0.06 better than the Capital IQ Consensus of $0.40; revenues rose 2.0% year/year to $45.1 mln vs the $43.91 mln Capital IQ Consensus.
  • For Q4, sees revs down 4.5-5% yr/yr
  • For FY15, sees revs up 1-2% yr/yr

4:05 pm InterNAP beats by $0.01, reports revs in-line; guidesFY15 revs in-line (INAP):

  • Reports Q3 (Sep) loss of $0.19 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of ($0.20); revenues fell 7.5% year/year to $78.31 mln vs the $78.41 mln Capital IQ Consensus.
  • Co issues in-line guidance for FY15, sees FY15 revs of $320-325 mln vs. $320.57 mln Capital IQ Consensus Estimate.

4:05 pm Qumu misses by $0.14, misses on revs (QUMU):

  • Reports Q3 (Sep) loss of $0.79 per share, $0.14 worse than the two analyst estimate of ($0.65); revenues rose 62.7% year/year to $9.6 mln vs the $9.92 mln Capital IQ Consensus.
  • Backlog was $31.3 million as of September 30, 2015 compared with $33.4 million as of June 30, 2015.
  • Annual revenue growth in 2015 of approximately 30%,

4:05 pm Brooks Automation agrees to acquire BioStorageTechnologies for $127 mln in cash; expects it to become accretiveto Co's non-GAAP earnings within the first half of fiscal 2016 (BRKS):  

4:04 pm Agenus enters into three transactions, includingagreement to acquire XOMA's (XOMA) antibody pilot plant manufacturing facility and capabilities (AGEN):

Additionally, Agenus obtained an exclusive license to a phagedisplay library from IONTAS, and entered into an agreement for cellline development technology with Selexis. These new capabilities,in combination with Agenus's Retrocyte DisplayTM and SECANT yeastdisplay platforms, will result in a broad, vertically integratedand highly productive in-vitro antibody discovery and productionplatform. The acquisition of XOMA's facility will enable Agenus tomanufacture checkpoint modulator antibodies to meet itsgrowing GMP antibody production requirements for development andfuture clinical trials.

  • Under the terms of the agreement with XOMA ( XOMA ), Agenus will pay at closing $5.0 million in cash and up to $1.0 million in common stock. In addition to the XOMA manufacturing facility and a team of qualified CMC scientists from XOMA, Agenus will also gain access to selected XOMA antibody technologies as part of the agreement. These costs, as well as costs related to the Iontas and Selexis transactions, should be more than offset by savings associated with reduced contract manufacturing expenses.

4:04 pm Globant beats by $0.03, beats on revs; guides Q4 EPSin-line, revs in-line (GLOB):

  • Reports Q3 (Sep) earnings of $0.26 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of $0.23; revenues rose 29.2% year/year to $67.1 mln vs the $64.7 mln Capital IQ Consensus.
  • Co issues in-line guidance for Q4, sees EPS of $0.21-0.25, excluding non-recurring items, vs. $0.25 Capital IQ Consensus Estimate; sees Q4 revs of $68-70 mln vs. $68.7 mln Capital IQ Consensus Estimate.

4:04 pm Microsemi reports EPS in-line, revs in-line; guides Q1EPS in-line, revs below consensus (MSCC):

  • Reports Q4 (Sep) earnings of $0.73 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of $0.73; revenues rose 8.4% year/year to $328.8 mln vs the $327.46 mln Capital IQ Consensus.
  • Co issues guidance for Q1, sees EPS of $0.70-0.74, excluding non-recurring items, vs. $0.72 Capital IQ Consensus Estimate; sees Q1 revs of $325-329 mln vs. $323.69 mln Capital IQ Consensus Estimate.

4:03 pm Kratos Defense and Security beats by $0.16, misses onrevs (KTOS):

  • Reports Q3 (Sep) loss of $0.02 per share, excluding non-recurring items, $0.16 better than the Capital IQ Consensus of ($0.18); revenues fell 15.3% year/year to $161.7 mln vs the $175 mln Capital IQ Consensus.
    • Kratos successfully completed its first flight of the UTAP-22, the Kratos Tactical Unmanned Aerial Vehicle (:UAV), a high performance jet aircraft designed specifically for survivability in challenging and hostile environments, on the test range at China Lake, CA.
    • Kratos recently completed a successful flight with its newest unmanned aerial target drone system, the BQM-177A, under the Subsonic Aerial Target (:SSAT) program, with all key flight performance objectives being achievedKratos recently completed a successful flight with its newest unmanned aerial
      target drone system, the BQM-177A, under the Subsonic Aerial Target (:SSAT)
      program, with all key flight performance objectives being achieved

4:03 pm Hawaiian Holdings reports October 2015 trafficstatistics, showing RPMS of ~1.25 bln +5.6% Y/Y (HA): October 2015 passengers transported +5.6% to 908,346...RevenuePassenger Miles +5.6% to 1,249,634....Available Seat Miles +5.1% to1,468,675...Load Factor +0.4 pts to 85.1%

4:03 pm Cumulus Media reports Q3 (Sep) results, misses on revs (CMLS):

  • Reports Q3 (Sep) loss of $2.32 per share, may not be comparable to the Capital IQ Consensus of $0.04; revenues fell 7.8% year/year to $289.4 mln vs the $297.57 mln Capital IQ Consensus. Co reported Adjusted EBITDA of $70.6 million, down 11.5% from the quarter ended September 30, 2014.

4:03 pm Tableau Software beats by $0.07, beats on revs; guideson call at 4:30 (DATA):

  • Reports Q3 (Sep) earnings of $0.14 per share, $0.07 better than the Capital IQ Consensus of $0.07; revenues rose 63.4% year/year to $170.8 mln vs the $157.61 mln Capital IQ Consensus. 
    • License revenue increased 57% to $109.5 million, up from $69.8 million in the third quarter of 2014. International revenue grew to $42.2 million, up 75%, from $24.1 million in the third quarter of 2014.
    • "we had another record quarter of new customer wins. More than 3,100 new customer accounts were added in Q3, bringing the total to more than 35,000 worldwide."

4:03 pm Marinus Pharmaceuticals to offer and sell shares of itscommon stock in an underwritten public offering; size not disclosed(MRNS): The announced that it intends to offer and sell shares ofits common stock in an underwritten public offering. The cocurrently intends to use the net proceeds of this offering toadvance the preclinical and clinical development of ganaxolone,including trials for the co's ganaxolone IV program, andregulatory, research and development, pre-commercial, general andadministrative and manufacturing expenses and for working capitaland general corporate purposes

4:03 pm Invitae misses by $0.01, misses on revs (NVTA):

  • Reports Q3 (Sep) loss of $0.71 per share, $0.01 worse than the Capital IQ Consensus of ($0.70); revenues rose 606.5% year/year to $2.19 mln vs the $2.55 mln Capital IQ Consensus. At September 30, 2015, cash, cash equivalents, restricted cash, and marketable securities totaled approximately $152.1 million.

4:03 pm Plantronics beats by $0.08, beats on revs; guides Q3 EPSbelow consensus, revs above consensus (PLT):

  • Reports Q2 (Sep) earnings of $0.70 per share, $0.08 better than the Capital IQ Consensus of $0.62; revenues fell 0.4% year/year to $215 mln vs the $206.98 mln Capital IQ Consensus.
  • Non-GAAP gross margin was 52.0% compared with 54.9%.
  • Co issues mixed guidance for Q3, sees EPS of $0.71-$0.81 vs. $0.82 Capital IQ Consensus Estimate; sees Q3 revs of $225-$235 mln vs. $225.19 mln Capital IQ Consensus Estimate.

4:02 pm Oncothyreon beats by $0.07; no revs (ONTY):

  • Reports Q3 (Sep) loss of CC$0.05 per share, CC$0.07 better than the Capital IQ Consensus of (CC$0.12).
  • Oncothyreon currently expects operating expenses in 2015 to be lower than in 2014, which included the upfront payment to Array BioPharma ( ARAY ) for the exclusive license to ONT-380. Oncothyreon currently expects cash used in operations in 2015 to be approximately $30.0 - $32.0 million.

4:02 pm J&J Snack Foods misses by $0.15, misses on revs (JJSF):

  • Reports Q4 (Sep) earnings of $1.05 per share, $0.15 worse than the Capital IQ Consensus of $1.20; revenues rose 2.5% year/year to $259.8 mln vs the $266.97 mln Capital IQ Consensus.

4:02 pm NIC Inc beats by $0.02, reports revs in-line (EGOV):

  • Reports Q3 (Sep) earnings of $0.19 per share, $0.02 better than the Capital IQ Consensus of $0.17; revenues rose 7.9% year/year to $75.05 mln vs the $74.59 mln Capital IQ Consensus.

4:02 pm Bankrate reaches an agreement to sell its insurancebusiness to Genstar Capital Partners for $140 mln in cash (RATE): The co has reached an agreement to sell its insurance business toAll Web Leads, Inc., a portfolio company of Genstar CapitalPartners.The purchase price to be paid by All Web Leads willconsist of $140.0 million to be paid in cash at the closing, and$25.0 million to be paid on the second anniversary of the closingdate in cash. Closure is expected by December 31, 2015

4:01 pm Hain Celestial reports EPS in-line, misses on revs;guides FY16 EPS in-line, revs in-line (HAIN):

  • Reports Q1 (Sep) earnings of $0.37 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of $0.37; revenues rose 6.9% year/year to $687.2 mln vs the $703.08 mln Capital IQ Consensus.
  • Co issues in-line guidance for FY16, sees EPS of $2.11-2.26, excluding non-recurring items, vs. $2.19 Capital IQ Consensus Estimate; sees FY16 revs of $2.97-3.11 bln vs. $3.02 bln Capital IQ Consensus Estimate.

3:51 pm Walter Energy (WLTGQ) enters into asset purchase agreement pursuant to which the newcompany will acquire substantially all of Walter Energy's Alabamaassets (WLT):

  • The APA contemplates, among other things, cash consideration of $5.4 million, a $1.25 billion credit bid of existing indebtedness and the assumption of certain liabilities. The agreement has been filed with the Bankruptcy Court for the Northern District of Alabama in connection with a proposed, court-supervised auction process under section 363 of the Bankruptcy Code. Accordingly, the APA is subject to higher or otherwise better offers, among other conditions. An asset sale was one of the possible means of achieving the restructuring sought by Walter Energy when it filed for chapter 11 protection in July. Electing this path now will allow the Company to continue moving forward expeditiously with its restructuring, and represents what the Company believes is the best path forward in a highly challenging industry environment.

3:47 pm Treasury Market Summary (BONDX):

Treasury Yields Edge Higher

  • U.S. Treasuries sold off this morning but recovered by the end of the session to only minor losses. Unit labor costs for the third quarter showed that upward wage pressure remains quite low in the U.S. and productivity showed an encouraging turn higher. Tomorrow morning, we will get the October Employment Situation Report
  • Yield Check:
    • 2-yr: +3 bps to 0.84%
    • 5-yr: +1 bp to 1.64%
    • 10-yr: +1 bp to 2.24%
    • 30-yr: +1 bp to 3.00%
  • News:
    • Initial jobless claims rose to 276K for the week ending 10/31 from 260K in the prior week. The Briefing.com consensus was for 262K
      • Continuing jobless claims jumped to 2163K for the week ending 10/24 from the prior reading of 2146K. The Briefing.com consensus was for 2145K
    • Productivity in the U.S. rose at a 1.6% annualized rate in the third quarter. The Briefing.com consensus was for a fall of 0.2%, following growth of 3.5% in Q2
      • Higher productivity meant that unit labor costs only grew 1.4% in Q3, missing the Briefing.com consensus of 2.2%. Unit labor costs fell a downwardly-revised 1.8% in Q2
      • Output grew by 1.2% while hours worked fell 0.5%, with the decline being led by the self-employed
    • The 2-year note yield touched its highest level since February 2011
    • Atlanta Fed President Lockhart (FOMC voter) Lockhart noted that rate liftoff remains a close call. A relatively small adjustment in an estimate of the neutral rate of interest, or revisions in his forecast of how quickly remaining output and inflation-target gaps might close, could quite easily point to a longer period for a zero federal funds rate
  • Commodities:
    • WTI crude: -2.09% to 45.35
    • Gold: -0.29% to $1,103.0/troy oz.
    • Copper: -3.01% to $2.2525/lb.
  • Currencies:
    • EUR/USD: +0.18% to $1.0885
    • USD/JPY: +0.16% to 121.70
  • Data out Friday:
    • October Employment Situation Report (08:30 ET)
    • September Consumer Credit (15:00 ET)
    • Fed Governor Brainard (FOMC voter) participates in forum at IMF conference (17:15 ET)

3:37 pm Earnings Calendar for tomorrow before the open(:SUMRX):

Tomorrow before the open look for the following companies toreport:

  • HUM, TWI, BTE, CI, MT, AEE, MOG.A, TNP, TICC, OSIR, CIO, EGY, SATS, BAM, DOC, EBIX, ERF, HMSY, HZNP, LMIA, LXU, PMC, SSP, TTI, WLH, IMN, TPH

3:37 pm Earnings Calendar for today after the close (:SUMRX):

Today after the close look for the following companies toreport:

  • BLDR, CBI, CTCT, MITK, MSCC, SWKS, TRIP, BCEI, JJSF, PLT, BBRG, DATA, FICO, HBM, QRVO, RRTS, CALD, CMLS, HK, MTD, PKI, PXLW, VTL, WAGE, MRC, ABCO, BFAM, BPI, DIS, DWA, ECOM, EXAR, GDOT, GLUU, INAP, MASI, MDRX, RATE, VTAE, AAOI, AEGR, AGO, ALDR, AMTG, ATSG, CLNE, CORT, FNGN, GERN, LNT, MED, MFLX, NKTR, RWT, SNAK, TRQ, VVC, WK, WTW, ABTL, ACAD, AIRM, AL, ALEX, AMBR, AMH, AMRS, ANET, ASPN, ATHX, BBG, BRKS, BRS, CCS, CERS, CLVS, CPST, CSOD, CUBE, CYTX, DIOD, DMD, EAC, EBS, ED, EFC, EGN, EGOV, ELON, ENTL, EOG, ERII, ETM, EVC, EVH, FXCM, GSBD, GST, GXP, HNSN, HTGC, INFI, INWK, IRG, KMPR, KTOS, MAIN, MDVN, MHK, MNST, NAVG, NEWR, NFG, NNI, NVDA, NVTA, OLED, ONTY, OREX, OUT, PETX, PGRE, PRO, QUMU, RBA, RMAX, RPTP, RRMS, SEMG, SKUL, SREV, SSRI, STMP, SWIR, TCRD, TCX, TEAR, TNGO, TRMR, TRUE, UBNT, UEIC, VRNS, WG, WIFI, WING, XOMA, DRH, LBTYA, ACHN, ALIM, CTRE, DXPE, ECPG, FTEK, GSAT, HE, ICUI, KHC, PRAA, SHAK, TTWO, YUME, CYBR, PODD, GLOB, PCTY, VCYT, HAIN, UEPS, GSM, SLH, ACET, AGTC, ARCW, MCFT

3:31 pm Tracon Pharmaceuticals reports positive interim resultsfrom its trial of Votrient in patients with soft tissue sarcoma;combination was well-tolerated and dose limiting toxicity was notobserved (TCON):

Co reported positive interim results from a clinical trialcombining the Company's TRC105 with the approved VEGF inhibitorVotrient (pazopanib) in patients with soft tissue sarcoma. Thepresentation reviewed the Phase 1b portion of a Phase 1b/2 study ofTRC105 in combination with Votrient in 18 patients with advancedsoft tissue sarcomas. All patients in the Phase 1b portion hadreceived at least one prior chemotherapy regimen, and five patientsreceived prior treatment with Votrient.

  • The combination was well-tolerated and dose limiting toxicity was not observed. Six of 18 patients (33%) had tumor reductions of greater than 10% by RECIST, of whom three patients remain on treatment, and median progression-free survival ( PFS ) to date is 5.5 months.
  • Five patients have had radiographic reductions in tumor volume, and two patients have demonstrated ongoing durable complete responses by RECIST, and remain on study for 62 and 31 weeks, respectively.
  • The Phase 2 portion of the study, which is also evaluating the combination of TRC105 and Votrient, has enrolled 62 of 63 planned patients to date.

3:08 pm Currency Market Summary (:FOREX):

Sterling Falls on BoE Dovishness

  • The U.S. Dollar Index fell 0.01% to 97.94 today, having run through a short bout of volatility overnight after German factory order growth missed expectations in September
  • EUR/USD: +0.16% to $1.0884
    • Eurozone retail sales fell 0.1% m/m in September, confounding economists' expectations for a modest gain. Retail sales were unchanged in August
    • In Germany, factory orders unexpectedly fell 1.7% m/m in September after declining 1.8% in August
  • GBP/USD: -1.14% to $1.5210
    • The Bank of England voted 8-1 in favor of holding its main policy rate at 0.5%
    • The central bank also forecast that consumer prices would grow at less than 1% until H2 2016 in its quarterly inflation report, while also citing downside risks to the outlook
    • The 2015 and 2016 GDP growth forecasts were both lowered to 2.7% and 2.5%, respectively
    • The BoE saw the domestic economic picture as strong, helped along by low energy prices and interest rates, while the risk factors were mostly external
    • The U.K.'s Halifax House Price Index rose a better-than-expected 1.1% m/m in October after falling 0.9% in September. The index was up 9.7% y/y
  • USD/CHF: +0.11% to 0.9952
    • Switzerland's SECO Consumer Climate Index rose less than expected to -18 in the fourth quarter from -19 in Q3
    • The Swiss CPI unexpectedly rose 0.1% in October after gaining the same amount in September
  • USD/JPY: +0.14% to 121.69
    • Japan's Ministry of Finance auctioned JPY 2.4 tln ($19.76 bln) of 10-year JGBs at a high yield of 0.320%. The auction tailed ever so slightly and drew a bid-to-cover ratio of 2.80
  • USD/CAD: +0.08% to 1.3164
    • Canada's Ivey PMI unexpectedly fell to 53.1 in October from 53.7 in September
  • AUD/USD: +0.02% to $0.7143
  • NZD/USD: +0.41% to $0.6619
  • USD/RUB: +0.36% to 63.43
    • Russia's services purchasing managers' index, as compiled by Markit, fell more than expected to 47.8 in October from 51.3 in September

2:08 pm Telecom Italia announces a proposal to convert savingshares into ordinary shares (shares halted) (TI):

The Board of Directors of Telecom Italia S.p.A. resolved tosubmit for approval to Company's shareholders' meeting a proposalfor voluntary and mandatory conversion of the Company's savingshares into ordinary shares, which will provide for both:

  • granting a right to the holders of savings shares to convert their savings shares into the Company's ordinary shares, receiving 1 ordinary share in exchange for 1 savings share held plus a cash payment of Euro 9.5 cents for each savings share
  • mandatory conversion of the saving shares which were not tendered as part of the Voluntary Conversion into ordinary shares at a conversion ratio equal to 0.87 ordinary share for each saving share held, without reduction of the share capital

It is expected that the Conversion will become effective beforethe distribution of the 2015 dividends, circumstance that has beentaken into consideration in the determination of the cash paymentof the Voluntary Conversion and the conversion ratio of theMandatory Conversion. Therefore, for the year 2015 the savingsshares will not be entitled to benefit from their current bylawsprivileges.

  • The Conversion is aimed at: simplifying the capital structure of the Company; and increasing the free float and improving the liquidity of the ordinary shares. In addition, proceeds from payments by savings shareholders that participate in the Voluntary Conversion will inter aliastrengthen the Company's equity structure and will be used to cover the innovative investments' plan of the Company for both fixed and mobile networks.

2:00 pm Notable movers of interest (SCANX):

The following are some of today's most notable movers ofinterest, categorized by market capitalization (large cap over $10billion and mid cap between $2-10 billion) and ranked by % change(all stocks over 100K average daily volume).

Large Cap Gainers

  • ADSK (63.26 +9.39%): Sachem Head Capital Management disclosed a 5.7% active stake in a 13D filing; Sachem intends to engage in discussions with Autodesk management
  • FLT  (155.22 +7.79%): Reported Q3 EPS of $1.67 ex items vs $1.61 estimate, revs rose 52.9% yoy to $451.5 mln vs $432.07 mln estimate; sees FY15 EPS of $6.18-6.26 ex items (narrowed from $6.17-6.27) vs $6.22 estimate, revs of $1.68-1.72 bln (lowered from $1.69-1.73 bln) vs $1.71 bln estimate
  • CLR (34.91 +5.15%): Reported Q3 EPS of ($0.12) ex items vs ($0.12) estimate, revs fell 45.8% yoy to $628.45 mln vs $636.31 mln estimate; Q3 production totaled 21.0 mln Boe or ~228.3k Boe/d; co sees Q4 production of 210k Boe/d

Large Cap Losers

  • ENDP (48.32 -20.12%): Reported Q3 EPS of $1.02 vs $1.00 estimate, revs rose 14.1% yoy to $746 mln vs $737.65 mln estimate; reaffirmed guidance for FY15 EPS of $4.50-4.60 ex items vs $4.56 estimate, revs of $3.22-3.27 bln vs $3.27 bln estimate
  • VRX (76.99 -16.30%): Continued volatility; WSJ reporting that Hedge Fund investor Bill Ackman may be considering selling shares
  • QCOM (51.66 -14.28%): Reported Q4 EPS of $0.91 ex items vs $0.86 estimate, revs fell 18.5% yoy to $5.46 bln vs $5.21 bln estimate; sees Q1 EPS of $0.80-0.90 ex items vs $1.08 estimate, revs of $5.2-6.0 bln vs $5.74 bln estimate; sees MSM chip shipments down 9-17% from prior year

Mid Cap Gainers

  • AWAY (39.68 +23.85%): To be acquired by Expedia ( EXPE ) for $38.31 pe rshare in cash, or ~$3.9 bln; reported Q3 EPS of $0.24 vs $0.20 estimate, revs rose 11.6% yoy to $130.68 mln vs $130.24 mln estimate
  • RL (131.77 +16.02%): Reported Q2 EPS of $2.13 vs $1.74 estimate, revs fell 1.2% yoy to $1.97 bln vs $1.95 bln estimate; sees Q3 revs +0-2% (~$2.03-2.07 bln) vs $2.04 bln estimate; sees FY15 revs flat at ~$7.62 bln vs $7.6 bln estimate
  • SFM (22.94 +15.37%): Reported Q3 EPS of $0.21 vs $0.19 estimate, revs rose 17.8% yoy to $903.1 mln vs $897.85 mln estimate; comparable store sales growth of 5.8% and two-year comparable store sales growth of 14.9%; sees FY15 EPS of $0.83-0.84 vs $0.81 estimate, comparable store sales growth of 5.0-5.5%, and net sales growth of 19-21%

Mid Cap Losers

  • FEYE (22.39 -23.13%): Reported Q3 EPS of ($0.37) vs ($0.45) estimate, revs rose 45.0% yoy to $165.6 mln vs $167.12 mln estimate; Q3 billings rose 28% yoy to $210.6 mln; sees Q4 EPS of ($0.38)-(0.36) vs ($0.40) estimate, billings of $240-260 mln, gross margin of 72-74%, and operating margin of (31%)-(28%); downgraded at Wells Fargo, BofA/Merrill, FBR Capital; Removed from Focus List at JP Morgan
  • BLUE (70.22 -22.11%): Reported Q3 EPS of ($1.18) vs ($0.96) estimate, revs fell 79.7% yoy to $1.3 mln vs $5.63 mln estimate; co announced that data from its ongoing clinical studies of LentiGlobin BB305 in beta-thalassemia major and severe sickle cell disease will be presented at the 57th Annual Meeting of the American Society of Hematology; Data contained in abstracts to be presented seen as disappointing
  • INOV (19.5 -15.91%): Reported Q3 EPS of $0.09 vs $0.09 estimate, revs rose 22.6% yoy to $105.46 mln vs $102.76 mln estimate; sees FY15 EPS of $0.49-0.54 vs $0.53 estimate, revs of $435-450 mln vs $436.85 mln estimate

1:51 pm Universal Corp increases dividend $0.01/share to$0.53/share and approves $100 mln stock repurchase program (UVV):  

1:31 pm Blue Earth reports that a US District Court hasdismissed the class action litigation against it by three of itsofficers (BBLU): The court granted plaintiff leave to amend the complaint, but thecourt expressed doubt about whether the plaintiff would be able tocure the defects in the complaint.

1:30 pm Disney Q4 Earnings Preview (DIS):

Financial Highlights:

  • Disney ( DIS ) is scheduled to report Q4 earnings after the bell this afternoon. The company has released past quarters' earnings at 4:15 ET (and a conference call is scheduled for 5 pm ET this evening). Disney does not typically issue forward guidance- and did not do so in last quarter's earnings release or on its conference call.
  • Street estimates are calling for Q4 adj. EPS of $1.14 on revenues of +9.1% to $13.52 bln.
  • Cap IQ consensus calls for FY16 adj. EPS of $5.60 on revenues of $56.09 bln
  • Disney has beaten EPS estimates in every quarter over the past two years (between $0.01 and $0.20). It has also exceeded revenue estimates in seven of the past eight quarters- this past Q3 being the sole exception, when revenues came in at $13.10 bln (vs. $13.23 bln consensus).

3Q15 Earnings/Segment Results:

  • This most recent quarter, the company reported Q3 earnings of $1.45 per share, $0.03 better than the Capital IQ Consensus Estimate of $1.42, on revenues that rose 5.1% Y/Y to $13.1 bln (vs a $13.23 bln consensus).
  • Q3 Segment Estimates: (Estimates via Topeka Capital Markets)
    • Media Networks: $5.47 bln or +4.8%
    • Parks and Resorts: $4.42 bln or +11.6%
    • Studio Entertainment: $2.03 bln or +13.9%
    • Consumer Products: $1.21 bln or +12.8%
    • Interactive: $386 mln or +6.6%
  • Recent segment rev trends have been recorded as such:
    • Media Networks: ($5.76 bln or 44% of revs in Q3): Growth of +5% (Q3) and +13% (Q2)
    • Parks and Resorts: ($4.13 bln or 31.5% of revs in Q3): Growth of +4% (Q3) and +6% (Q2)
    • Studio Entertainment:($2.04 bln or 15.6% of revs in Q3): Growth of +13% (Q3) and -6% (Q2)
    • Consumer Products: ($954 mln or 7.3% of revs in Q3): Growth of +6% (Q3) and +10% (Q2)
    • Interactive:($208 mln or 1.6% of revs in Q3): Growth of -22% (Q3) and -12% (Q2)

Additional Notables:

  • Disney's Q4 results may be looked at by investors as being a sign of the validity of last quarter's fear- that cord cutting and/or skinny bundling might lead to the erosion of domestic advertising revenues. The firm noted weakness in ESPN subs last quarter, and investors are likely to carefully scrutinize that flagship's performance (and of the Media Networks segment overall) for potential headwinds for FY16. 
    • Note: Disney's peer Time Warner ( TWX ) stated on its conference call yesterday that sub-losses due to over-the-top switching were more substantive this quarter than they anticipated (~1% greater in Q4). It also commented that such a trend was also potentially in-play for FY16, which caused the stock (and DIS) to drop sharply in intraday trade.
  • The firm's upcoming film, Star Wars: The Force Awakens will also be a hallmark of management commentary and analysis this quarter- with some analysts seeing the film as having all-time record global revenue potential. Updates on demand and integration of that franchise into parks will also likely be a subject of conversation on the call. 
  • Last week, Topeka Capital Markets reiterated its Buy rating and $136 price target on Disney stock. The firm sees 4.8% rev growth out of the Media Networks segment (on an interplay between strength at ESPN and weakness at ABC), and outsized rev growth at Parks- driven by anticipated sensational results for its Cruise line/higher Walt Disney World traffic. They anticipate a $2 bln global box office take from the new Star Wars film release, and see the film as a seminal cultural event.

Technical Viewpoint:

  • DIS stock got crushed following last quarter's earnings (largely on ESPN weakness commentary during the conference call), gapping down the next day's open by 8.9%. The stock continued to see heavy selling well into the market-wide drop in mid-August, catching lows near the $90/share. It has since bounced from that level and rallied back above is 50 and 100 day moving averages going into this afternoon's print.
  • Although the stock has slumped recently, largely on Time Warner ( TWX ) earnings commentary, it still sits well above its trailing 100 and 50 day MAs. Those levels- the 100 day MA at $109.49 and 50 day MA at $105.90 respectively- may offer support for underwhelming earnings, while the stock's all-time high of $122.08 may give intermediate-term resistance to an upside break.

Peers: TWX, FOXA, CMCSA

1:13 pm NXP Semi announces that its $2.7 bln Senior Secured TermLoan Facility- used for its acquisition of Freescale- will have a2020 maturity and be priced at Libor +3% (NXPI):  

1:01 pm Fresh recovery highs allows S&P +0.8 to join Dow +19in positive territory -- Nasdaq Comp -12 (:TECHX):  

12:56 pm Midday Market Summary: Biotechnology Weighs(:WRAPX):

The major averages hover in the red at midday with the Dow JonesIndustrial Average (unch) and S&P 500 (-0.1%) trading a bitahead of the Nasdaq Composite (-0.4%).

The stock market has spent the first half of the Thursdaysession in a 20-point range, but that has masked a relatively quietaffair that saw stocks surrender their opening gains in reaction toa notable pullback in biotechnology.

To that point, the iShares Nasdaq Biotechnology ETF(IBB 331.51, -6.12) has surrendered 1.7% with ValeantPharmaceuticals(VRX 80.37, -11.61) diving 12.6% amid continued concerns about thecompany's revenue recognition practices. The late-morning slide inValeant has weighed on the health care sector, but theheavily-weighted group has narrowed its loss to 0.5% after beingdown more than 1.0% earlier.

Similar to health care, the top-weighted technology sector(-0.3%) has struggled since the early going, but their losses havebeen largely offset by the relative strength in consumerdiscretionary (+0.2%) and financials (+0.4%).

As for technology, high-beta chipmakers have retreated after Qualcomm's(QCOM 51.84, -8.42) below-consensus guidance overshadowed betterthan expected results. Shares of QCOM have tumbled 14.0% while thePHLX Semiconductor Index is lower by 1.8%.

Elsewhere in the tech sector, Facebook(FB 109.09, +5.15) has surged 5.0% in reaction to better thanexpected results, helping offset the relative weakness in thechipmaker space.

Also of note, the energy sector (-0.3%) has displayed somevolatility in the early going and the group currently trades a bitbehind the broader market amid a 0.4% decline in crude oil, whichhas slipped to $46.13/bbl. Despite today's retreat, the energysector is higher by 3.7% for the week.

Treasuries have notched their lows within the past 90 minutesand they remain near those levels with the 10-yr yield higher bythree basis points at 2.25%.

Economic data released today included initial claims andproductivity/unit labor cost data:

  • Initial claims for the week ending October 31 increased 16,000 to 276,000 (Briefing.com consensus 262,000) from an unrevised 2600,000 level in the prior week. There were no special factors influencing the jump in claims, which are still running at encouragingly low levels.
    • The four-week moving average for initial claims increased by 3,500 to 259,250
    • Continuing claims for the week ending October 24 increased 17,000 to 2.163 million (Briefing.com consensus 2.145 mln) from the prior week's upwardly revised level of 2.146 million (from 2.144 mln)
  • The preliminary third quarter productivity report showed nonfarm business productivity increasing 1.6% quarter to quarter (Briefing.com consensus -0.2%) versus 3.5% in the second quarter
    • Output increased 1.2% while hours worked decreased 0.5%, marking the first decline in that series since the third quarter of 2009
    • Unit labor costs were up just 1.4% (Briefing.com consensus 2.2%)

12:48 pm Gilead Sciences announces FDA approval of Genvoya forthe treatment of HIV-1 infection (GILD):

Genvoya was studied in a Phase 3 HIV clinical program in morethan 3,500 patients across 21 countries, including treatment-nave,virologically suppressed, renally impaired and adolescentpatients.

  • Genvoya has a boxed warning in its product label regarding the risks of lactic acidosis/severe hepatomegaly with steatosis, and post treatment acute exacerbation of hepatitis B.
  • The approval is supported by 48-week data from two Phase 3 double-blind studies among 1,733 treatment-nave patients in which the regimen met its primary objective of non-inferiority compared to Stribild.
  • In the combined analysis of the studies, 92.4 percent of Genvoya patients and 90.4 percent of Stribild patients had HIV-1 RNA levels less than 50 copies/mL at Week 48.
  • Tests of certain renal and bone laboratory parameters also favored Genvoya over Stribild.
  • Additionally, the approval is supported by a Phase 3 study (Study 109) evaluating Genvoya among virologically suppressed patients who switched from TDF-based regimens.
  • Common adverse reactions (incidence =5%; all grades) in clinical studies were nausea (10%), diarrhea (7%), headache (6%), and fatigue (5%).

12:13 pm Symetra Financial shareholders approve recent merger;continues to expect the transaction to close late in Q1 or early2Q16 (SYA):  

12:12 pm Mitel Networks Correction: Beats by $0.04, beats onrevs; guides Q4 EPS above consensus, revs in-line -- Stock at threemonth high (MITL):

  • Reports Q3 (Sep) earnings of $0.12 per share, excluding non-recurring items, $0.04 better than the Capital IQ Consensus of $0.08; non-GAAP revenues rose 7.2% year/year to $290.7 mln vs the $285.19 mln Capital IQ Consensus.
  • Co issues guidance for Q4, sees EPS of $0.22-0.27 vs. $0.19 Capital IQ Consensus Estimate; sees Q4 non-GAAP revs of $315-340 mln vs. $320.52 mln Capital IQ Consensus.
    • This morning we incorrectly reported the co missed sales estimates. 
  • MITL +13% at three month high.

12:06 pm Stocks/ETFs that traded to new 52 week highs/lows thissession - New lows (113) outpacing new highs (104) (SCANX): Stocks that traded to 52 week highs: ABCD, ACXM, ADBE, AMZN, ATVI, AVNU, AWAY, AZO, BABY, BECN, BNCN,BOCH, BOKF, BWXT, BYD, CBF, CBU, CCRN, CHE, CHFC, COHR, CONE, CORE,CPS, CSFL, CSGS, CTRP, CUBI, CYTK, DEA, DHR, DMND, DRAD, DY, EBAY,EVBN, EXPE, EXTR, FB, FFG, FOXF, FRBA, FULT, G, GCI, GDEN, GNCMA,GOOG, GOOGL, HA, HUBS, IBOC, IM, INGR, IRMD, ISLE, JKHY, LFUS,LNCE, MATR, MATX, MPWR, MXL, NAZ, NFBK, NHC, NILE, NOW, NP, NTI,NYRT, OME, ONFC, PAR, PAYC, PCBK, PCLN, PDCE, PEGA, PLUS, PNQI,RHT, RIVR, RNR, SHOR, STL, SVBI, TPX, TSO, UBOH, UFPI, USCR, V, VC,VLO, VLY, VRSN, WCN, WDFC, WSFS, WST, WTR, XUE, YCB         

Stocks that traded to 52 week lows: AHGP, AMFW, ARC, ARPI, ATRS, AVP, BEP, BIOL, BNTC, CBMX, CCO,CIDM, CKH, CNAT, CNL, CPST, CREG, CROX, CSLT, CVA, DAVE, DIN, EAT,EMMS, ENBL, ENOC, ENVA, ERA, ETRM, EVAR, EVGN, EVTC, EXAM, FARO,FC, FDEU, FEYE, FREE, FUEL, GI, GNK, GNRT, GPOR, GSI, GSL, GYRO,HAIN, HCP, HDP, HMHC, JYNT, KFS, KND, LADR, LBY, LCI, LIQD, LLEX,LPSN, MITT, MNKD, MOSY, MYRG, NM, NMRX, NRX, NSH, NSM, NTK, OESX,OPGN, ORN, PDLI, PEIX, PHI, PPP, PRCP, PSIX, PSO, QCOM, RGLD, RLOC,ROKA, SALT, SBAC, SBLK, SCX, SEMG, SGM, SJT, SMMT, SPAR, SYRX, TDC,TDW, TGD, TIME, TPH, TUMI, TWIN, UNXL, URG, UUUU, VRX, WAB, WAC,WFM, WILN, WING, WMC, WPT, WRK, WSCI 

ETFs that traded to 52 week highs: FDN, IGV, XLK,

ETFs that traded to 52 week lows: COW, DBB, EPOL,

12:00 pm European Markets Closing Prices (:SUMRX): European markets are now closed; stock markets across Europeperformed as follows:

  • UK's FTSE: -0.8%
  • Germany's DAX: + 0.4%
  • France's CAC: + 0.6%
  • Spain's IBEX: -0.4%
  • Portugal's PSI: -1.4%
  • Italy's MIB Index: -0.4%
  • Irish Ovrl Index: -0.1%
  • Greece ASE General Index: -3.1%

12:00 pm Currency Commentary: DXY Stays Strong (:TOPNX):

  • The Dollar Index is holding the 98 level as market expectations for a hike to rates was ramped up by comments from the Fed's Yellen, Fischer, and Dudley. The members did stress that they remained data dependent. With that in mind we saw Initial Claims and Unit Labor Costs come in below expectations while the Productivity number beat expectations. Focus will turn to tomorrow's Jobs number due out at 8:30am ET.
  • The euro hit its lowest level since mid-July in overnight trade. The ECB released its autumn economic forecasts, cutting expectations for growth and inflation which was not a surprise. German Factory Orders also missed expectations. This will all lead to further expectations of the ECB increasing its purchase program and further diverging from a Fed that is set to hike rates. This is increasing calls for euro parity in the coming quarters by analysts.
  • The pound is a notable loser this morning as it tumbles below its 200 sma. The Bank of England met this morning and left its rates unchanged. This was widely expected but a dovish inflation report has pushed out expectations on when the Bank of England would follow the Fed into a tightening process. In an interview with Bloomberg TV, Bank of England Governor Mark Carney said that it was reasonable to expect the central bank to lift rates at some point in 2016. But it is evident in the price action in sterling that market participants are pushing this further out. 
  • The yen in the mean time is trying to hold its 100-sma (121.77). The currency has remained offered as it has declined about 2% over the past three weeks. The Bank of Japan released minutes from its latest meeting overnight. The focus was on the impact low oil prices were having in inflation (BONDX, FOREX). 

11:59 am Stock indices extend push off lows -- Dow -12, S&P-2.2, Nasdaq Comp -17 (:TECHX): Relative sector strength on the bounce has been noted in: BankKBE, Reg Bank KRE, Retail XRT, Energy XLE, Oil Service OIH, HealthXLV, Biotech IBB.

11:51 am Wells Fargo reaches settlement of $81.6 mln w/ U.S.Trustee regarding Payment Change Notices for the bankruptcy courtand escrow analyses for customers in Chapter 13 bankruptcy (WFC):  

11:47 am Caesarstone announces that Kibbutz Sdot Yam requests tonominate two independent directors instead of two of the nomineesrecommended by the Co (CSTE): Kibbutz Sdot Yam is encouraging Co to examine a share repurchaseprogram, as well.

11:32 am Goodyear Tire to redeem all of its outstanding $1 blnof 8.25% senior notes due 2020; results in interest expense savingsof ~$31 mln in 2016 and beyond (GT):

The redemption price will be 104.125% of the principal amount ofthe notes being redeemed, plus accrued and unpaid interest toDecember 7, 2015.

  • Co intends to use the net proceeds from its $1 bln offering of 5.125% senior notes due 2023, which closed November 5, together with current cash and cash equivalents, to fund the redemption. 
  • The transactions will result in interest expense savings of ~ $31 mln in 2016 and beyond.
  • Co continues to expect interest expense to range between $415 mln and $425 mln for 2015.

11:02 am Agilent sign agreement w/ Thermo Fisher (TMO) to improve exchange instrument controls (A):  

11:01 am TEGNA sells Clipped Magazine to Valassis (:VCI); termsnot disclosed (TGNA):  

11:01 am Dex Media enters into a forbearance agreement withlenders under its senior secured credit facilities (DXM):

The agreement is effective through November 23, 2015. Inaddition, the Company announced it has received a term sheet andrestructuring support agreement from the ad hoc committee oflenders holding more than 50% of its senior secured creditfacilities.

  • The Company and its advisors are reviewing the term sheet and RSA, and are continuing negotiations with the Company's lenders with a goal of agreeing on terms of a consensual restructuring. The Company's has a cash balance of $205.3 million

10:52 am S&P -11 slides to new session low of 2090 (SPY): After stalling at the 62% retracement of Tues/Wed pullback at2109 in early trade the index has edged back near a minor supportat 2090 mentioned in The Technical Take. A secondary zone is at2085/2084. The session low thus far is 2090 which also approximatesits 50 ema hourly (2092) (see The Technical Take hourly chart). Inorder to neutralize the weaker intraday action off Tues/Thur highsthe index will need to sustain a push back through 2096 and2099.

10:50 am Investment Tech to sell its Calgary-based unit ofinvestment research to Warburg Pincus for ~$120.5 mln in cash;expects to book a gain of $90-95 million after taxes (Shareshalted) (ITG):

Co has signed a definitive agreement to sell the Calgary-basedunit of ITG Investment Research to Warburg Pincus.

  • Under the terms of the agreement, Warburg Pincus will acquire the energy research group for $120.5 million in cash. ITG expects to book a gain of between $90 million and $95 million after taxes from this transaction. The transaction is expected to increase ITG's tangible book value by between $2.85 and $3.00 per share.
  • ITG is currently evaluating alternatives for the use of the proceeds from this transaction, including strategic initiatives and share repurchases.

10:32 am Major averages drop to new session lows -- Dow -53,S&P -9, Nasdaq Comp -33 (:TECHX): Sectors that have underperformed on a relative basis include:Semi SMH, Pharma PPH, Health XLV, Biotech IBB, Industrial XLI,Rail, Networking IGN.

10:28 am S&P -6 and Dow -41 join Nasdaq Comp -28 under Wedlows (:TECHX):  

10:21 am Nasdaq Comp -20 slides below yesterday's trough, Dow -7and S&P -3.2 set new session lows (:TECHX):  

10:14 am Valeant Pharma (-18%) collapses to 2+ year low (VRX):  

10:10 am S&P +0.7 rebound stalls at 62% retrace of Tues-Weddecline at 2109 and edges back (SPY): Noted in The Technical Take that the S&P will need toinitially sustain gains back above 2109 in order to improve thepattern off the high from Tuesday's (2116).

10:05 am Expedia sets a new session high of 139.04, its all timehigh from last week is at 139.58 (EXPE):  

10:01 am Idera Pharma reports preclinical data for IMO-2125,showing potent and systemic anti-tumor activity in preclinicalcancer models (IDRA):

Co announced new preclinical data demonstrating potent andsystemic anti-tumor activity in preclinical cancer models withintra-tumoral administration of IMO-2125 in combination with ananti-PD-1 monoclonal antibody.

  • Idera scientists presented data providing evidence that intra-tumoral IMO-2125 administration changes the tumor microenvironment by increasing infiltration of tumor-infiltrating lymphocytes and by modulating gene expression of multiple checkpoints, including PD-L1. In the study, treatment with a combination of intra-tumoral IMO-2125 with anti-PD-1 antibody showed more potent anti-tumor activity than either agent alone, with potent anti-tumor activity observed on treated as well as distant tumors.
  • Additionally, increased infiltration levels of TILs and increased PD-L1 and other checkpoint expression was observed in both treated and distant tumors.
  • Idera expects to initiate the first clinical study of intra-tumoral IMO-2125 in combination with ipilimumab in patients with metastatic melanoma in the fourth quarter of this year

9:59 am Major averages edge slightly above opening highs -- Dow+43, S&P +4, Nasdaq Comp +7 (:TECHX):  

9:42 am Market averages slip back off highs led by small-caps --Russell 2000 -2.8, Nasdaq Comp -2, S&P +0.02, Dow +20(:TECHX):  

9:41 am Cellectis surges following 'encouraging data from onepatient treated with 'off the shelf' UCART19 for Leukemia (ALL); competitors JUNO, KITE trading lower (CLLS):

  • Great Ormond Street Hospital (:GOSH) and University College London (:UCL) will present encouraging data from a first in man clinical use of UCART19, at the 57th American Society of Hematology ( ASH ) Annual Meeting in Orlando during the poster session.
  • GOSH has treated in June 2015 a young leukemia patient under a special license from the Medicines & Healthcare products Regulatory Agency(:MHRA) with Cellectis' TALENgene edited allogeneic UCART19 product candidate because no other therapies were available for refractory relapsed Acute Lymphoblastic Leukemia ( ALL ) following mismatched allogeneic stem cell transplantation.
  • From Abstract:
    • 'She received a single dose (4.5x106/kg) of UCART19 T cells without any significant toxicity. To date there has been no significant perturbation of cytokine levels in peripheral blood, and no indication of cytokine release syndrome. Although profoundly lymphopenic, UCART19 T cells were detectable by qPCR in the circulation by day 14 and at increased levels in both blood (VCN 0.35) and marrow (VCN 0.22) on day 28. The patient exhibited signs of count recovery and the bone marrow, while hypoplastic, was in cytogenetic and molecular remission. Chimerism was 90% donor, and a clearly demarcated population (7%) of third party cells indicated persistence of UCART19. A residual persistence of 3% recipient cells in the marrow suggests that leukemic clearance was not mediated by transplant mediated alloreactivity. Within the short period of follow up available, our intervention comprising lymphodepletion and infusion of UCART19 T cells has induced molecular remission where all other treatments had failed. This first-in-man application of TALEN engineered cells provides early proof of concept evidence for a ready-made T cell strategy that will now be tested in early phase clinical trials.'
    • Link to abstract .
  • "We are very glad for this young patient to have benefited from our highly innovative TALEN gene edited allogeneic CAR T therapy UCART19. We expect to accelerate our clinical development of TALEN gene-edited allogeneic CAR-T therapies to further confirm this encouraging clinical proof of concept." 

CLLS is attempting an 'off the shelf' CAR-T treatment while JUNO and KITE (both down 7%)treatments are patient specific.

9:40 am Relative sector performance (:TECHX): Sectors displaying relative strength in early dealings include:Internet FDN, Social Media SOCL, Transports IYT, Pharma PPH,Trucking, Bank KBE, Technology XLK, Rail. Groups that are on thedefensive are being led by: Steel SLX, Copper JJC, Crude Oil USO,Biotech IBB, Semi SMH, Gold Miners GDX, Mining XME, Home Const ITB,Oil Service OIH, Energy XLE.

9:39 am InfoSonics trades higher by 20%+ following earnings; coreported Q3 EPS of ($0.01) vs. ($0.04) in prior year period; revsrose 50% YoY to $12.2 mln - no ests (IFON):  

9:39 am Opening Market Summary: Technology Sector DisplaysOpening Strength (:WRAPX):

Equity indices began the trading day just above their flat linesbefore slipping into the red. As a result, the Dow, Nasdaq, andS&P 500 all trade near their unchanged levels with five sectorsshowing early gains.

The top-weighted technology sector (+0.4%) has shown relativestrength at the start while the remaining groups hover closer totheir flat lines. On the downside, energy (-0.6%) and materials(-0.5%) underperform with the energy sector following in thefootsteps of crude oil. The energy component is currently lower by0.6% at $46.05/bbl.

Elsewhere, Treasuries continue holding slim losses with the10-yr yield up two basis points at 2.24%.

9:37 am Choppy start with a slightly firmer tone -- Dow +18,S&P +1, Nasdaq Comp +2.9 (:TECHX):  

9:28 am Norwegian Cruise Line's NCL Corporation announces itwill issue $500 mln in unregistered senior unsecured notes due 2020(NCLH): Co expects to use the net proceeds from the offering toredeem and discharge its outstanding 5% Senior Notes due 2018 andfor other general corporate purposes, which may include debtrepayment and/or opportunistic repurchases of common stock fromtime to time under its ongoing share repurchase program.

9:27 am First Data announces offering of $1.5 bln of seniorsecured notes due 2024 (FDC):

Co intends to offer $750 mln aggregate principal amount ofsenior secured first lien notes due 2024 and $750 mln aggregateprincipal amount of senior secured second lien notes due 2024.

  • The proposed offering of the Notes is part of a refinancing transaction that includes a proposed refinancing of First Data's senior secured term loan facility due March 2017 with the proceeds from incremental term loans with face amounts of $750 mln and 200 mln (estimated at $223 mln equivalent) under its senior secured term loan facility due July 2022.

9:27 am On the Wires (:WIRES):

  • Onconova Therapeutics ( ONTX ) announced that an abstract relating to the Company's Phase 2 clinical trial of oral rigosertib and azacitidine in higher-risk myelodysplastic syndromes and acute myeloid leukemia has been selected for oral presentation at the 57th American Society of Hematology Annual Meeting
  • Immune Design ( IMDZ ) announced that preclinical research on G100, Immune Design's intratumoral TLR4 agonist-based product candidate, will be presented in an oral presentation at the 57th American Society of Hematology Annual Meeting
  • Idera Pharmaceuticals ( IDRA ) announced that new data from the Phase 1/2 clinical trial for IMO-8400, a TLR 7,8 and 9 antagonist, being evaluated for the treatment of relapsed, refractory patients suffering from Waldenstrm's Macroglobulinemia, will be presented at the 2015 American Society of Hematology Annual Meeting
  • Syneron Medical ( ELOS ) announced that the FDA has granted numerous additional indications for use of the CO2RE CO2 device. The new indications for use include gynecology applications, wrinkles, scars, and a wide range of dermatology and plastic surgery indications.
  • Karyopharm Therapeutics ( KPTI ) will present additional data on Selinexor (KPT-330) activity in combination with other active agents across hematologic malignancies and new pipeline programs at ASH in Orlando.
  • Atara Biotherapeutics ( ATRA ) announced that new data on two of its licensed clinical stage T-cell product candidates will be presented by its collaborating investigators at Memorial Sloan Kettering Cancer Center during the 57th American Society of Hematology Annual Meeting
  • TG Therapeutics ( TGTX ) announced that updated data for TG-1101, the Company's novel, glycoengineered anti-CD20 monoclonal antibody and TGR-1202 have been selected for presentation at the upcoming 57th American Society of Hematology Annual Meeting
  • Curis ( CRIS ) announced that Phase 1 data for CUDC-907, Curis' proprietary dual histone deacetylase and phosphoinositide 3-kinase inhibitor will be presented at the 57th Anull merican Society of Hematology Annual Meeting

9:26 am On the Wires (:WIRES) :

  • Nevada Gold & Casinos (UWN) announced that the Nevada Gaming Control Board has recommended approval of its application for a nonrestricted gaming license in conjunction with its pending acquisition of Club Fortune Casino in Henderson, NV.
  • Amgen (AMGN) announced that a number of important abstracts and new data from the company's oncology portfolio, including Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), Nplate (romiplostim) and Neulasta (pegfilgrastim), are scheduled for presentation at the 57th American Society of Hematology Annual Meeting
  • Aptose Biosciences (APTO) announced that preclinical data for its lead investigational anticancer therapeutic APTO-253 will be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition. Co will present data demonstrating the ability of APTO-253 to kill acute myeloid leukemia cells in the majority of patient samples, with a trend toward correlation with baseline KLF4 expression level. Moreover, APTO-253 demonstrated enhanced killing ability of AML cells in patient samples when combined with either the BET inhibitor JQ1 or with the FLT3 inhibitor quizartinib.
  • Acceleron Pharma (XLRN) will present data in six abstracts on the investigational protein therapeutics sotatercept, luspatercept and ACE-1332 at Ash in Orlando
  • Alnylam Pharmaceuticals (ALNY) will present new results from ongoing clinical studies with two of its subcutaneously administered investigational RNAi therapeutics -- ALN-AT3 and ALN-CC5 -- at ASH in Orlando, Florida
  • MEI Pharma (MEIP) published new data from the Company's Phase II clinical studies of the investigational drug Pracinostat in patients with previously untreated myelodysplastic syndrome and elderly patients with acute myeloid leukemia. Co also will present this data at ASH in Orlando
  • Prothena Corporation plc (PRTA) announced that new preclinical data related to its NEOD001 program, health-related quality of life data in patients with AL amyloidosis, as well as follow-up case studies from patients in the NEOD001 Phase 1/2 multiple ascending dose trial, will be presented at the 57th Annual American Society of Hematology

9:26 am PAR Technology gapping up following Q3 results (PAR) : Q3 EPS $0.11 vs. $0.07 last year; re +10% to $58 mln (no ests).

9:26 am Dunkin Brands announces that 46 new restaurants will be developed in Georgia over the next several years by six franchisees; remains on track for 2015 restaurant develop. target (DNKN) :  

9:18 am Spirit Realty Capital reports FFO in-line, beats on revs; narrows FY15 FFO guidance; guides FY16 AFFO in-line (SRC) :

  • Reports Q3 (Sep) funds from operations of $0.21 per share, in-line with the Capital IQ Consensus of $0.21; revenues rose 10.6% year/year to $168.43 mln vs the $166.63 mln Capital IQ Consensus.
  • Co narrows guidance for FY15, sees FFO of $0.86-0.87 ($0.85-0.87) prior vs. $0.83 Capital IQ Consensus Estimate.
  • Co issues in-line guidance for FY16, sees AFFO of $0.88-0.91 vs. $0.88 Capital IQ Consensus Estimate.

9:15 am S&P futures vs fair value: +2.90. Nasdaq futures vs fair value: +9.00. (:WRAPX) :

The stock market is on track for a higher open with S&P 500 futures trading three points above fair value after climbing steadily since 4:00 ET. The early morning advance in futures has coincided with buying interest in Europe that has pushed markets in Germany and France higher by 1.0% apiece.

Index futures have backed away from their highs, continuing the retreat after the release of weekly initial claims and preliminary Q3 Productivity/Unit Labor Cost data. We can't say that the preliminary third quarter productivity report will put any real inflation scare in the Fed. It showed nonfarm business productivity increasing 1.6% quarter to quarter (Briefing.com consensus -0.2%) versus 3.5% in the second quarter. Output increased 1.2% while hours worked decreased 0.5%, marking the first decline in that series since the third quarter of 2009. Unit labor costs were up just 1.4% (Briefing.com consensus 2.2%).

Separately, initial claims for the week ending October 31 increased 16,000 to 276,000 (Briefing.com consensus 262,000) from an unrevised 2600,000 level in the prior week. There were no special factors influencing the jump in claims, which are still running at encouragingly low levels.

Unlike equity futures, Treasuries have ticked to lows following the data with the 10-yr yield up one basis points at 2.23%.

On the corporate front, Facebook (FB 109.39, +5.45) is on track to open higher by 5.2% in reaction to better than expected results while Qualcomm (QCOM 57.05, -3.21) has surrendered 5.3% in pre-market after below-consensus guidance overshadowed better than expected results.

9:11 am Tribune Publishing misses by $0.02, beats on revs; reaffirms FY15 guidance (TPUB) :

  • Reports Q3 (Sep) earnings of $0.12 per share, excluding non-recurring items, $0.02 worse than the single analyst estimate of $0.14; revenues were unchanged from the year-ago period at $404.3 mln.
    • Advertising Revenues of $220 million, down slightly from the prior-year quarter and down 9.6%, excluding advertising revenues from the acquisition of The San Diego Union-Tribune;
    • Adj. EBITDA to $28 mln from $26 mln
  • Co reaffirms guidance for FY15, sees FY15 revs of $1.645-1.675 bln vs. $1.66 bln Capital IQ Consensus; EBITDA $145-160 mln.

9:07 am EnteroMedics announces a $25 mln registered direct offering of senior amortizing convertible notes (ETRM) :

Co intends to use the net proceeds from this offering to continue its commercialization efforts for the Maestro Rechargeable System, for clinical and product development activities and for other working capital and general corporate purposes.

  • The Notes will be payable in monthly installments, will accrue interest at a rate of 7.0% per annum from the date of issuance and will mature 24 months after the initial closing.
  • $1.5 mln of the Notes will be funded at the initial closing, and the balance will be funded in two tranches of $11.0 mln and $12.5 mln which are subject to the shareholders of the Co approving a reverse stock split of the Co's common stock and the approval of the issuance of the securities purchased by the Investors.

9:04 am Air Methods to acquire Tri-State Care Flight for $222.5 mln; expects deal to be immediately accretive to EPS (AIRM) :

Co has entered into a definitive agreement to acquire Tri-State Care Flight for $222.5 million. Tri-State generated net revenue of $81.5 million for the fiscal year ended Dec. 31, 2014.

  • The transaction, which was unanimously approved by Air Methods' Board of Directors, is expected to be immediately accretive to Air Methods' earnings per share by greater than $0.20 in year one and by greater than $0.30 in year two.
  • Air Methods expects to finance the acquisition through its credit facility, which was recently amended in August to provide for additional borrowing capacity.

9:03 am Rexahn Pharmaceuticals reports interim clinical data from its Phase IIa study of Archexin; dose levels tested to date appear to be safe and well tolerated (RNN) : Data from the ongoing Phase IIa clinical trial shows that Archexin, in combination with everolimus (Afinitor), appears to be safe and well tolerated at the doses tested to date. Co will present data on November 6, 2015 at the 14th International Kidney Cancer Symposium in Miami, Florida.

9:02 am Vringo provided an update on its global enforcement actions against ZTE (ZTCOF); plans to appeal the Tribunal's's judgment (VRNG) :

  • The Tribunal found claims 1 to 11 and 13 of European patent 1,221,212 (the "EP 212 Patent") invalid and claims 1 to 5 and 10 to 15 of European patent 1,186,119 (the "EP 119 Patent") not implemented in the relevant standard. Vringo filed the lawsuit on April 2, 2013, based on particular information uncovered during a seizure to obtain evidence of infringement, known as a saisie- contrefaon, which was executed at two of ZTE's facilities in France. Vringo plans to appeal the Tribunal's's judgment; the appeal will be heard de novo.
  • The EP 119 Patent has previously been found infringed by ZTE in Germany, where Vringo has enforced an injunction against ZTE. That injunction remains in place. Separately, the 119 patent was previously found valid by the European Patent office when validity its validity was challenged by Qualcomm (QCOM).

9:02 am Amec Foster Wheeler reports YTD results; lowers margin guidance; intends to cut dividend (AMFW) :

  • Scope Revenue was 3,871m (2014 pro forma: 3,940m), 1.8% lower than last year's pro forma result, and 3.4% lower on a like-for-like basis. The order book stood at 6.5bn at the end of September, compared to 6.6bn at the half year. Trading margin trends have continued from the first half, with ongoing pricing pressure from customers and dilution from mix.
  • For 2015, we expect to see a continuation of recent revenue trends - with growth in downstream and Middle Eastern Oil & Gas markets being offset by tougher conditions elsewhere, notably in upstream Oil & Gas and GPG.
    • Continue to expect 2015 underlying Scope Revenue to be modestly lower than last year's pro forma result. Based on current forecasts there is no longer any Y/Y net benefit from the translation of N American revenues into Sterling.
    • The changing mix of work in execution and continued customer pricing pressure, particularly in the Oil & Gas market, lead us to believe second half margins will be below those achieved in the first half of 2015. Cash generation remains solid, and conversion from Trading Profit is expected to remain in the historic range of 80-100%. Year-end net debt will be circa 1.1bn. This includes the impact of weaker H2 trading, adverse currency translation and assumes that the full payment for the Longview arbitration mentioned above is made.
  • Looking ahead to 2016, expect to see the same trends impacting business as in 2015. Growth in the order book towards 7bn between now and the year-end will support low single digit Scope Revenue growth. The anticipated benefits of the additional cost saving measures referred to above will partially offset the continued customer pricing pressure and mix - leading to further modest Trading Margin dilution.
  • Reduces dividend: The interim dividend of 14.8p per share, which was announced at the half year results, will be paid, as previously announced, on 5 January 2016 to shareholders on the register at the close of business on 27 Nov 2015. The Board now expects to recommend a final dividend for 2015 of circa 14.2p, half of the equivalent declared in 2014, at the full year results in March 2016. It is the current intention of the Board that ordinary dividends in 2016 will be approximately half that declared in 2014, with ~1/3rd paid at the interim, and 2/3rd as a final dividend.

9:02 am Pandora Media and Sony/ATV Music Publishing announce a multi-year licensing agreement for Sony/ATV's catalog of music (P) : Co and Sony/ATV Music PUblishing announce a multi-year licensing agreement for Sony/ATV's catalog of musical works. The public performance royalties Co also pays to rights holders of master recordings are not affected by this agreement.

9:01 am BioLineRx announces 'positive' results from the dose escalation part of BL-8040's Phase 2 clinical trial in relapsed or refractory acute myeloid leukemia (BLRX) :

Results showed that BL-8040, as a single agent and in combination with Cytarabine, was safe and well tolerated at all doses tested up to and including the highest dose level of 1.5 mg/kg, with no major adverse events. The composite complete remission rate, including both complete remission and complete remission with incomplete blood count recovery (CRi), was 38% in subjects receiving only one cycle of BL-8040 treatment at doses of 1 mg/kg and higher (n=16). Patients included in this part of the study were patients that had undergone a significant number of prior treatment cycles or that were refractory to induction treatment.

  • Treatment with BL-8040 had a triple effect on the leukemic cells. First, following only two days of monotherapy, BL-8040 triggered an average 40-fold mobilization of immature AML progenitor cells from the bone marrow to the peripheral blood, thereby sensitizing these cells to the Ara-C chemotherapy and improving its efficacy. Second, BL-8040 showed a direct and significant apoptotic effect on the immature leukemia progenitor cells in the bone marrow following the two days of monotherapy. Last, BL-8040 induced leukemia progenitor cells towards differentiation, as evidenced by a 58% median decrease in the number of bone marrow leukemia progenitor cells, along with a three-fold increase in differentiated granulocytes, in the bone marrow biopsy conducted on Day 3 of the treatment cycle prior to the Ara-C treatment, as compared to the biopsy performed at baseline.
  • "In light of the encouraging results, we look forward to discussions with the regulatory authorities regarding the future development plan for AML. We currently anticipate reporting topline results from the full study by early next year."

9:01 am FTI Consulting announces $50 mln stock repurchase program (FCN) :  

9:00 am Jaguar Animal Health initiates a proof-of-concept study for SB-300 (JAGX) :

SB-300 is a pharmaceutical formulation of a standardized botanical extract from the Croton lechleri tree, which is sustainably harvested, for the treatment of gastrointestinal ulcers in horses.

  • Additionally, Jaguar is planning trials to develop an equine-specific formulation of crofelemer for the treatment of diarrhea associated with acute colitis, a devastating and dehydrating condition that can lead to patient death in less than 24 hours.Crofelemer is an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. The Company intends to seek MUMS designation for the product.

8:59 am Alexandria RE announces an underwritten public offering of Senior Notes (ARE) : Co intends to use the net proceeds from this offering for the reduction of the outstanding balance on its unsecured senior line of credit.

8:57 am S&P futures vs fair value: +4.90. Nasdaq futures vs fair value: +11.50. (:WRAPX) :

The S&P 500 futures trade five points above fair value.

The Asian equity markets closed generally higher on a night that was very light in terms of macro data. Neither Japan nor China released any data points, but that did nothing to halt the upward momentum in the region. Chinese equities continued to outperform the region with the Shanghai closing nearly 2.0% higher on the day. There wasn't any pull back after yesterday's 4.0% gain, and the Mainland index got an additional sentiment boost following meetings between Chinese and Taiwanese officials that could potentially open up investment opportunities between the two nations. In Japan, the BoJ released the minutes from last week's meeting and the general take away was that the members continue to see progress within the domestic economy and expect inflation to pick up. This likely gave some perspective to investors for not adding any stimulus. With that said, the yen continued to see weakness overnight, which helped to propel the Nikkei 1.0% higher.

  • In economic data:
    • Indonesia's Q3 GDP +3.2% (expected 3.3%)
    • Taiwan's October CPI +0.3% (expected 0.2%)

------

  • Japan's Nikkei increased 1.0%. Japanese shares took off out of the gate and never looked back for the most part. The declines in the yen against the dollar after Janet Yellen's tone surrounding the liklihood of a Dec rate hike helped to provide a bid to the index. The Nikkei was also supported by following better than expected results from Japan Tobacco (+7.5%) and Fast Retailing's unit, Uniqlo (+4.9%). Softbank shares declined 1.2% today after it released earnings after the market closed yesterday.
  • Hong Kong's Hang Seng was unchanged today. The market was held in check today, with a mixed board across the components. Some of the notable movers to the upside were Ping AN +2.8%, and HSBC +1.9%, and China Life +1.0%. Some of the notable movers to the downside were Sino Land -2.7%, Want Want China -1.7%, and Hang Seng Bank -1.0%.
  • China's Shanghai Composite rose 1.8%, extending gains and moving back into bull market territory after it has moved up 20% from the summer lows. The telecom sector saw robust gains to give the index support after reports suggested the state was considering consolidating the sector. As such, China Unicom soared 10%, hitting its daily limit up following the news.

Major European indices trade mostly higher while UK's FTSE (-0.1%) underperforms. The Bank of England made no changes to its policy stance, keeping its interest rate and purchase program unchanged at their respective 0.50% and GBP375 billion. Furthermore, the central bank's policy minutes revealed no change in attitude among participants with eight members calling for no change to policy while one member remained in the rate hike camp.

  • Investors received several data points:
    • Eurozone September Retail Sales -0.1% month-over-month (expected 0.2%; prior 0.0%); +2.9% year-over-year (consensus 3.0%; prior 2.2%). Separately, Retail PMI 51.3 (prior 51.9)
    • Germany's September Factory Orders -1.7% month-over-month (expected 1.0%; previous -1.8%)
    • UK's October Halifax House Price Index +1.1% month-over-month (consensus 0.6%; prior -0.9%); +9.7% year-over-year (consensus 9.5%; last 8.6%)
    • Swiss October CPI +0.1% month-over-month (expected 0.0%; prior 0.1%); -1.4% year-over-year, as expected (prior -1.4%). Separately, Q4 SECO Consumer Climate -18 (expected -14; previous -19)

------

  • UK's FTSE hovers just below its unchanged level with drugmakers showing relative strength after AstraZeneca reported better than expected results. The stock has spiked 4.2% while peers Hikma Pharmaceuticals and Shire hold respective gains of 2.4% and 1.9%. On the downside, energy and mining names lag with Anglo American, Randgold Resources, BP, and Royal Dutch Shell down between 2.1% and 6.6%.
  • Germany's DAX trades up 0.9% with Adidas surging 8.1% in reaction to better than expected results. Most other index components also trade in the green while five listings trade in the red with Volkswagen down 3.4%.
  • In France, the CAC has climbed 1.0%. Societe Generale leads with a 6.9% gain after reporting above-consensus results while Credit Agricole is down 5.8% after missing estimates. Elsewhere, consumer names outperform with Danone, L'Oreal, and Kering up between 1.6% and 2.0%.

8:56 am South Jersey Inds reports Q3 (Sep) results; reaffirms FY15 EPS guidance (SJI) :

  • Reports Q3 (Sep) loss of $0.07 per share, may not be comparable to the Capital IQ Consensus of $0.11. While the thirdquarter is generally a lower producing period, these results were furtherhindered by increases in write-offs for uncollectible accounts in our utility,as well as increased post-retirement account expenses. Lower levels ofinvestment tax credits associated with solar project development alsocontributed to the year-over-year variance.
  • Co reaffirms guidance for FY15, sees EPS of $1.49-1.54 vs. $1.50 Capital IQ Consensus Estimate.

8:55 am On the Wires (:WIRES) :

  • Signal Genetics (SGNL) announced that a peer-reviewed paper highlighting the clinical utility of MyPRS in the everyday management of patients with multiple myeloma, was published on-line in the journal Leukemia.
  • ChemoCentryx (CCXI) announced data presentations from two of its chemoattractant receptor programs at the American Society of Nephrology Kidney Week Annual Meeting. The presentation includes a description and analysis of the statistically significant improvement in levels of protein in the urine across the entire Phase II patient population tested. CCX140 appeared to be well tolerated, with a low overall dropout rate over the 52-week treatment period
  • Merck (MRK) announced that its collaborative partner Samsung Bioepis will present new Phase 3 clinical data for three investigational immunology biosimilar candidates at the American College of Rheumatology and the Association for Rheumatology Health Professionals 2015 Annual Meeting
  • Halozyme Therapeutics (HALO) dosed the first patient w/ its IND, PEGPH20 in combination with Merck's (MRK) Keytruda in a clinical trial to determine the maximum tolerated dose of PEGPH20 and antitumor activity of the combined therapies.
  • Amedica Corporation (AMDA) entered into a multi-year private label agreement with a regional medical device company that markets solutions for the treatment of spinal disorders. Co will provide sterile-packed silicon nitride spinal interbody fusion devices to be available in key domestic markets.
  • Live Ventures (LIVE) announced that its wholly owned subsidiary, ModernEveryday.com, has expanded its distribution network into the Japanese market
  • Scientific Games Corporation (SGMS) was awarded 5-year contract Arizona lottery's integrated lottery gaming system

8:55 am European Markets Update: FTSE -0.1%, DAX +0.9%, CAC +1.0% (:SUMRX) :

Major European indices trade mostly higher while UK's FTSE (-0.1%) underperforms. The Bank of England made no changes to its policy stance, keeping its interest rate and purchase program unchanged at their respective 0.50% and GBP375 billion. Furthermore, the central bank's policy minutes revealed no change in attitude among participants with eight members calling for no change to policy while one member remained in the rate hike camp.

  • Investors received several data points:
    • Eurozone September Retail Sales -0.1% month-over-month (expected 0.2%; prior 0.0%); +2.9% year-over-year (consensus 3.0%; prior 2.2%). Separately, Retail PMI 51.3 (prior 51.9)
    • Germany's September Factory Orders -1.7% month-over-month (expected 1.0%; previous -1.8%)
    • UK's October Halifax House Price Index +1.1% month-over-month (consensus 0.6%; prior -0.9%); +9.7% year-over-year (consensus 9.5%; last 8.6%)
    • Swiss October CPI +0.1% month-over-month (expected 0.0%; prior 0.1%); -1.4% year-over-year, as expected (prior -1.4%). Separately, Q4 SECO Consumer Climate -18 (expected -14; previous -19)

------

  • UK's FTSE hovers just below its unchanged level with drugmakers showing relative strength after AstraZeneca reported better than expected results. The stock has spiked 4.2% while peers Hikma Pharmaceuticals and Shire hold respective gains of 2.4% and 1.9%. On the downside, energy and mining names lag with Anglo American, Randgold Resources, BP, and Royal Dutch Shell down between 2.1% and 6.6%.
  • Germany's DAX trades up 0.9% with Adidas surging 8.1% in reaction to better than expected results. Most other index components also trade in the green while five listings trade in the red with Volkswagen down 3.4%.
  • In France, the CAC has climbed 1.0%. Societe Generale leads with a 6.9% gain after reporting above-consensus results while Credit Agricole is down 5.8% after missing estimates. Elsewhere, consumer names outperform with Danone, L'Oreal, and Kering up between 1.6% and 2.0%.

8:50 am Gapping down (SCANX) : Gapping down
In reaction to earnings/guidance
: XENT -23.9%, GUID -21.5%, FEYE -18.4%, BLUE -17.9%, ALR -14.5%, CSLT -14.2%, LCI -14.1%, AVG -14%, FRSH -12%, ACLS -11.8%, MGA -8.2%, G -7.4%, CF -7.3%, WAC -7.3%, WFM -7.2%, ETP -7.1%, EPAM -6.9%, TUMI -6.2%, ENVA -5.8%, LPSN -5.4%, MBI -5.4%, CSTM -5.4%, ANDE -5.1%, QCOM -5%, PDLI -4.7%, ESI -4.7%, ATHM -4.6%, ZUMZ -4.1%, RLYP -3.4%, XNPT -3.3%, SEAS -3.2%, HOLX -3.1%, RGR -2.8%, VVUS -2.6%, RIG -2.6%, MET -2.6%, VER -2.3%, SBAC -2.2%, TWO -2.2%, FNHC -1.9%, HDP -1.8%, FUEL -1.8%, (appoints Randy Wootton as CEO), BKCC -1.7%, SFY -1.7%, SPPI -1.1%, (Eagle Pharma and Spectrum Pharmaceuticals (SPPI) enter into a co-promotion agreement for six Eagle products; Eagle to pay Spectrum a base fee of $12.8 mln and potential milestones), INOV -1.1%, SQNM -1.1%, WMGI -1%, PEIX -1%

Other news: LCI -14.1% (discloses update on pending acquisition of Kremers Urban Pharmaceuticals regarding transition of one of its customers), AVG -14% (announces that John Little will transition from his role as Chief Financial Officer), SABR -1.7% (announces the secondary public offering of 30 mln shares of common stock by existing stockholders; Co will repurchase ~$100 mln of the 30 mln shares from the underwriter), SPPI -1.1% (Eagle Pharma and Spectrum Pharmaceuticals (SPPI) enter into a co-promotion agreement for six Eagle products; Eagle to pay Spectrum a base fee of $12.8 mln and potential milestones), TVPT -0.9% ( files mixed securities shelf offering), VLRS -0.9% (reported October traffic)

Analyst comments: AVP -2.3% (downgraded to Sell from Neutral at UBS ), DYAX -0.9% (downgraded to Hold from Buy at Needham)

8:48 am Kimco Realty Correction: Beats FFO by $0.03; raises FFO guidance (KIM) :

  • Reports Q3 (Sep) funds from operations of $0.40 per share, $0.03 better than the Capital IQ Consensus of $0.37; revenues rose 13.0% year/year to $288.32 mln vs the $289.03 mln Capital IQ Consensus.
  • Co raises FY15 FFO to $1.54-1.57 from $1.52-1.56, may not compare to $1.45 Capital IQ Consensus
    • Last night we reported adj. FFO; that comment has been removed.

8:47 am Gapping up (SCANX) : Gapping up
In reaction to earnings/guidance
: CCRN +24.4%, PCOM +21%, SD +16.9%, CDXS +16.4%, MHGC +14.8%, BOJA +13.6%, AHS +13.4%, SCSS +13.1%, SEDG +10.9%, FLT +8.3%, MRIN +8.1%, HABT +8%, GDDY +7.7%, MELI +7.5%, TXMD +7%, HDSN +5.9%, POWR +5.8%, BRKR +5.7%, LNTH +5.7%, XPO +5.5%, ACAS +5.1%, OSUR +4.9%, FB +4.8%, MATR +3.7%, HUBS +3.6%, KW +2.9%, COHR +2.8%, LFVN +2.8%, AHT +2.2%, BREW +2.1%, MCHP +2%, OME +1.8%, CLR +1.8%, CTL +1.6%, SUN +1.5%, UHAL +1.4%, IMH +1.3%, TNH +1.2%, WSR +1.1%, PSEC +1%

M&A news: SD +16.9% (acquired the assets of EE3 for $190 mln in cash, adds 136,000 largely contiguous net acres and multiyear niobrara shale drilling inventory in North Park Basin, Colorado; co also reported earnings),AWAY +23.3% (HomeAway to be acquired by Expedia (EXPE) for $38.31/share, or ~$3.9 bln), EXPE +4.1%

Other news: NRX +13.3% (announced successful results from a preclinical toxicity study of intravenous Pyridorin),ETRM +10.3% (presents two year follow up results from the ReCharge Study of vBloc Neurometabolic Therapy in obesity ),OASM +4.8% (confirms the previously published findings from a head-to-head comparison study of its lead human cancer product Paclical and Celgene's Abraxane),INO +4.7% (reports interim data analysis showing that its INO-3112 DNA-based immunotherapy generated specific T-cell responses),RXII +4.5% (initiates a Phase 1/2 clinical trial of RXI-109, as a potential treatment to prevent the progression of retinal scarring),EXPE +4.1% (HomeAway to be acquired by Expedia (EXPE) for $38.31/share, or ~$3.9 bln),ADSK +3.7% (: Sachem Head Capital Management discloses 5.7% active stake in 13D filing; Sachem Head intends to engage with management ),GLUU +3.2% (Integrated Core Strategies (Millennium International Management) discloses 5.2% passive stake in 13G filing),.

Analyst comments: ISIS +3% (upgraded to Overweight from Neutral at Piper Jaffray), MCHP +2% (upgraded to Buy from Neutral at B. Riley & Co),SHOP +1.9% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)

8:46 am Eyegate Pharmaceuticals announces interim data for its EGP-437 ophthalmic solution in Macular Edema patients; suggests that iontophoresis can deliver EGP-437 to the back of the eye (EYEG) :

Co announces interim data on the effects of iontophoretic delivery of their EGP-437 ophthalmic solution on Macular Edema patients that suggests that iontophoresis can non-invasively deliver EGP-437 to the back of the eye.

  • The non-invasive delivery of EGP-437 has demonstrated a positive response in some patients with macular edema.
  • A positive response was observed in some of the patients, with pseudophakic eyes responding better than phakic eyes. Additionally, the investigational therapy showed no serious treatment emergent adverse effects including no increase in ocular pressure even at three times the iontophoretic dose that was used for the Co's Phase 3 non-infectious anterior uveitis trial.
  • Co expects additional data from the extension of trial in mid-2016.
  • The extension stage of the trial will recruit an additional 15 patients with a modified dosing regimen, 3 consecutive days at the same iontophoretic dosage.
  • The extension of the trial will also evaluate the efficacy of iontophoretic EGP-437 in phakic versus pseudophakic eyes to collect additional data on the differences in the responses of both types of eyes.
  • The extension of the trial is expected to begin by the end of 2015.

8:44 am Boulder Brands beats by $0.02, beats on revs; reaffirms FY15 EPS guidance (BDBD) :

  • Reports Q3 (Sep) earnings of $0.08 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of $0.06; revenues fell 0.7% year/year to $132.9 mln vs the $130.17 mln Capital IQ Consensus.
  • Co reaffirms guidance for FY15, sees EPS of $0.20-0.25 vs. $0.20 Capital IQ Consensus Estimate.

8:44 am TCP Capital reports Q4 net invest income of $0.40, a penny above the CapIQ Consensus est; declares Q4 dividend of $0.36 per share (TCPC) :  

8:40 am Market View: Dec. E-mini stock-index futures remain bid but are well off better levels here following the 8:30 am ET economic data points (:TECHX) :

  • ESz5 now @ 2101.25 +6.50

  • NQz5 now @ 4720.00 +10.50

  • YMz5 now @ 17839 +52

8:39 am Koppers Holdings beats by $0.01, misses on revs; reaffirms FY15 EPS guidance, revs guidance (KOP) :

  • Reports Q3 (Sep) earnings of $0.66 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.65; revenues fell 1.4% year/year to $433.8 mln vs the $454.72 mln two analyst estimate.
  • Co reaffirms guidance for FY15, sees EPS of $1.65-1.75, excluding non-recurring items, vs. $1.73 Capital IQ Consensus Estimate; sees FY15 revs of approx $1.7 bln vs. $1.68 bln Capital IQ Consensus Estimate.

8:38 am Actua beats by $0.05, reports revs in-line; improved to FY15 EPS above consensus, lowered top end of revenue guidance, below consensus (ACTA) :

  • Reports Q3 (Sep) loss of $0.07 per share, $0.05 better than the Capital IQ Consensus of ($0.12); revenues rose 63.9% year/year to $34.1 mln vs the $33.88 mln Capital IQ Consensus.
  • Co issues guidance for FY15, improved to $(0.36)-(0.33) vs. ($0.38) Capital IQ Consensus Estimate, from ($0.40)-(0.36);lowered top end of FY15 revs to $133-134 vs. $135.58 mln Capital IQ Consensus Estimate, from $133-138 mln.

8:37 am Wausau Paper reports EPS in-line, revs in-line (WPP) :

  • Reports Q3 (Sep) earnings of $0.05 per share, in-line with the single analyst estimate of $0.05; revenues were unchanged from the year-ago period at $95.45 mln.
  • Wausau Paper is in the process of being acquired by SCA Americas.

8:37 am Opko Health to present data suggesting that patients with stage 3 or 4 CKD require higher levels of serum 25D than previously thought in order to control elevated iPTH (OPK) : Co to present additional Phase 3 data on Rayaldee at Kidney Week 2015 on Thursday, November 5 at 10 AM PST. 

8:35 am Medical Properties Trust beats by $0.01, beats on revs (MPW) :

  • Reports Q3 (Sep) funds from operations of $0.32 per share, $0.01 better than the Capital IQ Consensus of $0.31; revenues rose 41.8% year/year to $114.6 mln vs the $110.81 mln Capital IQ Consensus.
  • Normalized FFO is expected to range between approximately $1.30 and $1.33 on an annual run-rate basis. This estimate does not include potential earnings from MPT's equity investment in Capella.

8:35 am Pericom Semi's Board sends letter to shareholders urging them to vote for the proposed merger with Diodes Inc. (DIOD), cautions of risks in the offer from Montage Technology (PSEM) :  

8:34 am AMC Networks beats by $0.24, beats on revs (AMCX) :

  • Reports Q3 (Sep) earnings of $1.09 per share, excluding non-recurring items, $0.24 better than the Capital IQ Consensus of $0.85; revenues rose 21.7% year/year to $632.2 mln vs the $604.8 mln Capital IQ Consensus.
  • "AMC Networks had outstanding performance in the quarter, with significant increases in net revenues and operating cash flow driven by the continued popularity of our networks' original programming, notably BBC AMERICA's "Doctor Who" and AMC's newest original series, "Fear the Walking Dead," which premiered to record numbers, becoming the biggest series debut in cable television history."
  • "We continue to invest in our international business, growing our portfolio of strong local brands and launching the AMC brand into new markets. We are confident our approach to creating great content and building networks with distinct brands that resonate with viewers will continue to drive our performance over the near- and long-term and deliver value for our shareholders."

8:33 am Aqua Metals closes on $10 mln loan for the development of its first AquaRefinery (AQMS) :

Co announces a $10 mln loan from Green Bank for the development of its first AquaRefinery.

  • The loan will provide non-dilutive capital to finance the growth of Co and enhance the development of the Co's first AquaRefinery currently under construction in the Tahoe-Reno Industrial Center in Nevada.

8:33 am Stellar Biotechnologies commences trading on the Nasdaq Capital Market today following successfull uplisting (:SBOT) :  

8:33 am CymaBay Therapeutics announces results from two Phase 2 studies of Arhalofenate at the American College of Rheumatology Annual Meeting (CBAY) :

  • One was a double-blind, placebo controlled phase 2b study which enrolled 239 subjects with gout, hyperuricemia and a history of flares. The primary efficacy endpoint , a comparison of flare rates between the arhalofenate 800 mg and allopurinol 300 mg groups, was met with arhalofenate showing a 46% reduction in flare rate. Additional key outcomes included a 41% lower flare rate for the arhalofenate 800 mg group compared to placebo and reductions in sUA for the arhalofenate 600 and 800 mg groups at 12 weeks vs. placebo that were statistically significant. Arhalofenate was well tolerated and appeared safe.
  • The second was a single-center, open label phase 2 study that enrolled two cohorts of gout patients with hyperuricemia. Cohorts were administered arhalofenate 600 or 800 mg as monotherapy, followed by combination with febuxostat, and finally by febuxostat as monotherapy. The combination of febuxostat and arhalofenate demonstrated a potent serum uric acid lowering activity. For the highest dose combination, a 63% reduction from baseline in sUA was observed resulting in 100 and 79% of patients achieving a sUA

8:32 am U.S. Physical Therapy misses by $0.01, reports revs in-line (USPH) :

  • Reports Q3 (Sep) earnings of $0.47 per share, $0.01 worse than the Capital IQ Consensus of $0.48; revenues rose 8.1% year/year to $84 mln vs the $83.66 mln Capital IQ Consensus.
  • Same store visits increased 3.3% for de novo and acquired clinics open for one year or more and same store revenue increased 2.5% as the average net rate per visit decreased by $0.84.
  • The gross margin for the third quarter of 2015 was $18.9 mln or 22.5%, as compared to $18.8 mln or 24.1% in the 2014 period.
  • Total clinic operating costs were $65.2 mln, or 77.5% of net revenues, in 3Q15, as compared to $59.0 mln, or 75.9% of net revenues, in the 2014 period. The increase was primarily attributable to $5.1 mln in operating costs of new clinics opened or acquired in the past 12 months.

8:32 am S&P futures vs fair value: +5.60. Nasdaq futures vs fair value: +11.30. (:WRAPX) :

The S&P 500 futures trade six points above fair value.

The latest weekly initial jobless claims count totaled 276,000 while the Briefing.com consensus expected a reading of 262,000. Today's tally was above the unrevised prior week count of 260,000. As for continuing claims, they rose to 2.163 million from 2.146 million.

Unit labor costs increased 1.4% during the third quarter, which was lower than the 2.2% increase that had been anticipated by the Briefing.com consensus. During the same period, productivity increased 1.6%, according to the preliminary reading while the consensus expected a decrease of 0.2%.

8:31 am Iteris Holdings awarded $8.9 mln 511 traveler information contract by the San Francisco Bay area MTC (ITI) :

Co receives the 511 San Francisco Bay Area System Integrator, Data Management & Dissemination, and Interactive Voice Response Phone System service contract by the Metropolitan Transportation Commission.

  • Work on the four-year, $8.9 mln service agreement commences immediately.

8:31 am On the Wires (:WIRES) :

  • bluebird bio (BLUE) will present data from its ongoing clinical studies of LentiGlobin BB305 in beta-thalassemia major and severe sickle cell disease at the American Society of Hematology Meeting. Co will also present preclinical data from its lead oncology program, bb2121.
  • Semtech Corporation (SMTC) LoRa technology has been selected by Tata Communications for its deployment of an Internet of things network in cities in India.
  • Lpath (LPTN) announced it will present data from the Nexus Phase 2 study of iSONEP at the American Academy of Ophthalmology Meeting in Las Vegas
  • ESSA Pharma (EPIX) has been issued a 'no objection letter' for the Clinical Trial Authorization application that Co has submitted from Health Canada. The letter will allow ESSA to include Canadian sites in its ongoing Phase 1/2 clinical study of its novel agent, EPI-506. Enrollment in the clinical trial in Canada is expected to commence in the next few weeks.
  • ChromaDex (CDXC) announced it has entered into a joint development agreement with The Procter & Gamble Company (PG). Under the terms of the agreement, ChromaDex will provide P&G exclusivity to proprietary ingredients for use in P&G branded products. P&G will make an undisclosed up-front payment to ChromaDex as well as other payments based on achievement of various milestones.
  • MarineMax (HZO) announced that it has expanded its financing facility to provide for borrowings of up to $260 million from the previous limit of $235 million. The expanded facility has a three-year term, expiring in October 2018, and it has two, one-year options for renewal

8:30 am Ecolab's Nalco Champion subsidiary acquires Ultra Fab Industries; terms not disclosed (ECL) : Ultra Fab Industries Ltd. is a privately held company based in Calgary, Canada, that designs and manufactures customized solutions and specialized chemical injection systems for the oil and gas industry.

8:29 am Transmontaigne Partners misses by $0.17, misses on revs (TLP) :

  • Reports Q3 (Sep) earnings of $0.37 per share, $0.17 worse than the Capital IQ Consensus of $0.54; revenues rose 4.5% year/year to $37.3 mln vs the $38.32 mln Capital IQ Consensus.

8:25 am Goldman Sachs BDC amends its senior secured revolving credit agreement (GSBD) :

Aggregate commitments under the Revolving Credit Facility increased from $560 million to $570 million. 

  • The Revolving Credit Facility includes an accordion feature that permits the Company, under certain circumstances, to increase its total borrowing capacity to a maximum of $1.0 billion. The stated interest rate on the RevolvingCredit Facility was changed from LIBOR plus 2.25% to either LIBOR plus 1.75% or LIBOR plus 2%

8:24 am European Yields (BONDX) :

Gilt Yields Fall on Bank of England's Dovishness

  • European government bonds were a mixed bag today, with England, France, and Portugal seeing lower yields while Germany and Spain's edged higher. Since the end of the ECB rally, when Mario Draghi sent government debt soaring as he said all options for further monetary easing were on the table, the 10-year German Bund yield has moved 19 bps higher. The jump in yields for France, Italy, and Spain has been similarly dramatic. While an expansion/extension of the ECB's EUR 1.1 tln asset purchase program or a reduction in the deposit rate from its current level of -0.2% should stimulate the economy and eventually lead to higher yields, this bond sell-off is sooner than one might have predicted. To our minds, it is more likely a function of the sell-off in the Treasury market, and European sovereign has been swept up in the storm. The result may be that the European Central Bank has difficulty boosting growth in its economy as long as the Federal Reserve is in a tightening cycle, particularly if EUR/USD fails to fall significantly further. It is just that currency adjustment that many hedge funds and analysts at Goldman Sachs are expecting into year-end
  • Eurozone retail sales fell 0.1% m/m in September, confounding economists' expectations for a modest gain. Retail sales were unchanged in August
    • European Central Bank President Mario Draghi said this morning that "We must consider if weaker global environment impacts ability to return to price stability"
    • In Germany, factory orders unexpectedly fell 1.7% m/m in September after declining 1.8% in August
  • The Bank of England voted 8-1 in favor of holding its main policy rate at 0.5%
    • The 2015 and 2016 GDP growth forecasts were both lowered to 2.7% and 2.5%, respectively
    • The central bank also forecast that consumer prices would grow at less than 1% until H2 2016 in its quarterly inflation report, while also citing downside risks to the outlook
    • The U.K.'s Halifax House Price Index rose a better-than-expected 1.1% m/m in October after falling 0.9% in September. The index was up 9.7% y/y
  • Switzerland's SECO Consumer Climate Index rose less than expected to -18 in the fourth quarter from -19 in Q3
    • The Swiss CPI unexpectedly rose 0.1% in October after gaining the same amount in September
  • Yield Check:
    • France, 10-yr OAT: -2 bps to 0.95%
    • Germany, 10-yr Bund: +1 bp to 0.61%
    • Greece, 10-yr note: +1 bp to 7.63%
    • Italy, 10-yr BTP: unch at 1.57%
    • Portugal, 10-yr note: -2 bps to 2.53%
    • Spain, 10-yr ODE: +2 bps to 1.77%
    • U.K., 10-yr Gilt: -3 bps to 1.97%

8:24 am Bluebirdbio sells off on updated trial data at ASH (abstract); two B0/B0 genotypes beta-thal patients needed one blood transfusion, the other remains transfusion -- call at 8:30 (BLUE) :

  • "We are pleased to see a median HbAT87Q level of 5.2 g/dL in the seven Northstar patients with beta-thalassemia major of all genotypes followed for six months or more, as this represents a substantial proportion of their total hemoglobin. It is exciting that transfusion independence has been achieved in all of our patients with beta-thalassemia major with non-0/0 genotypes followed for at least six months in Northstar and HGB-205. Varying degrees of transfusion reduction have been observed in patients with 0/0 genotypes. As would be expected, longer follow-up is required to assess the extent of HbAT87Q production and the impact on transfusion requirements in these patients with 0/0 genotypes since they produce no functional beta-globin at baseline. Turning to sickle cell disease, our first treated patient is producing increased levels of HbAT87Q since we last reported on this study in June. HbAT87Q represented 48 percent of total hemoglobin at nine months post-infusion, and the patient remains transfusion independent without sickle cell-related adverse events as of the data cut-off. These results support the transformative potential of gene therapy, and we look forward to sharing more data at ASH."
  • HGB-204 Abstract 201:
    • All four non-0/0 subjects have been transfusion-free for at least 90 days, with a median of 287 days transfusion-free (range: 171 to 396 days).  
    • Two of the 0/0 subjects have received a single transfusion post-discharge, and one remains transfusion-dependent.
  • Outcomes of Gene Therapy for Severe Sickle Disease and Beta-Thalassemia Major via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral Beta AT87Q-Globin Vector (Abstract #202)
    • The subject with severe SCD is producing ~ 51.5% anti-sickling hemoglobin (48 percent HbAT87Q, 1.8 percent HbF, 1.7 percent HbA2) at nine months post-infusion.
    • The subject with severe SCD remains free of transfusions.
    • The subject with severe SCD has not had a post-treatment hospitalization for a disease-related event despite ceasing chronic transfusions on Day +88.
    • Both subjects with beta-thalassemia major have remained transfusion-free for at least 15 months post-infusion, with consistent expression of HbAT87Q -- both subjects are 0/E genotype

8:21 am Aegerion Pharma postpones today's earnings call, will now host its Q3 call and business update on Monday after the close (AEGR) :  

8:20 am Brookfield Infrastructure confirms it has acquired a 14.9% stake in Asciano Limited (AANOF) for ~$1.2 bln (BIP) : Subject to agreeing to a bid implementation agreement with Asciano, which is being progressed, Brookfield Infrastructure intends to make a takeover offer for Asciano for the same consideration as the 'standard consideration' under the existing scheme of arrangement announced on August 17, 2015. The takeover offer would be subject to a 50.1% minimum acceptance condition and would have similar conditions(1) to the scheme of arrangement, including ACCC merger clearance. BIP has also entered into arrangements giving it economic interests in a further approximately 4.3% of Asciano.

8:19 am Yulong Eco-Materials expects to report that Q1 net income will increase by ~50% y/y to ~$3.5 mln (YECO) : The main reason for this anticipated improvement is the estimated $2 million in fiscal 2016 Q1 revenue contributed by the company's waste hauling and recycling division, which commenced operations in the fourth quarter of fiscal 2015. The gross margin on this revenue is about 60 percent, the highest of all company divisions. Yulong expects to report that its overall fiscal 2016 Q1 revenue grew by about 14 percent to over $13 million.

8:16 am adaptimmune therapeutics reports data from a clinical study of ny-eso affinity enhanced t-cell therapy, showing a 50% response rate in Synovial Sarcoma (ADAP) :

Co presents updated data on its lead clinical program, an affinity enhanced T-cell receptor therapy targeting the NY-ESO-1 cancer antigen in synovial sarcoma, at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer.

  • In the primary efficacy analysis, 50 percent of synovial sarcoma patients receiving Adaptimmune's affinity enhanced T-cell therapy targeting NY-ESO responded, and 75 percent remain alive and on long term-follow up. Sixty percent of patients receiving the target dose responded, and 90 percent remain alive and on long term-follow up
  • Adaptimmune's affinity enhanced T-cell therapy targeting NY-ESO in multiple myeloma generated responses that were better than expected for autologous stem cell transplant alone, despite the patients having advanced stage disease with 60 percent of patients having tumor chromosomal abnormalities.
  • Authors also stated that Seventy-five percent of all subjects who received any dose of NY-ESO-1 T cells - and 90 percent of subjects who received the minimum intended cell dose - are alive and on long term follow-up. Forty-two percent of patients who received any dose have survival data beyond one year.

8:16 am EZchip reports in-line Q3; guides Q4 revs below consensus; CEO urges shareholder to approve acquisition by MLNX for $25.50 (EZCH) :

  • Reports Q3 (Sep) earnings of $0.36 per share, in-line with the Capital IQ Consensus of $0.36; revenues rose 60% year/year to $30.7 mln vs the $30.5 mln Capital IQ Consensus.
  • Co issues downside guidance for Q4, sees Q4 revs of ~$25 mln vs. $33.12 mln Capital IQ Consensus, due to near-term inventory adjustments across several key customers that are serving the carrier networking space. The Company believes that this slowdown does not reflect the long-term outlook for the Company's performance nor the underlying business.
  • CEO: "As EZchip's founder and largest individual shareholder, I, together with the entire EZchip Board, urge shareholders to vote FOR the transaction with Mellanox (MLNX) at the upcoming Annual General Meeting."

8:15 am Apache beats by $0.35, misses on revs (APA) :

  • Reports Q3 (Sep) loss of $0.05 per share, excluding non-recurring items, $0.35 better than the Capital IQ Consensus of ($0.40); revenues fell 56.5% year/year to $1.5 bln vs the $1.58 bln Capital IQ Consensus.
  • Apache operated an average of 28 rigs worldwide and drilled 111 gross operated wells, 92 of which were North American onshore.

2015 outlook and guidance update:

  • Despite a significantly reduced capital program, production volumes have shown tremendous resiliency; as a result, Apache is again raising 2015 production-guidance ranges.
  • The co is increasing its full-year 2015 North American onshore production guidance to a range of 307,000-309,000 boe per day, which is up from prior guidance of 305,000 to 308,000 boe per day. On a pro forma basis, this represents more than 2% year-over-year growth.
  • Internationally, Apache delivered strong third-quarter production growth through record production efficiency in the North Sea, sustained solid base performance and better-than-expected contributions from new wells.
  • These results enable the company to raise its full-year 2015 international and offshore pro forma production guidance to 172,000-174,000 boe per day, up from a previous range of 164,000 to 168,000 boe per day. This represents substantial year-over-year growth of 10-12%.

8:14 am Winthrop Realty Trust declares liquidating distribution of $1.00 per common share; co is liquidating and winding down pursuant to a plan of liquidation (FUR) :  

8:10 am Melco Crown Entertainment misses by $0.04, misses on revs (MPEL) :

  • Reports Q3 (Sep) earnings of $0.06 per share, $0.04 worse than the Capital IQ Consensus of $0.10; revenues fell 15.9% year/year to $945.73 mln vs the $958.11 mln Capital IQ Consensus.
  • Adj property EBITDA was US$237.3 mln vs US$305.7 mln yr-ago. The 22% yr/yr decline was attributable to lower contribution from the group-wide rolling chip segment and mass market table games segment.

8:09 am Ralph Lauren beats by $0.39, reports revs in-line; guides Q3 revs in-line; guides FY16 revs in-line (RL) :

  • Reports Q2 (Sep) earnings of $2.13 per share, $0.39 better than the Capital IQ Consensus of $1.74; revenues fell 1.2% year/year to $1.97 bln vs the $1.95 bln Capital IQ Consensus; constant FX rev +4% vs. +3-5% guidance.
  • Co issues in-line guidance for Q3, sees Q3 revs +0-2% to ~$2.03-2.07 bln vs. $2.04 bln Capital IQ Consensus Estimate.
    • Based on current exchange rates, foreign currency will have an approximate 250 basis point negative impact on revenue growth. Operating margin for the third quarter of Fiscal 2016 is expected to be ~200-250 basis points below the comparable prior year period, primarily due to negative foreign currency effects and infrastructure investments.
  • Co issues in-line guidance for FY16, sees FY16 revs of flat YoY from $7.62 bln vs. $7.6 bln Capital IQ Consensus Estimate.
    • Co is maintaining its Fiscal 2016 outlook. The company expects consolidated net revenues for Fiscal 2016 to be ~flat on a reported basis and increase by 3-5% in constant currency (from mid single digit growth). Based on current exchange rates, foreign currency will have an ~400 basis point negative impact on Fiscal 2016 revenue growth. Operating margin for Fiscal 2016 is still expected to be 180-230 basis points below the prior year's level due to negative foreign currency effects. 

8:06 am LyondellBasell authorizes an interim dividend of $0.78/share (LYB) :  

8:05 am Perficient beats by $0.03, beats on revs; guides FY15 EPS in-line, revs in-line (PRFT) :

  • Reports Q3 (Sep) earnings of $0.36 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of $0.33; revenues rose 3.3% year/year to $120.9 mln vs the $118.38 mln Capital IQ Consensus.
  • Co issues in-line guidance for FY15, sees EPS of $1.20-1.24 vs. $1.20 Capital IQ Consensus Estimate; sees FY15 revs of $458-468 mln vs. $461.19 mln Capital IQ Consensus Estimate.

8:04 am Sprouts Farmers Market beats by $0.02, reports revs in-line; guides FY15 EPS above consensus (SFM) :

  • Reports Q3 (Sep) earnings of $0.21 per share, $0.02 better than the Capital IQ Consensus of $0.19; revenues rose 17.8% year/year to $903.1 mln vs the $897.85 mln Capital IQ Consensus.
  • Reports Comparable store sales growth of 5.8% and two-year comparable store sales growth of 14.9%.
  • Gross profit for the quarter increased 16% to $261.5 million, resulting in a gross profit margin of 29.0%, a decrease of 50 basis points compared to the same period in 2014. This primarily reflects the impact of continued price investments in certain categories.
  • Co issues upside guidance for FY15, sees EPS of $0.83-$0.84 vs. $0.81 Capital IQ Consensus Estimate. Sees FY15 comparable store sales growth of 5-5.5% and net sales growth of 19-21%. Expects unit growth of 27 new stores. For Q4, expects comparable store sales growth of 5-6%.

8:03 am Inovio Pharma reports interim data analysis showing that INO-3112 generated specific T-cell responses and was well tolerated in patients with HPV associated head and neck cancer (INO) :

Co announced an interim data analysis showing that its INO-3112 DNA-based immunotherapy generated specific T-cell responses and was well tolerated in all evaluable patients with head and neck cancer associated with human papillomavirus (:HPV) types 16 and 18.

  • The immunology results show that INO-3112 generated robust HPV16/18 specific CD8+ T cell responses and antibodies against HPV16/18 in all 10 tested patients who received all treatments. The characteristics of the immune response data mirror those previously observed in a phase II clinical study of VGX-3100 for HPV-associated cervical dysplasia.

8:03 am RBC Bearings beats by $0.04, misses on revs (ROLL) :

  • Reports Q2 (Sep) adj earnings of $0.76 per share, $0.04 better than the Capital IQ Consensus of $0.72; revenues rose 32.1% year/year to $148.7 mln vs the $155.22 mln Capital IQ Consensus.

8:03 am Strategic Hotels & Resorts reports FFO in-line, beats on revs (BEE) :

  • Reports Q3 (Sep) funds from operations of $0.25 per share, in-line with the Capital IQ Consensus of $0.25; revenues rose 16.1% year/year to $354.4 mln vs the $349.02 mln Capital IQ Consensus.
  • Management has suspended the issuance of earnings guidance in light of the Company entering into a definitive merger agreement with affiliates of Blackstone Real Estate Partners VIII L.P.

8:03 am ChromaDex enters into a joint development agreement with Procter & Gamble (PG) (CDXC) : Under the terms of the agreement, ChromaDex will provide P&G exclusivity to its new proprietary ingredient for use in P&G branded products. P&G will make an undisclosed up-front payment to ChromaDex as well as other payments based on achievement of various milestones.

8:02 am Investment Tech beats by $0.18, beats on revs (ITG) :

  • Reports Q3 (Sep) earnings of $0.12 per share, excluding non-recurring items, $0.18 better than the Capital IQ Consensus of ($0.06); revenues fell 10.7% year/year to $120.4 mln vs the $118.62 mln Capital IQ Consensus.
  • There were no non-GAAP adjustments to earnings in the third quarter of 2014, however there was a net tax benefit of $2.4 million, or $0.07 per diluted share, from resolving a multi-year contingency in the U.S.
  • Average daily trading volume in the U.S. of 152 million shares versus 147 million shares in the third quarter of 2014. POSIT average daily U.S. volume was 67 million shares compared to 72 million shares in the third quarter of 2014.

8:02 am Axion Power Intl completes a private placement of $9 million in senior convertible notes & warrants (AXPW) : Co has completed a private placement of $9 million principal amount of senior convertible notes and warrants with institutional investors. At closing, Axion will receive $1.60 million in proceeds, and will receive seven subsequent monthly tranches in the principal amount of $1,000,000 each and an eighth monthly tranche in the principal amount of $150,000.

8:02 am Infinity Prpty & Casualty beats by $0.35 (IPCC) :

  • Reports Q3 (Sep) operating earnings of $1.41 per share, $0.35 better than the Capital IQ Consensus of $1.06; revenues rose 1.7% year/year to $372.4 mln vs the $350.4 mln two analyst estimate; book value $61.71.

8:02 am Relmada Therapeutics Responds to the 13D Filing by Laidlaw, strongly disagrees with Laidlaw's mischaracterizations and 'proposals' (RLMD) : Co stated: "While Relmada welcomes the views and input of all of its shareholders, the Board of Directors and management of the Company strongly disagree with Laidlaw's mischaracterizations and "proposals" set forth in their 13D filing. Such filing, which appears not to have been timely made, contains numerous inaccuracies and appears to disclose information about Relmada that could only have been obtained in violation of Laidlaw's responsibilities to the Company."

8:02 am Libbey beats by $0.18, misses on revs (LBY) :

  • Reports Q3 (Sep) earnings of $0.75 per share, $0.18 better than the Capital IQ Consensus of $0.57; revenues fell 6.6% year/year to $201.8 mln vs the $214.81 mln Capital IQ Consensus.
  • "Our core foodservice channel continues to be very strong around the globe in the face of declining restaurant traffic trends. This is the sixth consecutive quarter of growth in foodservice for the Company. Unfortunately, that was offset in the third quarter by weakness in our retail and business-to-business channels."

8:02 am Kona Grill announces authorization for a $10 mln share repurchase plan (KONA) : The current authorization replaces the Co's 2012 $5 mln repurchase plan under which $1.8 mln remained available for repurchase.

8:01 am Microvision reports EPS in-line, misses on revs (MVIS) :

  • Reports Q3 (Sep) loss of $0.07 per share, in-line with the two analyst estimate of ($0.07); revenues rose 146.4% year/year to $2.39 mln vs the $4 mln single analyst estimate.

8:01 am CACI Intl receives $38.5 mln task order to continue providing defense health readiness engineering support for the Theater Medical Information Program (CACI) : Co has been awarded a $38.5 million task order to continue providing defense health readiness engineering support for the Theater Medical Information Program for the Space and Naval Warfare Systems Center Atlantic.

8:01 am AEP Industries appoints John Powers as Chief Operating Officer and President, effective immediately (AEPI) : Co announced John J. Powers, EVP of Sales and Marketing and a member of the Board of Directors, has been appointed to the newly created position of Chief Operating Officer and has assumed the role of President, effective immediately

8:00 am Chimerix reports Q3 results; Topline Data from SUPPRESS Trial of Brincidofovir anticipated in early 2016 (CMRX) :

  • Q3 EPS ($0.70) vs ($0.57) Capital IQ Consensus; revs +92% to $2.3 mln vs $2.20 mln Capital IQ Consensus.
  • Topline Data from SUPPRESS Trial of Brincidofovir for Prevention of Cytomegalovirus in Hematopoietic Cell Transplant Recipients Anticipated in Early 2016
  • Dosing Initiated in Phase 3 SUSTAIN and SURPASS Trials of Brincidofovir for Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients

8:00 am On the Wires (:WIRES) :

  • UQM Technologies (UQM) announced the receipt of a new purchase order from Proterra for the UQM PowerPhase 220 HD motor and controller systems with deliveries starting in early January 2016. The units will be used in the Proterra Catalyst Bus program
  • Cask Data announced that it is raising a $20 million Series B financing round led by Safeguard Scientifics (SFE) with participation from Battery Ventures, Ignition Partners and other existing investors

7:59 am RAIT Financial Trust reports Q3 Cash Available for Distribution per share of $0.27, vs. $0.00 for 3Q14 (RAS) :  

7:58 am Braskem SA reports Q3 results (BAK) : Co reports Q3 (Sep) net income of R$1,482 million, reflecting the good operating performance and the adoption of hedge accounting. Resin exports totaled to 454 kton, 22% and 43% up on 2Q15 and 3Q14, respectively. Exports of key basic petrochemicals reached 482 kton, up 35% and 19% from 2Q15 and 3Q14, respectively. The international unit posted record-high PP sales volume of 502 kton, representing growth of 2% on 2Q15, driven by a strong operating performance and recovery of the US economy. The construction of the petrochemical complex in Mexico reached 98% of completion, with progress made on the pre-commissioning activities.

7:57 am Antares Pharma reports Q3 results (ATRS) :

  • Q3 ($0.04) vs ($0.04) Capital IQ Consensus Estimate; revs $11.1 mln vs $9.93 mln Capital IQ Consensus.
  • "We believe the third quarter operating and financial results speak to the progress we are making against three of our top-priority goals, including continuing to grow Otrexup, delivering epinephrine devices to Teva and progressing the QuickShot Testosterone clinical program."

7:56 am S&P futures vs fair value: +7.80. Nasdaq futures vs fair value: +15.30. (:WRAPX) :

U.S. equity futures trade near their pre-market highs amid upbeat action overseas. The S&P 500 futures hover eight points above fair value after hitting pre-market highs during the past 30 minutes.

On the economic front, weekly Initial Claims (Briefing.com consensus 262,000) and preliminary Q3 Productivity/Unit Labor Cost data will be reported at 8:30 ET.

Treasuries sit just below their flat lines with the 10-yr yield at 2.23%.

In U.S. corporate news of note:

  • Facebook (FB 108.60, +4.66): +4.5% in reaction to better than expected results.
  • Qualcomm (QCOM 56.27, -3.99): -6.6% after below-consensus guidance overshadowed better than expected results.
  • Whole Foods (WFM 28.75, -2.01): -6.5% after below-consensus earnings and cautious guidance overshadowed a $1 billion increase in the company's buyback and a 4.0% quarterly dividend hike to $0.135/share.
  • AstraZeneca (AZN 33.01, +0.88): +2.7% after beating bottom-line estimates and guiding ahead of analyst expectations.
  • Celgene (CELG 122.49, -4.68): -3.7% after reporting a one-cent beat on below-consensus revenue.
  • Select Comfort (SCSS 23.75, +2.31): +10.8% after beating estimates and reaffirming its guidance.

Reviewing overnight developments:

  • Asian markets ended mixed. Japan's Nikkei +1.0%, China's Shanghai Composite +1.8%, and Hong Kong's Hang Seng settled flat
    • In economic data:
      • Indonesia's Q3 GDP +3.2% (expected 3.3%)
      • Taiwan's October CPI +0.3% (expected 0.2%)
    • In news:
      • The Bank of Japan released the minutes from its latest meeting, but there was no change in the tone among policymakers as they continue expecting an uptick in inflation
  • Major European indices trade higher across the board. France's CAC +1.2%, Germany's DAX +1.0%, and UK's FTSE +0.1%. Elsewhere, Italy's MIB +0.5% and Spain's IBEX +0.7%
    • Investors received several data points:
      • Eurozone September Retail Sales -0.1% month-over-month (expected 0.2%; prior 0.0%); +2.9% year-over-year (consensus 3.0%; prior 2.2%). Separately, Retail PMI 51.3 (prior 51.9)
      • Germany's September Factory Orders -1.7% month-over-month (expected 1.0%; previous -1.8%)
      • UK's October Halifax House Price Index +1.1% month-over-month (consensus 0.6%; prior -0.9%); +9.7% year-over-year (consensus 9.5%; last 8.6%)
      • Swiss October CPI +0.1% month-over-month (expected 0.0%; prior 0.1%); -1.4% year-over-year, as expected (prior -1.4%). Separately, Q4 SECO Consumer Climate -18 (expected -14; previous -19)
    • Among news of note:
      • The Bank of England made no changes to its policy stance, keeping its interest rate and purchase program unchanged at their respective 0.50% and GBP375 billion. Furthermore, the central bank's policy minutes revealed no change in attitude among participants with eight members calling for no change to policy while one member remained in the rate hike camp.

7:54 am Alliqua beats by $0.05, misses on revs; lowers FY15 revenue guidance (ALQA) :

  • Reports Q3 (Sep) non-GAAP loss of $(0.18) per share, $0.05 better than the Capital IQ Consensus of $(0.23); revenues rose 236% year/year to $5.0 mln vs the $5.54 mln Capital IQ Consensus.
  • Co guides to FY15 revenue of $15-16 mln, down from prior guidance of $16.3-18.8 mln and vs consensus of $17.6 mln. The decrease in guidance is primarily driven by lower than expected sales of Biovance, offset partially by higher than expected sales of MIST Therapy and contract manufacturing revenue.

7:54 am Easterly Government Properties reports FFO in-line, beats on revs; guides FY15 FFO above consensus; guides FY16 FFO above consensus (DEA) :

  • Reports Q3 (Sep) funds from operations of $0.26 per share, in-line with the Capital IQ Consensus of $0.26; revs $19.85 mln vs $18.76 mln consensus.
  • Co issues upside guidance for FY15, sees FFO of $1.01-1.05 vs. $1.00 Capital IQ Consensus Estimate.
  • Co issues upside guidance for FY16, sees FFO of $1.14-1.18 vs. $1.10 Capital IQ Consensus Estimate.

7:54 am Nuverra Environmental Solutions misses by $0.24, misses on revs (NES) :

  • Reports Q3 (Sep) adj. loss of $0.81 per share, $0.24 worse than the Capital IQ Consensus of ($0.57); revenues fell 45.2% year/year to $76.5 mln vs the $90.15 mln Capital IQ Consensus. 
  • "The third quarter saw volume and pricing headwinds as customers reduced drilling and completion activities. To position the company to weather these trends, which we expect to continue into 2016, we continued to focus on our cost-management and efficiency initiatives with a goal of operating within our cash flow as we work to complete the next steps to transform our business."

7:53 am Genocea Biosciences reports Q3 (GNCA) : Reports Q3 (Sep) loss of ($0.37) per share, excluding non-recurring items, $0.07 better than the Capital IQ Consensus of a loss of ($0.44); revenues rose year/year to $0.233 mln vs the $0.07 mln Capital IQ Consensus.

7:48 am EndoChoice beats by $0.04, reports revs in-line; guides FY15 EPS below consensus, revs below consensus (GI) :

  • Reports Q3 (Sep) loss of $0.47 per share, $0.04 better than the Capital IQ Consensus of ($0.51); revenues rose 29.9% year/year to $18.4 mln vs the $18.23 mln Capital IQ Consensus.
  • Co issues downside guidance for FY15, sees EPS of ($2.90)-($2.85) vs. ($2.83) Capital IQ Consensus Estimate; sees FY15 revs of $72-74 mln vs. $74.51 mln Capital IQ Consensus Estimate.

7:47 am Toyota Motor reports 1H16 results; revenue increased 8.9% YoY (TM) : Co reports FY16 first half results. Revenue increased 8.9% YoY to 14,091.4 billion yen in FY2016 first half. Operating income increased by 17.1% YoY to 1,583.4 billion yen in FY2016 first half. Net income increased 11.6% YoY to 1,258.1 billion yen in FY2016 first half. Consolidated vehicle unit sales in Japan and overseas decreased by 4.4% YoY to 4,278 thousand units in FY2016 first half. Vehicle unit sales in Japan decreased by 4.4% to 984 thousand units while overseas vehicle unit sales decreased by 4.4%, to 3,294 thousand units in FY2016 first half.

7:43 am Agrium beats by $0.04, misses on revs; guides FY15 EPS midpoint above consensus (AGU) :

  • Reports Q3 (Sep) earnings of $0.71 per share, excluding non-recurring items, $0.04 better than the Capital IQ Consensus of $0.67; revenues fell 13.6% year/year to $2.52 bln vs the $2.87 bln Capital IQ Consensus.
  • Co issues upside guidance for FY15, sees EPS of $7.10-7.40 vs. $7.10 Capital IQ Consensus Estimate.

7:43 am Repligen beats by $0.01, beats on revs; guides FY15 revs above consensus, raises low end of net income guidance (RGEN) :

  • Reports Q3 (Sep) earnings of $0.08 per share, $0.01 better than the Capital IQ Consensus of $0.07; revenues rose 29.4% year/year to $19.8 mln vs the $19.19 mln Capital IQ Consensus.
  • Product gross profit for the third quarter of 2015 was $11.4 ml compared to product gross profit of $8.2 mln for the third quarter of 2014, an increase of 38%.
  • Co issues upside guidance for FY15, sees FY15 revs of $81-$83 mln vs. $80.20 mln Capital IQ Consensus Estimate. Its revenue projection for 2015 is comprised exclusively of bioprocessing product sales and reflects growth in the range of 34%-37%, an increase from previous guidance of 29%-36%. It expects the additional five months of ATF System sales in 2015 versus 2014 to effectively offset the impact of foreign currency translation, which we estimate will be negative 9%.

    Co expects product gross margin for the year 2015 is expected to be 57%-59%, an increase from our previous guidance of 56%-58%. Total income from operations for the year 2015 is expected to be $15-$16 mln, an adjustment to its previous guidance of $14-$16 million. Net income is expected to be $11-$12 million, an adjustment to previous guidance of $10-$12 million.

7:42 am Lexington beats by $0.01, reports revs in-line; raises FY15 FFO guidance but remains below consensus; announces 10 mln share buyback (LXP) :

  • Reports Q3 (Sep) funds from operations of $0.27 per share, $0.01 better than the Capital IQ Consensus of $0.26; revenues fell 1.1% year/year to $105.43 mln vs the $105.85 mln Capital IQ Consensus.
  • Co issues downside guidance for FY15, sees FFO of $1.05-1.07 vs. $1.08 Capital IQ Consensus Estimate, $1.02-1.06
  • Co announced a 10 mln common share repurchase authorization and repurchased 1.6 million common shares, at an average price of $8.34 per share.

7:41 am Spartan Motors misses by $0.07, misses on revs (SPAR) :

  • Reports Q3 (Sep) net of breakeven, excluding non-recurring items, $0.07 worse than the two analyst estimate of $0.07; revenues fell 5.3% year/year to $136.6 mln vs the $150.1 mln two analyst estimate. Order backlog increased to $275.3 million at September 30, 2015, from $233.4 million at September 30, 2014

7:41 am CECO Environ. beats by $0.05, beats on revs (CECE) :

  • Reports Q3 (Sep) earnings of $0.27 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus of $0.22; revenues rose 55.2% year/year to $98.23 mln vs the $94.61 mln Capital IQ Consensus.
  • Non-GAAP operating margin improved to 13.2% from 12.9% n the prior-year period.

7:41 am Overnight Treasury Summary (BOND) :

Treasuries Flatline Overnight

  • Treasuries are generally unchanged this morning and the yield curve is just a touch steeper ahead of the release of weekly jobless claims and unit labor costs for the third quarter of 2015. There are several FOMC members speaking publicly today, although many are simply giving introductory remarks or participating in panels that have nothing to do with the macroeconomic outlook or near-term direction of monetary policy. Positioning should be tentative ahead of Friday's release of the October Employment Situation Report. S&P 500 futures are pointing to a higher open, up 0.34% to 2,109.4
  • Yield Check:
    • 2-yr: -1 bp to 0.83%
    • 5-yr: unch at 1.63%
    • 10-yr: +1 bp to 2.23%
    • 30-yr: +1 bp to 3.01%
  • International News:
    • The Bank of England voted 8-1 in favor of holding its main policy rate at 0.5%
      • The central bank also forecast that consumer prices would grow at less than 1% until H2 2016 in its quarterly inflation report, while also citing downside risks to the outlook
      • The 2015 and 2016 GDP growth forecasts were both lowered to 2.7% and 2.5%, respectively
      • The BoE saw the domestic economic picture as strong, helped along by low energy prices and interest rates, while the risk factors were mostly external
    • The U.K.'s Halifax House Price Index rose a better-than-expected 1.1% m/m in October after falling 0.9% in September. The index was up 9.7% y/y
    • Eurozone retail sales fell 0.1% m/m in September, confounding economists' expectations for a modest gain. Retail sales were unchanged in August
      • In Germany, factory orders unexpectedly fell 1.7% m/m in September after declining 1.8% in August
    • Russia's services purchasing managers' index, as compiled by Markit, fell more than expected to 47.8 in October from 51.3 in September
      • The Bank of Russia's reserves fell to $369.2 bln from $374.6 bln
    • Japan's Ministry of Finance auctioned JPY 2.4 tln ($19.76 bln) of 10-year JGBs at a high yield of 0.320%. The auction tailed ever so slightly and drew a bid-to-cover ratio of 2.80
  • Data out Today:
    • October Challenger Job Cuts (07:30 ET)
    • Initial Jobless Claims for the week ending 10/31 and Continuing Jobless Claims for the week ending 10/24 (08:30 ET)
    • Q3 Productivity and Unit Labor Costs -- Preliminary (08:30 ET)
    • Natural Gas Inventories for the week ending 10/31 (10:30 ET)
  • Fed Speakers:
    • Philadelphia Fed President Harker (non-FOMC voter) -- introductory remarks (08:30 ET)
    • New York Fed President Dudley (FOMC voter) -- introductory remarks (08:30 ET)
    • Fed Vice Chair Fischer (FOMC voter) -- participates in discussion (09:10 ET)
    • Chicago Fed President Evans (FOMC voter) -- introductory remarks (10:40 ET)
    • Fed Governor Tarullo (FOMC voter) -- "Sharing Responsibility for the Regulation of International Banks" (13:25 ET)
    • Atlanta Fed President Lockhart (FOMC voter) (14:30 ET)
    • Former Fed Chair Bernanke -- gives lecture at "Unconventional Monetary and Exchange Rate Policies" Conference (16:00 ET)

7:41 am Celgene beats by $0.01, misses on revs; reaffirms FY15 guidance; raises REVLIMID guidance, lowers ABRAXNE (CELG) :

  • Reports Q3 (Sep) earnings of $1.23 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $1.22; revenues rose 17.8% year/year to $2.33 bln vs the $2.4 bln Capital IQ Consensus. 
    • REVLIMID sales for the third quarter increased 12 percent to $1,453 million. U.S. sales of $895 million and International sales of $558 million increased 18 percent and 3 percent year-over-year, respectively. Volume was the main driver of the increase as both market share and duration trends are positive across major geographies.
  • Co reaffirms guidance for FY15, sees EPS of $4.75-4.85, excluding non-recurring items, vs. $4.82 Capital IQ Consensus Estimate; sees FY15 revs of $9.0-9.5 bln vs. $9.28 bln Capital IQ Consensus Estimate. 
    • REVLIMID net sales are expected to be ~$5.8 billion, an increase from the previous range of $5.6 billion to $5.7 billion
    • ABRAXANE net sales are expected to be in the range of $950 million to $1.0 billion, a decrease from the previous range of $1.0 billion to $1.25 billion
  • Adjusted 2015 operating margin remains unchanged at ~52%.  
  • Over 150 abstracts expected at medical congresses in Q4, including many at ASH

7:40 am Media General reports Q3 (Sep) results, revs in-line; guides Q4 revs in-line (MEG) :

  • Reports Q3 (Sep) loss of $0.38 per share, may not be comparable to the two analyst estimate of $0.03; revenues rose 101.3% year/year to $322 mln vs the $323.13 mln Capital IQ Consensus.
  • Co issues in-line guidance for Q4, sees Q4 revs of $366-377 mln vs. $375.16 mln Capital IQ Consensus Estimate.

7:39 am Chemours beats by $0.14, reports revs in-line (CC) :

  • Reports Q3 (Sep) earnings of $0.40 per share, excluding non-recurring items, $0.14 better than the Capital IQ Consensus of $0.26; revenues fell 8.9% year/year to $1.49 bln vs the $1.5 bln Capital IQ Consensus.
    • In the third quarter, Titanium Technologies segment sales were $616 mln, an 18% decline versus the prior-year quarter.
    • Fluoroproducts segment sales in the third quarter were $575 mln, flat versus the prior-year quarter
    • In the third quarter, Chemical Solutions segment sales were $295 mln, a 4% decline versus the prior-year quarter
    • In the third quarter, Chemical Solutions segment sales were $295 mln, a 4% decline versus the prior-year quarter.

7:38 am Enviva Partners misses by $0.01, beats on revs (EVA) :

  • Reports Q3 (Sep) earnings of $0.27 per share, $0.01 worse than the Capital IQ Consensus of $0.28; revenues rose 53.2% year/year to $116.6 mln vs the $104.49 mln single analyst estimate.
  • "Consistent with previous guidance, the Partnership expects its existing business to generate net income in the range of $5.6 million to $6.6 million and adjusted EBITDA in the range of $14.8 million to $15.8 million, and to incur maintenance capital expenditures in the range of $0.5 million to $1.0 million and interest expense net of amortization of debt issuance costs and original issue discount of $2.5 million in the fourth quarter of 2015. As a result, the Partnership expects to generate distributable cash flow of $11.3 million to $12.3 million during the fourth quarter of 2015."

7:37 am Atlas Air Worldwide reports EPS in-line, misses on revs; guides Q4 EPS above consensus (AAWW) :

  • Reports Q3 (Sep) earnings of $1.23 per share, in-line with the Capital IQ Consensus of $1.23; revenues fell 3.4% year/year to $449.9 mln vs the $472.74 mln Capital IQ Consensus.
  • Co issues upside guidance for Q4, sees EPS of slightly more than $1.50 vs. $1.50 Capital IQ Consensus Estimate.

7:37 am Apollo Investment reports EPS in-line, revs in-line (AINV) :

  • Reports Q2 (Sep) earnings of $0.21 per share, in-line with the Capital IQ Consensus of $0.21; Total investment income fell 17.2% year/year to $98.42 mln vs the $98.89 mln Capital IQ Consensus.

7:37 am Martha Stewart misses by $0.07, misses on revs (MSO) :

  • Reports Q3 (Sep) loss of $0.03 per share, $0.07 worse than the two analyst estimate of $0.04; revenues fell 41.2% year/year to $17.4 mln vs the $20.9 mln two analyst estimate.

7:37 am Blue Nile beats by $0.01, reports revs in-line; guides Q4 EPS in-line, revs in-line; authorizes $100 mln renewed share repurchase program (NILE) :

  • Reports Q3 (Sep) earnings of $0.17 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.16; revenues rose 3.9% year/year to $109.9 mln vs the $110.83 mln Capital IQ Consensus.  Earnings per diluted share included stock-based compensation expense of $0.07 for the third quarter 2015 and $0.05 for the third quarter 2014.
  • Co issues in-line guidance for Q4, sees EPS of $0.41-0.47, excluding non-recurring items, vs. $0.44 Capital IQ Consensus Estimate; sees Q4 revs of $158-168 mln vs. $163.98 mln Capital IQ Consensus Estimate. 
  • Blue Nile's Board of Directors authorized the renewal of the Company's share repurchase program. The Company is authorized to repurchase up to $100.0 million of its common stock over the next 27 months.

7:36 am TECO Energy beats by $0.02, reports revs in-line (TE) :

  • Reports Q3 (Sep) earnings of $0.33 per share, $0.02 better than the Capital IQ Consensus of $0.31; revenues rose 1.0% year/year to $693.8 mln vs the $698.88 mln Capital IQ Consensus. 
  • On Sept. 4, we announced that Emera, Inc. would acquire TECO Energy for $27.55 per share. On Sept. 21, we closed the sale of TECO Coal, our last unregulated business, thus completing our transformation to a regulated utility business.

7:36 am Gogo beats by $0.04, beats on revs; reaffirms FY15 revs guidance; raises EBITDA (GOGO) :

  • Reports Q3 (Sep) loss of $0.37 per share, $0.04 better than the Capital IQ Consensus of ($0.41); revenues rose 21.5% year/year to $126.4 mln vs the $123.71 mln Capital IQ Consensus. Service revenue increased to $107.2 million, up 31% from $81.6 million in Q3 2014.
    • Adjusted EBITDA increased to $9.7 million, up 738% or $8.5 million from $1.2 million in Q3 2014.
  • Co reaffirms guidance for FY15, sees FY15 revs of $485-505 mln vs. $491.51 mln Capital IQ Consensus; raises FY15 EBITDA to $30-35 mln from $15-25 mln.
  • "We are extremely pleased with our strong financial performance for the quarter, and even more pleased with the flight test results of 2Ku, our next generation global connectivity solution, and that portends great things for our future."

7:35 am Primoris Services reports EPS in-line, misses on revs (PRIM) :

  • Reports Q3 (Sep) earnings of $0.37 per share, in-line with the Capital IQ Consensus of $0.37; revenues fell 9.3% year/year to $555.9 mln vs the $601.49 mln Capital IQ Consensus.
    • Third quarter 2015 revenues were impacted by the delay in certain capital projects as a result of lower oil prices and as a result of close-outs of large projects in the prior year

7:34 am Calgon Carbon misses by $0.02, misses on revs (CCC) :

  • Reports Q3 (Sep) earnings of $0.23 per share, $0.02 worse than the Capital IQ Consensus of $0.25; revenues fell 3.4% year/year to $133 mln vs the $141.3 mln Capital IQ Consensus.

7:34 am Houston Wire & Cable misses by $0.02, beats on revs (HWCC) :

  • Reports Q3 (Sep) earnings of $0.06 per share, excluding non-recurring items, $0.02 worse than the Capital IQ Consensus of $0.08; revenues fell 19.0% year/year to $78.3 mln vs the $73.98 mln Capital IQ Consensus.
  • Gross margin at 20.6% decreased 120 basis points from the third quarter of 2014 primarily due to lower product margins and vendor rebates, partially offset by lower customer incentives.
  • Debt decreased to $38.8 million, the lowest level since Q1 2010

7:32 am Aeropostale receives a notice of non-compliance from the NYSE for failing to meet the exchange's minimum market cap standard; co plans to submit a plan to cure the deficiency (ARO) :  

7:32 am Meridian Bioscience misses by $0.01, beats on revs; guides FY15 EPS in-line, revs in-line (VIVO) :

  • Reports Q4 (Sep) earnings of $0.20 per share, $0.01 worse than the Capital IQ Consensus of $0.21; revenues rose 0.9% year/year to $47.1 mln vs the $45.7 mln Capital IQ Consensus.
  • Co issues in-line guidance for FY15, sees EPS of $0.86-0.90 vs. $0.86 Capital IQ Consensus Estimate; sees FY15 revs of $195-200 mln vs. $193.50 mln Capital IQ Consensus Estimate.

7:32 am Crocs appoints Carrie Teffner as CFO, effective December 16, 2015 (CROX) : Prior to joining Crocs' board of directors, Teffner served as EVP and CFO for PetSmart

7:31 am Core-Mark misses by $0.08, reports revs in-line; revises FY15 EPS guidance, reaffirms FY15 revs guidance; raises dividend (CORE) :

  • Reports Q3 (Sep) GAAP earnings of $0.65 per share, $0.08 worse than the Capital IQ GAAP Consensus of $0.73; revenues rose 8.9% year/year to $2.99 bln vs the $2.97 bln Capital IQ Consensus.
  • Co revises EPS guidance for FY15, sees GAAP EPS of $2.08-2.15 (prior $2.03-2.10) vs. $2.12 Capital IQ Consensus Estimate; reaffirms FY15 revs guidance of $11-11.2 bln vs. $11.07 bln Capital IQ Consensus Estimate.
  • Core-Mark also announced its Board of Directors has approved a $0.16 cash dividend per common share for the fourth quarter, or $0.64 annually, an increase of $0.03 per quarter from the prior dividend.

7:30 am Realogy misses by $0.05, beats on revs (RLGY) :

  • Reports Q3 (Sep) earnings of $0.76 per share, excluding non-recurring items, $0.05 worse than the Capital IQ Consensus of $0.81; revenues rose 8.9% year/year to $1.67 bln vs the $1.65 bln Capital IQ Consensus. 
  • Co is raising its outlook for Adjusted EBITDA to a range of $830 million to $845 million, up from its previously provided range of $810 million to $840 million. The Company is also raising its Adjusted EBITDA margin outlook for the full year 2015 to a range of 14.4% to 14.6%, up from its previously provided range of 14.1% to 14.3%.

7:29 am On the Wires (:WIRES) :

  • CareFusion, a BD company (BDX) announced its AirLife business line has signed an exclusive agreement with ResMed (RMD) to distribute nasal high flow interface products from the company
  • Siliconware Precision Industries (SPIL) Board of Directors resolved to invest in 100% owned subsidiary, Siliconware Investment Co, for NTD 2.401 billion and acquire 48,020,000 common shares- and for Siliconware Investment to invest in Yann Yuan Investment for NTD 2.4 billion and acquire 48,000,000 common shares.
  • KVH Industries' (KVHI) guidance and stabilization business awarded two contracts totaling $2.7 mln: a $1.3 mln contract to provide field service representative support to an allied country in the Middle East related to Co's tactical navigation systems; and, a $1.4 mln contract for the delivery of TACNAV systems for use by an international military customer
  • xG Technology (XGTI) announced an order for ~$200K from the US State Dpmt for xMax mobile broadband wireless netowrking equipment and associated support services.
  • Skyline Medical (SKLN) initiated 12 new trials of the STREAMWAY System in 8 different states across the U.S.

7:29 am Dawson Geophys beats Q3 estimates; demand to remain soft in FY16 (DWSN) :

  • Q3 ($0.13) vs ($0.42) two analyst estimate; revs $62.5 mln vs $55.94 mln two analyst estimate
  • "The Company operated approximately ten crews in the United States with limited activity in Canada during the third quarter of 2015. Improved weather conditions, operational discipline, and strong financial management, in the Company's areas of operations lead to increased crew utilization in the third quarter of 2015 as compared to the second quarter of 2015, and resulted in a 108% increase in EBITDA from the same period in 2014. Despite the year-over-year improvement in EBITDA, demand for services is at reduced levels from recent years and is anticipated to remain so into 2016 in response to decreased and uncertain commodity prices and reduced client expenditures. The Company anticipates operating eight to ten crews in the United States with limited activity in Canada during the fourth quarter ending December 31, 2015 and into the latter part of the first quarter of 2016."

7:29 am On the Wires (:WIRES) :

  • Affymetrix (AFFX) and XRGenomics announced that they will collaborate on research and development of a new generation of diagnostic tests for age-related diseases. XRGenomics has utilized Affymetrix technology to develop novel gene expression-based signatures that enable translational research and biomarker test development activities in areas such as dementia, Alzheimer's, and other age-related diseases.
  • Isis Pharmaceuticals (ISIS) announced the start of a Phase 3 study to evaluate the efficacy and safety of volanesorsen in patients with familial partial lipodystrophy. The study's primary objective will be to evaluate the efficacy and safety of a 300 mg once weekly dose of volanesorsen given over 12 months. The primary endpoint of the study is percent change in fasting triglycerides from baseline after three months of dosing.
  • Genocea Biosciences (GNCA) announced a collaboration with Memorial Sloan Kettering Cancer Center to screen the T cell responses of melanoma and non-small cell lung cancer patients treated with checkpoint inhibitors against the complete repertoire of patient-specific putative cancer neoantigens. The goals of the collaboration are to identify signatures of T cell response in cancer patients associated with response or non-response to CPI therapy and to discover new T cell cancer vaccine antigens.
  • Biocept (BIOC) announced that findings demonstrating the ability to reliably detect actionable genetic alterations used in the diagnosis, monitoring and treatment of patients with lung cancer using its blood based biopsy, instead of surgical biopsy

7:25 am Pattern Energy reports Q3; raises dividend 2.5% QoQ (PEGI) :

  • Reports Q3 (Sep) GAAP loss of $0.40 per share, may not compare to the Capital IQ Consensus of ($0.12); revenues rose 25.5% year/year to $89.7 mln vs the $87.97 mln Capital IQ Consensus.
    • The changes in net loss are primarily due to third quarter other expense items associated with Gulf Wind's early extinguishment of debt and termination of associated interest rate instruments. In addition, the net loss for the third quarter increased due to unrealized losses on interest rate derivatives, and losses in unconsolidated investments as a result of decreasing forward interest rate curves.
  • Cash available for distribution (CAFD) of $22.3 mln, up 104%
  • Adjusted EBITDA of $58.7 million, up 32%
  • Proportional GWh sold of 1,256 GWh, up 77%
  • Re-iterated 2015 cash available for distribution estimate of $81 million to $87 million
  • Raises dividend 2.5% QoQ to $0.372

7:24 am Charter Comm subsidiary to offer $2.5 bln in aggregate principal amount of senior unsecured notes due 2026 (CHTR) :

Co announces that its subsidiary, CCOH Safari, LLC, intends to offer $2.5 bln in aggregate principal amount of senior unsecured notes due 2026.

  • Co Charter intends to use the net proceeds from the sale of the Notes to partially finance Co's previously announced transactions with Time Warner Cable Inc. (TWC) and Bright House Networks, LLC.
  • The Notes will be assumed by Co's subsidiaries, CCO Holdings, LLC and CCO Holdings Capital Corp.

7:22 am TreeHouse Foods beats by $0.03, misses on revs (in-line with Monday's preannouncement); reaffirms FY15 EPS guidance (THS) :

  • Reports Q3 (Sep) earnings of $0.86 per share, $0.03 better than the Capital IQ Consensus of $0.83; revenues rose 0.4% year/year to $798.64 mln vs the $822.37 mln Capital IQ Consensus.
  • Co reaffirms guidance for FY15, sees EPS of $3.00-3.15 vs. $3.07 Capital IQ Consensus Estimate.
  • Adjusted earnings before interest, taxes, depreciation, amortization, and non-cash stock based compensation, or Adjusted EBITDA, was $99.8 million in the third quarter of 2015, a 3.6% decrease compared to the prior year. Adjusted EBITDA was lower this quarter due to competitive pressures in most categories and unfavorable foreign exchange.

7:19 am Chesapeake Utilities beats by $0.07, misses on revs (CPK) :

  • Reports Q3 (Sep) earnings of $0.33 per share, $0.07 better than the Capital IQ Consensus of $0.26; revenues rose 0.3% year/year to $91.91 mln vs the $96.01 mln two analyst estimate.

7:19 am McEwen Mining reports Q3 operating and financial results (MUX) : Co reports Q3 adjusted EPS of $0.00 vs $0.03 in the prior year period. Co also reports record quarterly production of 43,390 gold equivalent ounces and earnings from mining operations of $13.4 mln for Q3. The El Gallo Mine in Mexico was the star performer in the quarter, producing at total cash costs and all-in sustaining costs (AISCF) per gold equivalent ounce of $454 and $570, respectively.

7:18 am Duke Energy misses by $0.04, misses on revs; sees FY15 EPS at low half of prior range (DUK) :

  • Reports Q3 (Sep) earnings of $1.47 per share, $0.04 worse than the Capital IQ Consensus of $1.51; revenues rose 1.4% year/year to $6.48 bln vs the $6.77 bln Capital IQ Consensus.
    • Earnings for the third quarter of 2015 were higher than the prior year quarterly results, primarily due to warmer weather compared to the previous year. The company also experienced strong growth in the Regulated Utilities business, including the impact of the recently completed North Carolina Eastern Municipal Power Agency (:NCEMPA) acquisition.
    • During 2015, the co has been able to offset weakness in the International business with favorable weather, solid operational performance in the regulated business, and benefits from closing certain strategic initiatives earlier than anticipated
  • Co issues in-line guidance for FY15, sees EPS of $4.55-4.65 from $4.55-4.75 vs. $4.63 Capital IQ Consensus Estimate. 

7:18 am Huntington Ingalls misses by $0.03, beats on revs (HII) :

  • Reports Q3 (Sep) earnings of $1.98 per share, excluding non-recurring items, $0.03 worse than the Capital IQ Consensus of $2.01; revenues rose 4.8% year/year to $1.8 bln vs the $1.71 bln Capital IQ Consensus. 
  • New contract awards were ~$0.8 billion for the quarter, bringing total backlog at the end of Q3 2015 to $23.3 billion, of which $12.5 billion was funded.

7:15 am Cogent Communications beats by $0.01, beats on revs (CCOI) :

  • Reports Q3 (Sep) earnings of $0.07 per share, $0.01 better than the Capital IQ Consensus of $0.06; revenues rose 7.6% year/year to $103.01 mln vs the $100.83 mln Capital IQ Consensus.

7:15 am Coty beats by $0.29, misses on revs (COTY) :

  • Reports Q1 (Sep) earnings of $0.59 per share, excluding non-recurring items, $0.29 better than the Capital IQ Consensus of $0.30; non-GAAP revenues fell 5.9% year/year to $1.11 bln vs the $1.14 bln Capital IQ Consensus.
  • Note: In July 2015, COTY announced it will merge with the Procter & Gamble's (PG) Specialty Beauty Business. Since that time much has happened. Over the last few months, the financing structure for this transaction has been put in place. Extensive discussions with the twelve licensors have taken place with respect to the transfer of their fragrance licenses to Coty. To date, ten out of the twelve licenses will transfer to Coty upon regulatory approval and completion of the transaction. Co says this has allowed it to stay on track with the regulatory clearance process. As a result, co continues to anticipate the deal will close in the second half of calendar 2016.

7:15 am EnerNOC misses by $0.16, misses on revs; guides Q4 EPS in-line, revs below consensus (ENOC) :

  • Reports Q3 (Sep) earnings of $0.74 per share, excluding non-recurring items, $0.16 worse than the Capital IQ Consensus of $0.90; revenues fell 34.0% year/year to $217.3 mln vs the $232.18 mln Capital IQ Consensus.
  • Co issues guidance for Q4, sees EPS of ($1.13) - ($0.97) vs. ($0.99) Capital IQ Consensus Estimate; sees Q4 revs of $50-60 mln vs. $65.90 mln Capital IQ Consensus Estimate. 
  • Co signed a multi-year software contract with UK energy retailer SmartestEnergy. SmartestEnergy will leverage the Company's software to launch new products for its business customers.

7:14 am Rice Energy beats by $0.03, misses on revs (RICE) :

  • Reports Q3 (Sep) earnings of $0.03 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of ($0.00); revenues rose 81.5% year/year to $143.6 mln vs the $157.53 mln Capital IQ Consensus.
  • Effective Oct 30, 2015, the borrowing base under its upstream credit facility was increased by $100 mln to $750 mln, representing a 15% increase.
  • On Nov 4, 2015, Rice Midstream Holdings received $200 mln from RMP as consideration for the water services business acquisition.
  • As of Sept 30, 2015, its liquidity position pro forma for its borrowing base redetermination, water services business drop down and excluding RMP and the potential earn out, was $1.2 bln, consisting of $625 mln available under its upstream credit facility, $300 mln available under its retained midstream credit facility and $240 mln of cash on hand.
  • Co had 66% of its Q3 production hedged at an average Henry Hub floor price of $4.02 per MMBtu. For Q4, co has 503 BBtu/d of its expected production hedged at a weighted average fixed floor price of $3.78/MMBtu. In addition, co currently has hedged an average of 489 and 375 BBtu/d in 2016 and 2017, respectively, at a weighted average floor price of $3.51 and $3.34/MMBtu.

7:14 am ANSYS beats by $0.03, reports revs in-line; guides Q4 EPS below consensus, revs below consensus; guides FY16 EPS below consensus, revs in-line (ANSS) :

  • Reports Q3 (Sep) earnings of $0.90 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of $0.87; revenues rose 1.1% year/year to $238.2 mln vs the $238.42 mln Capital IQ Consensus. Recurring revenue, which is comprised of lease license and annual maintenance revenue, totaled 72% of revenue for the third quarter.
  • Co issues downside guidance for Q4, sees EPS of $0.83-0.88, excluding non-recurring items, vs. $0.94 Capital IQ Consensus Estimate; sees Q4 revs of $252-260 mln, excluding non-recurring items, vs. $266.15 mln Capital IQ Consensus Estimate.
  • Co issues guidance for FY16, sees EPS of $3.58-3.76, excluding non-recurring items, vs. $3.79 Capital IQ Consensus Estimate; sees FY16 revs of $1.01-1.05 bln, excluding non-recurring items, vs. $1.04 bln Capital IQ Consensus Estimate.

7:14 am Radius Health misses by $0.10; on track to submit MAA in the EU and NDA in the U.S. for abaloparatide-SC by the end of this year (RDUS) :

  • Reports Q3 (Sep) loss of $0.68 per share, $0.10 worse than the Capital IQ Consensus of ($0.58). 
  • "Radius was pleased to have the opportunity to present the positive results of our Phase III ACTIVE and ACTIVExtend trials for our investigational drug abaloparatide-SC for the treatment of postmenopausal osteoporosis at the American Society for Bone and Mineral Research, and we are on track to submit our MAA in the EU and NDA in the U.S. by the end of this year."

7:14 am BCE Inc beats by $0.08, reports revs in-line; reaffirms FY15 guidance (BCE) :

  • Reports Q3 (Sep) earnings of CC$0.93 per share, CC$0.08 better than the Capital IQ Consensus of CC$0.85; revenues rose 2.9% year/year to CC$5.34 bln vs the CC$5.3 bln Capital IQ Consensus.
    • Reports 126,000 total net customer additions -- 68,000 IPTV and 58,000 high-speed Internet
  • Co reaffirms guidance for FY15, sees EPS of C$3.28-3.38 vs. C$3.31 Capital IQ Consensus Estimate; reaffirms revenue growth of 1-3%.

7:11 am Alaska Comms beats by $0.06, reports revs in-line; reaffirms FY15 revs guidance; CFO and Chief Revenue Officer separate from the company (ALSK) :

  • Reports Q3 (Sep) earnings of $0.02 per share, $0.06 better than the single analyst estimate of ($0.04); revenues fell 30.2% year/year to $54.74 mln vs the $54.79 mln single analyst estimate.
  • Co reaffirms guidance for FY15, sees FY15 revs of $220 mln vs. $232.12 mln single analyst estimate.
  • On November 4, 2015, Wayne Graham, Chief Financial Officer, and the Company, agreed that that Mr. Graham would separate from the Company effective November 30, 2015. Additionally, on November 4, 2015, David Eisenberg, Chief Revenue Officer and the Company agreed that Mr. Eisenberg would separate from the Company effective November 30, 2015. The Company also appointed Laurie Butcher, Senior Vice President, Finance, to serve as the Company's primary financial and accounting officer effective on November 5, 2015

7:11 am Main Street Capital COO Dwayne L. Hyzak given additional role as President of Co. (MAIN) :  

7:11 am Enbridge misses by $0.02; guides FY15 EPS below consensus (ENB) :

  • Reports Q3 (Sep) earnings of CC$0.47 per share, CC$0.02 worse than the Capital IQ Consensus of CC$0.49.
  • Co issues downside guidance for FY15, sees EPS at lower end of prior guidance of C$2.05-2.35 vs. C$2.22 Capital IQ Consensus Estimate.

7:10 am CyrusOne beats by $0.03, beats on revs; raises FY15 FFO above consensus, reaffirms FY15 rev, EBITDA (CONE) :

  • Reports Q3 (Sep) funds from operations of $0.57 per share, $0.03 better than the Capital IQ Consensus of $0.54; revenues rose 31.1% year/year to $111.2 mln vs the $108.65 mln Capital IQ Consensus.
  • Co issues guidance for FY15, sees FFO of $2.11-2.15 from $2.07-2.13, excluding non-recurring items, vs. $2.08 Capital IQ Consensus Estimate; reaffirms FY15 revs of $398-404 mln vs. $398.90 mln Capital IQ Consensus Estimate.

7:10 am Rice Midstream Partners reports EPS in-line, beats on revs (RMP) :

  • Reports Q3 (Sep) earnings of $0.21 per share, in-line with the Capital IQ Consensus of $0.21; revenues rose 1156.3% year/year to $20.1 mln vs the $19.6 mln Capital IQ Consensus. 
  • Average daily throughput for the third quarter was 671 MDth/d, a 3% increase relative to second quarter 2015.
  • "We expect to increase distributions by $0.003 per unit in the fourth quarter 2015 to $0.1965 per unit, which represents a 5% increase above our minimum quarterly distribution of $0.1875/unit"

7:09 am HHGregg misses by $0.01, reports revs in-line (HGG) :

  • Reports Q2 (Sep) loss of $0.37 per share, $0.01 worse than the Capital IQ Consensus of ($0.36); revenues fell 3.4% year/year to $488.9 mln vs the $488.24 mln Capital IQ Consensus.
  • Comparable store sales decreased 3.5% compared to the prior year second quarter, but improved by 280 basis points as compared to the first quarter of fiscal 2016.
  • "We remain on track to meet or exceed our three key financial objectives for the year, which are focused on driving improvements for comparable store sales, cost savings and positive EBITDA for the fiscal year. We were pleased with the continued traction in our net sales during the second quarter driven by delivering on our fiscal 2016 revenue generation initiatives. In addition, we have continued our cost savings efforts and remain on track to meet our plan to save $50 million in fiscal 2016. The steady progress we have made with our transformation plan has positioned our company well as we embark on the holiday season."

7:09 am Sarepta Therapeutics reports EPS in-line (SRPT) :

  • Reports Q3 (Sep) loss of $1.11 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of ($1.11).
    • Co said, "We are encouraged by the established body of clinical, biochemical and safety data for eteplirsen, which we plan to present at the tentatively scheduled Advisory Committee meeting in January".

7:09 am Consolidated Comms Illinois misses by $0.01, misses on revs (CNSL) :

  • Reports Q3 (Sep) earnings of $0.18 per share, excluding non-recurring items, $0.01 worse than the Capital IQ Consensus of $0.19; revenues rose 30.2% year/year to $194 mln vs the $200.92 mln Capital IQ Consensus.
  • The Company is reiterating its full year guidance:
    • Cash Interest Expense $76.5 million to $77.5 million (2014 pro forma results $81.4 million)
    • Cash Income Taxes $2.0 million to $3.0 million (2014 $12.4 million)
    • Capital Expenses $128.0 million to $132.0 million (2014 $131.3 million)

7:07 am ComScore beats by $0.03, misses on revs; guides Q4 revs below consensus; announces that Adobe is acquiring its enterprise analytics technology, Digital Analytix (SCOR) :

  • Reports Q3 (Sep) earnings of $0.43 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of $0.40; revenues rose 12.5% year/year to $92.41 mln vs the $93.93 mln Capital IQ Consensus.
  • Co issues downside guidance for Q4, sees Q4 revs of $95-103 mln vs. $103.2 mln Capital IQ Consensus Estimate.
  • Co also announces that Adobe (ADBE) is acquiring its enterprise analytics technology, Digital Analytix. SCOR says this divesture improves its competitive position, allowing complete focus on its mission to make audiences and advertising more valuable across all the screens that matter.
  • Note: Co announced in September that it is merging with Rentrak (RENT).

7:07 am Engility misses by $0.03, misses on revs; guides FY15 EPS in-line, revs in-line (